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Abstract
Background: Human epidermal growth factor receptor-2 (HER2) expression
predicts response to anti-HER2 therapy in breast and gastric cancer. HER2 status is
assessed by tumour biopsy but this may not be representative of the larger tumour
mass or other metastatic sites; risking misclassification and selection of suboptimal
therapy. The G3 designed ankyrin repeat protein (DARPin) binds HER2 with high
affinity at an epitope that does not overlap with trastuzumab and is biologically inert.
This research aims to assess the pre-clinical efficacy and safety of G3 DARPin
HER2 PET and SPECT imaging.
Methods: Hexahistidine (His6), histidine-glutamate (HE)3 and untagged-G3
DARPins were manufactured using a GMP-compatible Pichia pastoris protocol and
radiolabelled with
125I or site-specifically with
111In. BALB/c mice were injected with
radiolabelled-G3 DARPins and biodistribution was evaluated. The lead construct,
(HE)3-G3 was radiolabelled with
111In,
125I or
68Ga for assessment in mice bearing
HER2-positive human breast tumour (BT474) xenografts. Mice received (HE)3-G3 at
50-100 times the human equivalent dose to assess acute toxicity.
Results: (HE)3-G3 had significantly lower liver uptake than His6-G3 and untagged-
G3 in non-tumour bearing mice when radiolabelled with
125I or
111In. In mice bearing
HER2-positive tumour xenografts,
111In-(HE)3-G3 was better maintained in tumours
and cleared faster from serum than
125I-(HE)3-G3, achieving superior tumour-to-
blood ratios of 343.7±161.3 vs. 22.0±11.3 at 24 h, respectively. On microSPECT/CT
111In and
125I labelled (HE)3-G3, imaged HER2-positive tumours at 4 h post-
administration but
111In-(HE)3-G3 had less non-specific uptake.
68Ga-(HE)3-G3 can
image HER2-positive tumours at up to 2 h post-administration by PET scanning.
(HE)3-G3 DARPin was well tolerated by mice treated at 50-100 times the human
equivalent dose over 24 h.
Conclusion: Radiolabelled (HE)3-G3 is a versatile radioligand with potential to
acquire whole-body HER2 scans. (HE)3-G3 will be assessed in a regulatory
standard pre-clinical toxicity study, prior to embarking on a first in human trial.3
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Chapter 1 Introduction31
1.1 Background
In recent years, our knowledge and understanding of the molecular processes which
cause cancer and result in cancer progression have increased greatly. This has led
to the development of targeted therapies which disrupt these molecular processes. It
is important to stratify patients on the basis of biomarkers which reflect these
molecular processes to improve patient outcome in response to targeted agents.
Although histological analysis is the main method used to determine molecular
biomarker expression, it does not sufficiently address tumour heterogeneity and is
limited by sampling a single site at a single time point. Molecular imaging could
potentially assess whole body biomarker expression, which could serve as a means
to predict and assess treatment responses to targeted agents.
1.2 Human epidermal growth factor receptor 2
Human epidermal growth factor receptor 2 (HER2) is one of four members of the
HER family (HER 1-4), which are collectively involved in the regulation of cell
survival, growth and differentiation (Ross, Slodkowska et al. 2009). The HER2 gene
was discovered by Weinberg and colleagues in 1984 (Schechter, Stern et al. 1984).
The gene is located on the long arm of chromosome 17 (17q12) and encodes for a
185,000 Da transmembrane receptor protein with tyrosine kinase activity (Akiyama,
Sudo et al. 1986).
In 1985, HER2 gene amplification was reported in the human breast cancer cell line,
MAC117 (King, Kraus et al. 1985). In 1987, Slamon et al. determined that HER2
gene amplification was an independent prognostic factor which predicted overall
survival and time to relapse among 189 breast cancer patients (Slamon, Clark et al.
1987). HER2 is overexpressed in 20-25% of breast cancer patients (Slamon, Clark
et al. 1987; Owens, Horten et al. 2004; Ross, Slodkowska et al. 2009). Assessment
of HER2 status is now an important prognostic and predictive marker in the
management of early and advanced breast cancer.
1.2.1 Biology of HER2
The HER pathway is a complex biological network composed of extracellular
polypeptides, transmembrane receptors and protein kinases that transmit signals to32
the nucleus which activate or inhibit transcription factors of genes that regulate
cellular function (Figure 1.1) (Citri and Yarden 2006).
Ligand binding to a HER extracellular domain can activate HER dimerisation and
trans-phosphorylation of the intracellular domains. HER2 is unique in not having a
ligand, so HER2 activation depends on heterodimerisation with another HER family
member, as HER2 homodimerisation only occurs when it is expressed at high levels
(Citri and Yarden 2006). The phosphorylated tyrosine residues interact with multiple
intracellular signalling molecules leading to activation of downstream pathways.
Signalling through the phosphatidylinositol 3'-kinase (PI3K)–Akt–mammalian target
of rapamycin (mTOR) pathway inhibits apoptosis, while the rat sarcoma (RAS)-
receptor activation factor (RAF)-mitogen extracellular signal kinase (MEK)-mitogen-
activated protein kinase (MAPK)-pathway activates cell proliferation (Hudis 2007).
HER2 is the preferred dimerisation partner for HER1 (epidermal growth factor
receptor, EGFR), HER3 and HER4, since its dimerisation domains are continually
exposed. HER3 is activated by the ligand neuregulin-1 but does not have any
tyrosine kinase activity and thus it must form heterodimers to effect intracellular
signalling. HER3 has multiple sites which can interact with PI3K, thus HER2-HER3
heterodimers are potent activators of the anti-apoptosis pathway PI3K-Akt-mTOR
(Citri and Yarden 2006; Moasser 2007).
HER2 can also be activated by forming complexes with other transmembrane
receptors. For example, HER2 interacts with insulin-like growth factor receptor-1,
which contributes to resistance against the HER2 targeted monoclonal antibody,
trastuzumab (Nahta, Yuan et al. 2005). The oestrogen receptor can activate HER2
signalling and HER2/oestrogen receptor cross-talk has been shown to cause
tamoxifen-resistance in vitro (Shou, Massarweh et al. 2004). p95HER2 is an
aberrant form of HER2 which is constitutively active as it has lost its extracellular
domain which normally serves as an inhibitor prior to its activation by receptor
dimerisation (Molina, Saez et al. 2002). Breast cancer cells expressing p95HER2
are resistant to trastuzumab as it cannot bind to the extracellular domain but remain
sensitive to the receptor tyrosine kinase inhibitor, lapatinib (Scaltriti, Rojo et al.
2007).33
Figure 1.1 HER family heterodimer formation and downstream signalling, resulting in
vascular endothelial growth factor transcription and other physiological responses
required for carcinogenesis. Adapted from (Arteaga, Sliwkowski et al. 2012).
(AR, amphiregulin; BTC, betacellulin; EPG, epigen; EPR, epiregulin; HB-EFG,
heparin-binding EGF-like ligand; NRG, neuregulin, TGF; transforming growth factor)
1.2.2 Prognostic significance of HER2 in breast cancer
Between 1987 and 2009, 107 studies involving 39,730 patients have assessed the
role of HER2 status in breast cancer. The majority of these studies (88%) have
confirmed that either HER2 gene amplification or HER2 protein expression levels
predict breast cancer outcome by univariate or multivariate analysis (Ross,
Slodkowska et al. 2009).
HER2 overexpression occurs less frequently with invasive lobular carcinoma than
with invasive ductal carcinoma but when present in either, it confers a significantly
worse prognosis (Rosenthal, Depowski et al. 2002). HER2 status is frequently
associated with high grade invasive carcinoma (Ross, Slodkowska et al. 2009).
HER2 overexpression is consistently associated with extra-mammary and intra-
mammary Paget’s disease (Fu, Lobocki et al. 2001). In node positive breast cancer,
HER2 overexpression is associated with a poor outcome but in node negative34
disease, the prognostic value of HER2 status is less certain (Quenel, Wafflart et al.
1995).
The introduction of anti-HER2 therapy has altered the prognosis as well as the
pattern of distribution of metastatic HER2-positive breast cancer. Previously, HER2-
positive breast cancer was more likely to spread to the major viscera. However,
since the advent of anti-HER2 therapy, progressive metastatic extra-cranial disease
has diminished and has been superseded by central nervous system involvement
(Lin and Winer 2007).
1.2.3 Rate and clinical implications of HER2 discordance in breast cancer
Turner et al. identified 60 studies reporting HER2 discordance; interestingly both
HER2 loss and HER2 gain were reported in many of these studies. The reviewed
studies were assigned to three different categories (Turner and Di Leo 2013):
i. The primary tumour and distant metastases, HER2 discordance rates were 0-
34% in 21 studies.
ii. The primary tumour and local regional recurrence and/or distant metastases,
HER2 discordance rates ranged from 0-22% in 25 studies.
iii. The primary tumour and synchronous lymph node metastases, HER2
discordance rates were 0-9% in 14 studies.
In a large pooled analysis of two prospective studies involving 289 patients, the
reported rate of HER2 discordance assessed by fluorescent in situ hybridisation
(FISH) between primary and corresponding recurrent disease was only 5.5% (Amir,
Clemons et al. 2012). Furthermore, there is evidence that HER2 status between
metastatic disease relapses is not stable. Lindström et al. found that HER2 status
changed in 15.7% (5/32) of patients between consecutive relapses with changes
from negative to positive and vice versa (Gancberg, Di Leo et al. 2002; Lindstrom,
Karlsson et al. 2012).35
The available literature concerning the clinical impact of HER2 discordance is
limited, inconclusive and conflicting. For example, Turner et al. used nine
retrospective studies and one prospective study to determine the impact of HER2
discordance between primary disease and metastatic recurrence on survival. Based
on their analysis, HER2 loss appears to result in worse post-relapse survival and
overall survival but these data are confounded by lack of treatment in the receptor
loss setting. Although re-biopsy of metastatic relapse can lead to changes in
management, this does not occur in all patients with receptor discordance, as
clinicians are concerned by false negative or false positive histology results (Turner
and Di Leo 2013).
HER2 discordance occurs between primary and metastatic disease and between
relapses of metastatic disease. Due to the limitations of biopsies and design of
studies investigating discordance, the true rate of HER2 discordance and clinical
impact of discordance are uncertain.
1.2.4 Current methods for detecting HER2-positive breast cancer
It is important to have a standardised and validated method for accurate
assessment of HER2 status in breast cancer. HER2 status can be determined by
either HER2 protein expression or gene amplification. Methods employed to test
HER2 protein expression include immunohistochemistry (IHC), western blotting and
enzyme-linked immunosorbent assay (ELISA) of tumour cytosol. Southern blotting,
chromogenic in situ hybridisation (CISH), polymerase chain reaction (PCR) and
fluorescent in situ hybridisation (FISH) have been used to assess HER2 gene
amplification (Ross 2009).
Southern blotting, western blotting and PCR require large amounts of tissue, they
are prone to false negatives due to combined analysis with surrounding benign
tissue and false positives due to combined analysis with adjacent in situ HER2
expressing benign breast disease (Moreno, Lloveras et al. 1997; Pegram, Pauletti et
al. 1998). By contrast, FISH and IHC correlate HER2 expression with tissue
morphology so are able to identify both benign surrounding tissue and in situ
disease, limiting the risks of both false positives and false negatives.36
1.2.4.1 HER2 Immunohistochemistry
According to the American Society of Clinical Oncologists (ASCO) / College of
American Pathologists (CAP) guideline update, a positive HER2 IHC test result
(score 3+), is defined as circumferential membrane staining that is complete,
intense, and within >10% of tumour cells (Wolff, Hammond et al. 2007; Wolff,
Hammond et al. 2013). The advantages of HER2 IHC analysis are that it is easy to
perform, inexpensive and widely available. However, test accuracy is affected by a
series of factors, including antibody sensitivity, antibody specificity, assay dilution
and antibody clonality (monoclonal or polyclonal). The method of tissue fixation is
important; fresh frozen tissue is preferable as paraffin-embedded tissues limit
antibody access to the HER2 epitope (Press, Hung et al. 1994; Vani, Sompuram et
al. 2008). Furthermore, inaccuracies can occur as a result of interpretation errors
(Vani, Sompuram et al. 2008).
The US Food and Drug Administration (FDA) have approved the HercepTest (Dako)
which utilises a polyclonal antibody (Jacobs, Gown et al. 1999). The Pathway kit
(Ventana) which utilises a monoclonal antibody for HER2 IHC testing is also FDA
approved (Powell, Hicks et al. 2007).
1.2.4.2 HER2 fluorescent in situ hybridisation
FISH combines simultaneous evaluation of tissue morphology and gene
amplification. In contrast to IHC, it is less affected by tissue fixation and analytical
variables, while being reliable, sensitive, reproducible and accurate. However, FISH
is more labour intensive and complex than IHC (Shah and Chen 2011).
According to the ASCO/CAP guideline update, a positive result for HER2 gene
amplification by FISH is either ≥ 6 HER2 gene copies per cell or a FISH ratio of 
HER2 gene signals to centromere chromosome 17 (CEP17) signals ≥ 2.0 (Wolff, 
Hammond et al. 2013). The FDA has approved the PathVysion (Abbott Molecular),
INFORM (Ventana) and HER2 FISH pharmDx (Dako) for HER2 FISH testing.
PathVysion and HER2 FISH pharmDx use probes targeting CEP17 and HER2 gene,
enabling calculation of a HER2/CEP17 ratio. While INFORM uses a single probe
targeting the HER2 gene.37
Conventionally, the number of CEP17 signals has been assumed to reflect the
number of copies of chromosome 17 in the tumour cell. Thus, tumours with
increased CEP17 signals have been thought to represent tumour chromosome 17
polysomy. On this basis, the incidence of polysomy 17 in invasive breast cancer has
been reported in 20-30% of invasive breast carcinoma patients (Shah, Wang et al.
2009). However, the HER2 gene is located near the centromere, so both CEP17
and HER2 could be co-amplified in the absence of true chromosome 17 polysomy
and this may result in under reporting of HER2 gene amplification by FISH (Yeh,
Martin et al. 2009). Probes for other chromosome 17 genes can be used to
distinguish between centromere amplification and true polysomy. Patients with
increased mean CEP17 and HER2 copy numbers (or assumed polysomy) who had
been classified as unequivocal or non-amplified were reclassified as HER2 amplified
when other chromosome 17 genes were co-evaluated. Although this re-classification
affects approximately 3% of breast cancer patients it would be worth assessing
chromosome 17 reference genes among patients assessed as unequivocal and
non-amplified by FISH (Tse, Hwang et al. 2011). However, the 2013 ASCO/CAP
guideline update does not require the discrimination of true polysomy from
centromere amplification (Wolff, Hammond et al. 2013).
1.2.4.3 Correlation between HER2 IHC and FISH
There is good concordance between tumours which score 0, 1+ & 3+ on IHC and
FISH test results. The concordance rate is 96% using single probe FISH testing and
97% for dual probe FISH testing which co-utilises CEP17 signals (Lal, Salazar et al.
2004). Disagreement between IHC 3+ and FISH may be due to intra-tumour
heterogeneity, variable processing, variable tissue fixation and difficulty
distinguishing between chromosome 17 centromere amplification and genuine
polysomy (Shah and Chen 2011). By contrast, one quarter of breast tumours which
have an IHC score 2+ are HER2-positive on FISH testing (Lal, Salazar et al. 2004).
Parallel assessment of 2963 breast cancer specimens from 135 different hospitals
demonstrated that FISH has a significantly higher failure rate (5% vs. 0.08%), longer
testing time (36 h vs. 4 h), longer interpretation time (7 minutes vs. 45 seconds) and
higher reagent cost ($140 vs. $10) than IHC. The authors recommended the broad
use of IHC and only limited use of FISH for IHC 2+ cases, which is supported by the38
ASCO/CAP guideline update (Yaziji, Goldstein et al. 2004; Wolff, Hammond et al.
2013).
1.2.5 Treatment for HER2-positive breast cancer
In modern clinical trials, HER2-positive breast cancer patients are defined as
patients with tumours with an IHC score 3+ or a FISH amplification ratio ≥  2.0, thus 
in keeping with the ASCO/CAP guideline update (Baselga, Cortes et al. 2012; Wolff,
Hammond et al. 2013).
1.2.5.1 Trastuzumab
Trastuzumab was the first anti-HER2 therapy and further anti-HER2 therapies are
now available which target both the HER2 extracellular and intracellular pathway.
Anti-HER2 therapies have dramatically improved the prognosis of early and
advanced HER2-positive breast cancer. HER2 status is the most important factor for
predicting responses to anti-HER2 therapies.
Trastuzumab is a humanised monoclonal antibody, widely used for HER2-positive
patients in the neo-adjuvant, adjuvant and metastatic setting. Although trastuzumab
is approved as a single agent therapy it is frequently combined with chemotherapy.
Trastuzumab is composed of two antigen-specific sites which bind to the
juxtamembrane portion of the HER2 receptor extracellular domain (ECD: subdomain
4) and the remainder of the antibody is a human immunoglobulin (Ig) G1 with a
conserved fragment crystallisable region (Fc). Binding of trastuzumab to HER2
suppresses downstream signalling; resulting in cell cycle arrest and reduced
angiogenesis (Figure 1.1). Trastuzumab recruits immune effector cells which are
responsible for antibody-dependent cell-mediated cytotoxicity (ADCC), prevents
HER2 ECD cleavage from forming p95HER2 and increases endocytotic HER2
receptor destruction but has a limited effect on HER2 heterodimerisation (Hudis
2007).
In the seminal phase III trial, Slamon et al. compared chemotherapy alone with
combined chemotherapy and trastuzumab for patients receiving first line treatment
for metastatic HER2-positive disease determined by IHC (Table 1.1). Patients
received combination chemotherapy consisting of anthracycline (doxorubicin or39
epirubicin) and cyclophosphamide or single-agent paclitaxel if they had previously
received adjuvant anthracycline chemotherapy. Combining chemotherapy with
trastuzumab significantly increased the median time to disease progression (7.4
months vs. 4.6 months, p<0.001), objective response rate (50% vs. 32%, p<0.001)
and median survival (25.1 months vs. 20.3 months, p=0.046). Cardiac dysfunction
assessed using the New York Heart Association criteria was higher among patients
who received trastuzumab with chemotherapy compared to their counterparts who
received anthracycline-cyclophosphamide alone (27% vs. 8%) and paclitaxel
chemotherapy alone (13% vs. 1%) (Slamon, Leyland-Jones et al. 2001). In a
subsequent study for patients receiving first line therapy for metastatic HER2-
positive disease, combined docetaxel and trastuzumab increased the median time
to disease progression (11.7 months vs. 6.1 months, p=0.0001) and median survival
(31.2 months vs. 22.7 months, p=0.325) compared to docetaxel alone. Only 1% of
patients who received docetaxel-trastuzumab experienced symptomatic heart failure
(Marty, Cognetti et al. 2005).
Table 1.1 Seminal phase III anti-HER2 therapy trials in patients with advanced
HER2-positive breast cancer.
Trial Patients (n) Treatment Median
progression-
free survival
(PSF) or time
to progression
(TTP)
(p value)
Median
overall
survival
(p value)
Trastuzumab
and
chemotherapy
(Slamon,
Leyland-Jones
et al. 2001)
First line treatment
for metastatic
breast cancer
(469)
Chemotherapy
Chemotherapy + trastuzumab
4.6 months
7.4 months
(p<0.001)
TTP
20.3 months
25.1 months
(p=0.046)
Lapatinib and
capecitabine
(Cameron,
Casey et al.
2008)
Trastuzumab-
refractory
metastatic breast
cancer
(399)
Capecitabine
Capecitabine + lapatinib
4.3 months
6.2 months
(p<0.001)
TTP
15.3 months
15.6 months
(p=0.177)
CLEOPATRA
(Baselga,
Cortes et al.
2012)
First line treatment
for metastatic
breast cancer
(808)
Pertuzumab, trastuzumab + docetaxel
Placebo, trastuzumab + docetaxel
18.5 months
12.4 months
(p<0.001)
PFS
Not reported
Not reported
EMILIA
(Verma, Miles et
al. 2012)
Trastuzumab-
refractory
metastatic breast
cancer
(991)
T-DM1
Lapatinib + capecitabine
9.6 months
6.4 months
(p<0.001)
PFS
30.9 months
25.1 months
(p<0.001)
TTP: time from randomisation to time of progressive disease (deaths are censored).
PFS: time from randomisation to objective tumour progression or death.40
In the adjuvant setting, four large randomised phase III studies have assessed
combined trastuzumab with chemotherapy for HER2-positive disease; NSABP B-31,
Herceptin Adjuvant (HERA), North Central Cancer Treatment Group N9831 and
Breast Cancer International Research Group (BCIRG) 006 trials. The addition of one
year of trastuzumab to adjuvant chemotherapy increases disease-free survival and
overall survival (Piccart-Gebhart, Procter et al. 2005; Romond, Perez et al. 2005;
Joensuu, Kellokumpu-Lehtinen et al. 2006; Slamon, Eiermann et al. 2011). For
example, BCIRG 006 demonstrated that at a median follow up 65 months, the
overall survival rate was 87% for patients who received adjuvant chemotherapy
alone compared to 91-92% (p<0.05) for patients who received adjuvant trastuzumab
combined with chemotherapy (Slamon, Eiermann et al. 2011). However, 2 years of
adjuvant trastuzumab does not improve disease-free survival (p=0.86) and overall
survival (p=0.63) compared to 1 year of adjuvant trastuzumab (Table 1.2).
Table 1.2 Seminal phase III adjuvant trastuzumab trials in patients with HER2-
positive early stage breast cancer.
Trial Name
(follow up)
Patients (n) Treatment Disease-free survival
(p value)
Overall
survival
(p value)
BCIRG 006
(65 months)
(Slamon,
Eiermann et al.
2011)
Node positive or
high risk node
negative
(3,222)
Dox-Cyclo Docetaxel
Dox-Cyclo Docetaxel-T
Docetaxel-Carbo-T
75%
84% (p<0.001 vs.
chemo alone)
81% (p<0.04 vs.
chemo alone)
87%
92% (p<
0.001 vs.
chemo alone)
91% (p=0.04
vs. chemo
alone)
HERA
(8 years)
(Goldhirsch,
Gelber et al. 2013)
Node positive or
high risk node
negative
completed
adjuvant
chemotherapy
(5,099)
Observation
T for 1 year
T for 2 years
64.8%
71.2% (p<0.0001 vs.
observation)
71% (p<0.0001 vs.
observation)
77.4%
82.7%
(p=0.0001 vs.
observation)
82.4%
(p=0.0001 vs.
observation)
(Carbo, carboplatin; Chemo, chemotherapy; Cyclo, cyclophosphamide; Dox, doxorubicin; T, trastuzumab)
1.2.5.2 Pertuzumab
Trastuzumab can prevent spontaneous formation of homodimers (HER2-HER2) and
ligand-independent heterodimer (HER2-HER1, HER2-HER3 and HER2-HER4), by
binding to subdomain 4 of the HER2 ECD but cannot prevent ligand-induced HER2
heterodimers. Pertuzumab is an IgG1 class humanised monoclonal antibody which
binds to the dimerisation domain (subdomain 2) of the HER2 ECD, blocking ligand-
induced HER2 heterodimerisation, including the potent HER2-HER3 heterodimer.41
Pertuzumab can also induce ADCC. (Agus, Gordon et al. 2005; Metzger-Filho,
Winer et al. 2013).
In a phase III study patients with metastatic HER2-positive disease received
trastuzumab and docetaxel with or without pertuzumab as first line therapy. The
addition of pertuzumab increased median progression-free survival from 12.4
months to 18.5 months (p<0.001) and the interim analysis of overall survival showed
a strong trend in favour of the pertuzumab treatment arm. Furthermore, the addition
of pertuzumab does not adversely affect the side effect profile of chemotherapy and
trastuzumab, including left ventricular dysfunction (Table 1.1) (Baselga, Cortes et al.
2012). In a phase II neo-adjuvant study, patients with early HER2-positive breast
cancer who received combined pertuzumab with trastuzumab-docetaxel therapy had
significantly improved pathological complete response (pCR) rates compared with
patients who received trastuzumab-docetaxel therapy alone (49% vs. 31%,
p=0.0141). Pertuzumab is currently being investigated in the adjuvant setting
(Gianni, Pienkowski et al. 2012).
1.2.5.3 Lapatinib
Lapatinib is an oral receptor tyrosine kinase inhibitor of HER1 and HER2. It is
approved for use in combination with capecitabine for trastuzumab-refractory HER2-
positive metastatic breast cancer. In a phase III trial, the median time to progression
was increased from 4.3 months for capecitabine alone to 6.3 months (p<0.001) with
combined treatment (Table 1.1). The addition of lapatinib did not significantly
improve overall survival (HR: 0.78, 95% CI: 0.55-1.12, p=0.177) but did significantly
improve the overall response rate (24% vs. 14%, p=0.017) (Cameron, Casey et al.
2008).
1.2.5.4 Trastuzumab emtansine
Trastuzumab emtansine (T-DM1) is an antibody drug-conjugate which enables
specific delivery to HER2 expressing cells. T-DM1 is composed of the cytotoxic anti-
microtubule agent DM1, a maytansine 1 derivative conjugated with trastuzumab via
the linker [N-maleimidomethyl]cyclohexane-1-carboxylate (MCC). On average there
are 3.5 DM1 molecules conjugated to the Fc region of trastuzumab via MCC linkers
(Lewis Phillips, Li et al. 2008; Krop, Beeram et al. 2010). In the EMILIA phase III42
trial, T-DM1 significantly prolonged progression-free survival (9.6 vs. 6.4 months,
p<0.001) and overall survival (30.9 vs. 25.1 months, p<0.001) for patients with
advanced trastuzumab refractory HER2-positive metastatic disease compared to
capecitabine and lapatinib combined (Table 1.1). In addition, T-DM1 had lower rates
of grade 3 or 4 adverse events than combined capecitabine and lapatinib; 41% vs.
57% (Verma, Miles et al. 2012).
1.3 Molecular Imaging
Molecular imaging is defined as the visualisation, characterisation and measurement
of biological processes at the molecular and cellular level (Mankoff 2007). There is a
great need to develop molecular imaging in cancer medicine for HER2 and other
important molecular biomarkers. Histological analysis remains vital but it is neither
feasible nor safe to biopsy multiple metastatic sites in each patient. Furthermore,
histology is limited by single site and single time point sampling, intra-tumour
heterogeneity, tumour accessibility and tumour evolution resulting in discordance
between disease relapses. Whilst conventional imaging lacks specificity and
sensitivity, particularly for sub-centimetre lesions, in addition it does not inform
clinical decisions regarding molecular targeted agents.
Molecular imaging potentially offers whole body, real-time information, which can
evaluate expression of a molecular marker with implications for treatment and
prognosis. It has the potential to enhance the sensitivity and specificity of cancer
imaging.
HER2 imaging using single photon emission computed tomography (SPECT) and
positron emission tomography (PET), could potentially be used to inform clinical
decisions in the treatment of patients with advanced breast cancer. Firstly, HER2
imaging could be used to identify patients who were HER2-negative at the outset
but become HER2-positive during follow-up and thus could benefit from anti-HER2
therapy. Secondly, it could be used to monitor patients receiving anti-HER2 therapy
who develop HER2-negative disease, these patients would either require cessation
of anti-HER2 therapy or additional combination therapy. The cost of anti-HER2
therapy is considerable and better methods are needed in order to inform clinical43
decisions to start and stop these therapies. HER2 imaging may prove to be a cost
effective way of achieving this (Goldstein, Sosabowski et al. 2013).
1.3.1 Nuclear medicine imaging modalities
SPECT and PET molecular imaging are based on the detection of radiolabelled
ligands. Ideally, the physical half-life of the selected radioisotope should match the
biological half-life of the ligand.
1.3.1.1 Single photon emission computed tomography
Radioisotopes used in SPECT imaging emit single gamma photons which are
detected by a gamma camera. Detection of single photons provides no information
about the direction of travel, so photons are filtered by a lead collimator containing
small parallel holes which excludes photons that do not travel perpendicular to the
detector surface. Counting events are acquired using detectors that rotate around
the subject from which 3-dimensional images can be reconstructed using a
computer algorithm.
1.3.1.2 Positron emission tomography imaging
The radioisotopes used in PET scanning emit positrons. Each positron combines
with an electron, which then annihilate and convert into two 511 keV gamma
photons which are emitted in opposite directions, 180 ± 0.5° apart. The PET camera
contains a ring of oppositely paired detectors (coincidence coupled detectors) which
identify the two gamma photons simultaneously (a coincidence event) and
determines their direction of travel. There is therefore no need for a lead collimator
and events without an equal and opposite event are excluded as scatter events.
Most cancers exhibit increased glucose metabolism, which may be partly driven by
cancer growth in the presence of a strained blood supply, resulting in hypoxia.
Hypoxic conditions upregulate the GLUT1 glucose transporter and stimulate
anaerobic glycolysis. However, under normoxia and hypoxia, cancer cells
demonstrate accelerated glucose metabolism compared to non-cancer cells, which
may  be  partly  related  to  hypoxia-inducible  factor  (HIF)-1α  up-regulation  and 
oncogenic mutations (Wahl, Herman et al. 2011).44
Fluorine18-fluorodeoxyglucose (
18F-FDG) positron emission tomography (PET)/CT
can identify tumour sites with high levels of glucose uptake and is used to image a
range of solid malignancies and lymphoma.
18F-FDG-PET has an established role in
staging patients with potentially operable high risk breast cancer, since PET has
equal sensitivity to conventional CT in detecting metastatic disease but leads to
fewer false-positive results in this setting (Port, Yeung et al. 2006). Preliminary
studies have not shown any convincing evidence that the maximum standardized
uptake value (SUVmax) on
18F-FDG-PET scans can distinguish between HER2-
positive and HER2-negative disease in high risk operable breast cancer (Osborne,
Port et al. 2010). Thus, an alternative approach is required to image HER2-positive
disease.
1.3.1.3 Comparison of single photon emission computed tomography and
positron emission tomography imaging
PET has a higher sensitivity than SPECT imaging by approximately two to three
orders of magnitude, as PET is able to detect a higher proportion of emitted events.
As discussed, SPECT rejects photons which do not approach the lead collimator at
the correct angle to pass through its holes; consequently SPECT detects
approximately 0.01% of emitted events. Physical collimators are not required for
PET imaging, as each positron interaction with an electron, generates two photons
which travel in opposite directions reaching the oppositely paired PET cameras
simultaneously (coincidence detection). Consequently, approximately 1% of emitted
events are detected by PET (Rahmim and Zaidi 2008).
The enhanced sensitivity of PET has important advantages compared to SPECT.
PET has improved signal-to-noise ratios and higher spatial resolution (~5 mm vs.
~10 mm) (Zanzonico 2012). In addition, PET has a shorter scan acquisition time and
more accurate data quantification compared to SPECT (Rahmim and Zaidi 2008).
An advantage of SPECT is that its radiotracers typically have longer half-lives than
PET tracers. Thus, SPECT can be used to analyse slower biological processes,
such as the localisation of monoclonal antibodies to tumours which can take several
days (Wahl, Herman et al. 2011).45
1.3.2 HER2 molecular imaging
A range of immunoglobulins, immunoglobulin-derivatives and non-immunoglobulin
binding proteins have been investigated for HER2 molecular imaging (Table 1.3).
Assessed immunoglobulin-derivatives include fragment antigen binding (Fab)
regions of antibodies, diabodies which are composed of non-covalent single chain
fragment variable (scFv) dimers and nanobodies consisting of a solitary heavy chain
(Figure 1.2). Non-immunoglobulin binding proteins developed for HER2 imaging
include affibody molecules (Figure 1.3) and designed ankyrin repeat proteins (Figure
1.5).
Figure 1.2 IgG antibody and its derivatives; fragment antigen binding (Fab) regions,
F(ab’)2, diabody and nanobody with their approximate molecular weights.
The properties of the ‘ideal’ radioligand for molecular imaging; include the ability to
reach the tumour site(s) rapidly, efficient extravasation, good tissue penetration,
high affinity for the target and high specificity for the tumour. Meanwhile unbound
ligand should be rapidly excreted from the bloodstream with limited hepatic uptake,46
facilitating high contrast images and reducing the time between infusion and optimal
image acquisition (Table 1.4).
Table 1.3 Human HER2 imaging trials in advanced breast cancer.
Imaging
agent
Imaging
modality
No. of patients
&
characteristics
No. patients all
tumours identified
by HER2 imaging
New lesions
identified
Limitations
Copper-64
Trastuzumab
(Mortimer,
Bading et al.
2013)
PET 8
metastatic and
HER2-positive
patients
Unknown
Overall 89% of all
lesions identified at 2
days post Copper-64
Trastuzumab
Comparator:
18F-FDG
PET and CT
None -Lower sensitivity
than
18F-FDG-PET
(93%)
-Incomplete whole
body imaging
-Difficulty visualising
lymph nodes
Zirconium-89
Trastuzumab
(Dijkers, Oude
Munnink et al.
2010)
PET 14
metastatic &
HER2-positive
patients
6 of 12 patients (50%)
who received
sufficient doses
Comparator: CT, MRI
& Bone scan
2 patients with
brain lesions,
confirmed by
MRI
-Low Sensitivity
-No biopsies to
confirm specificity
Indium-111
Trastuzumab
(Perik, Lub-De
Hooge et al.
2006)
SPECT 17 recruited
(15 assessed)
metastatic &
HER2-positive
Unknown
Overall 45% of all
known tumour lesions
identified & only 1
patient no tumour
lesions identified.
Comparator: routine
staging including CT
13 patients
new lesions
identified (but
none biopsied)
-Low Sensitivity
-No biopsies to
confirm specificity
Gallium-68
F(ab’)2-
trastuzumab
(Beylergil,
Morris et al.
2013)
PET 15 metastatic
patients,
including HER2-
positive (n=8)
& HER2-
negative (n=7)
0 of 8 HER2-positive
patients, including 4
HER2+ patients no
lesions identified
Among the 7 HER2-
negative patients no
lesions identified.
Comparator:
18F-
FDG-PET
None -Low sensitivity and
not confirmed by
biopsies.
1
st generation
affibody
molecule
(ABY-002)
with
Indium-111
and
Gallium-68
(Baum, Prasad
et al. 2010)
SPECT
(Indium-
111)
and
PET
(Gallium-
68)
3
metastatic &
HER2-positive
patients
1 of 3 patients.
-Patient 1: 4 of 5
known lesions
-Patient 2: 0 of 2
known lesions
-Patient 3: 5 of 5
known lesions
Comparator :
18F-FDG
PET/CT.
Chest wall
lesion (not
biopsied)
Sartorius
muscle lesion
(biopsy, HER2
IHC score 2+)
-High background
liver & kidney
uptake
2
nd generation
affibody
molecule
(ABY-025) with
Indium-111
(Sorensen,
Sandberg et al.
2014)
SPECT 7 metastatic
patients,
including HER2-
positive (n=5) &
HER2-negative
(n=2) primary
disease
2 of 7 patients None -24/4h tumour
uptake ratio to
determine HER2
status requires
scans over 2 days47
Table 1.4 Pharmacokinetic and physical properties of an ‘ideal’ radioligand for
molecular imaging.
Stages ‘Ideal’ pharmacokinetics and physical properties
Extravascular accumulation Efficient extravasation
Good tissue penetration
Tumour identification High tumour affinity
High tumour specificity
High tumour retention
Biodistribution Low normal tissue retention
Excretion Rapid clearance from bloodstream & whole body
1.3.3 Antibody based imaging
IgG molecules have high affinity for target antigens and ideal pharmacokinetics for
therapeutic applications. Their long half-life limits application for molecular imaging.
As sufficient blood clearance is required to achieve optimal tumour-to-blood ratios
prior to imaging but during this time interval tumour uptake can fall. Furthermore,
their large molecular weight (150 kDa) results in low tumour penetration (Figure 1.2).
Radiolabelled trastuzumab and pertuzumab have been investigated in pre-clinical
imaging studies and radiolabelled trastuzumab has been tested in clinical imaging
trials (Table 1.3).
Antibody based single photon emission computed tomography
Trastuzumab radiolabelled with indium-111 (
111In; half-life 2.8 days) via
diethylenetriamine penta-acetic acid (DTPA) has been developed for clinical SPECT
imaging.
111In-DTPA-trastuzumab has high stability, high labelling yields, high
immunoreactivity and maintains the internalisation properties of trastuzumab (Lub-
de Hooge, Kosterink et al. 2004).
In mice xenografts,
111In-DTPA-trastuzumab uptake was significantly higher in mice
bearing HER2-positive tumours from the human ovarian cancer cell line, SKOV3,
than in mice bearing HER2-negative tumours from the human small cell lung cancer
cell line, GLC4. At 48 h,
111In-DTPA-trastuzumab HER2-positive tumour uptake
peaked at 16.30±0.64 percent of the injected radioactive dose per gram of tissue (%
ID/g), while for HER2-negative tumours it was 4.40±0.70 % ID/g (p<0.001).
111In-48
DTPA-trastuzumab was cleared slowly from blood, so the tumour-to-blood ratio was
<3 over 48 h and the tumour-to-blood ratio only reached 6 at 168 h. In addition, the
liver, kidneys and spleen had high
111In-DTPA-trastuzumab uptake. Interestingly,
HER2-positive metastases had higher uptake than their corresponding HER2-
positive primary tumours in mouse xenografts (Lub-de Hooge, Kosterink et al.
2004). In breast cancer xenografts, corrected
111In-DTPA-trastuzumab tumour
uptake can differentiate between HER2 IHC scores 0 to 3+, provided circulating
radioactivity and non-specific antibody localisation are taken into consideration. The
uncorrected
111In-DTPA-trastuzumab tumour uptake was associated with a tumour
response to trastuzumab in mouse xenografts (McLarty, Cornelissen et al. 2009).
A clinical trial, assessed 15 patients with metastatic HER2-positive breast cancer
receiving paclitaxel and trastuzumab by
111In-DTPA-trastuzumab SPECT scanning
(5 mg, 100-150 MBq) during the first and twelfth week of their treatment (Table 1.3).
Planar whole body imaging using a two headed gamma camera was performed at
five time points over 7 days post-administration of
111In-DTPA-trastuzumab.
111In-
DTPA-trastuzumab SPECT imaging identified 45% of tumour lesions seen by
conventional imaging and one patient had no visible lesions on HER2 scanning. For
most patients more tumour lesions were visualised on HER2 scans performed
during the first week of treatment than after 12 weeks of paclitaxel and trastuzumab.
For 13 patients, lesions not previously identified by conventional scanning were
identified by HER2 SPECT scans performed during the first week of treatment but
no biopsies were performed to assess the HER2 status of the new lesions (Perik,
Lub-De Hooge et al. 2006).
In the absence of biopsies from lesions seen on conventional imaging but not
detected on HER2 SPECT scans and vice versa, it is not possible to assess the
accuracy of
111In-DTPA-trastuzumab SPECT scanning. The assumed low detection
rate (45%) could be due to limitations in identifying small tumours. It could also
reflect the unsuitable pharmacokinetics of antibodies for imaging, including low
tumour-to-blood ratios which limit the identification of tumour sites even at later
imaging time points. (Perik, Lub-De Hooge et al. 2006).49
In pre-clinical tests,
111In-DTPA-pertuzumab SPECT scans detected HER2 down
regulation following trastuzumab therapy. In mice bearing HER2-positive tumours
(MDA-MB-361),
111In-DTPA-pertuzumab tumour uptake decreased 2-fold after three
days of trastuzumab and 4.5-fold after three weeks of trastuzumab compared to
phosphate buffered saline (PBS) treated controls. Following three weeks of
trastuzumab, the decreased
111In-DTPA-pertuzumab uptake was associated with
reduced HER2 expression and elimination of tumour cells assessed by IHC. If down
regulation of HER2 detected by
111In-DTPA-pertuzumab SPECT imaging correlates
with clinical response then it could be used as an early predictor of trastuzumab
response and non-responders could commence an alternative therapy sooner
(McLarty, Cornelissen et al. 2009).
Antibody based positron emission tomography
Antibody based PET imaging requires positron emitters with a relatively long half-life
to enable image acquisition several days post-infusions, when tumour-to-blood
ratios reach sufficiently high levels for scanning. Zirconium-89 (
89Zr; half-life 3.3
days) radiolabelled trastuzumab has been developed for HER2 PET imaging, as its
half-life enables imaging up to 7 days post-infusion. The radiolabelling efficiency
after conjugation with the succinylated derivative of desferrioxamine B (N-SucDf)
chelating group and ultrafiltration was 98.1±1.1 %, similar to that achieved with
111In-
DTPA-trastuzumab.
89Zr-trastuzumab was stable in vitro for up to 7 days, had
preserved high binding for HER2-positive cells (SKOV3) and low binding for HER2-
negative cells (GLC4) (Dijkers, Kosterink et al. 2009).
The biodistribution of
89Zr-trastuzumab and
111In-trastuzumab were compared in
HER2-positive (SKOV3) and HER2-negative (GLC4) tumour bearing mice. Both
radioligands achieved significantly higher uptake in the HER2-positive tumours than
HER2-negative tumours at day 1 and by day 6 the differences between HER2-
positive and HER2-negative tumour radioligand uptake were even greater. For
89Zr-
trastuzumab and
111In-trastuzumab blood levels (%ID/g) fell by over 3-fold from day
1 to day 6, resulting in optimal tumour-to-blood and tumour-to-normal tissue ratios 6
days post-administration. For both
89Zr-trastuzumab and
111In-trastuzumab, the liver
and spleen had the highest normal tissue uptake (Dijkers, Kosterink et al. 2009).50
89Zr-trastuzumab HER2 PET imaging has been used to assess changes in HER2
expression of SKOV3 tumour bearing mice treated with NVP-AUY922, a heat shock
protein 90 (Hsp90) inhibitor, since HER2 down regulation is a potential biomarker for
early response. MicroPET imaging demonstrated a 41% reduction in
89Zr-
trastuzumab tumour uptake after NVP-AUY922 therapy. The PET scan results were
confirmed by ex vivo
89Zr-trastuzumab biodistribution and HER2 IHC staining (Oude
Munnink, Korte et al. 2010).
The
89Zr-trastuzumab PET trial recruited 14 patients with HER2-positive metastatic
breast cancer to determine the optimal dosage and timing for imaging (Table 1.3).
Patients received 37 MBq of
89Zr-trastuzumab intravenously and were tested in
three cohorts. Trastuzumab-naïve patients received 10 mg (cohort 1, n=2) or 50 mg
(cohort 2, n=5), while patients receiving concomitant trastuzumab received 10 mg
(cohort 3, n=7). Each dose consisted of
89Zr-trastuzumab (~1.5 mg) and non-
radioactive trastuzumab (~8.5 or 48.5 mg). Each patient had a PET scan at an early
time point (1-3 days) and later time point (4-7 days) post
89Zr-trastuzumab
administration (Dijkers, Oude Munnink et al. 2010).
For trastuzumab-naïve patients, 10 mg trastuzumab produced sub-optimal tumour
imaging with a low blood pool, high liver uptake and enhanced intestinal excretion,
probably due to rapid hepatic clearance. However, 50 mg trastuzumab administered
to naïve patients resulted in lower liver uptake, lower intestinal excretion, prolonged
serum pooling and reasonable tumour-to-non-tumour ratios. Trastuzumab has dose-
dependent pharmacokinetics, as its terminal half-life is extended by increased
trastuzumab exposure, possibly due to saturable elimination of low doses from
circulation, thus supporting this finding. Serum HER2 ECD levels can fall during
trastuzumab therapy and the authours’ hypothesised that HER2 ECD could have
bound to the administered trastuzumab in treatment-naïve patients, resulting in
enhanced hepatic clearance. However, serum HER2 ECD levels were not measured
to confirm this (Leary, Hanna et al. 2009; Dijkers, Oude Munnink et al. 2010).
For patients receiving concomitant trastuzumab the 10 mg trastuzumab dose was
adequate as it was associated with slow serum clearance. The optimal time to
perform
89Zr-trastuzumab PET scans was at 4-5 days post-administration, as there51
was time for blood clearance and there was sufficient tumour uptake, resulting in
good tumour-to-non-tumour ratios (Dijkers, Oude Munnink et al. 2010).
Although cohorts 2 and 3 had sufficient
89Zr-trastuzumab in circulation, in six of
these twelve patients
89Zr-trastuzumab PET did not detect all known tumour lesions.
Liver lesions were not visualised in three of the seven patients with known liver
metastases, including two patients in cohort 2 and one patient in cohort 3. Bone
lesions were not visualised in two of the nine patients with known bone metastases,
both patients were in cohort 3. Three patients had known lung metastases (all in
cohort 3) which were only detected in one patient by
89Zr-trastuzumab PET
scanning. Yet, brain metastases were identified in three patients; this was a new
finding for two patients, subsequently confirmed by MRI brain scans. The mean
relative uptake value (RUVmean) was highest in liver metastases which was
significantly higher than the normal liver, 12.8±5.8 vs. 5.9±2.4, p=0.007. In addition,
RUVmean for brain metastases and bone metastases were significantly higher than
their normal surrounding tissue (Dijkers, Oude Munnink et al. 2010).
No biopsies were performed in the study, so the level of HER2 expression required
for
89Zr-trastuzumab tumour uptake on PET imaging is unknown. In the absence of
biopsies, it is unclear whether the relatively low rate of HER2 tumour detection (50%
for cohort 2 and 3 combined) was due to variable HER2 tumour expression or
limitations of
89Zr-trastuzumab PET imaging (Dijkers, Oude Munnink et al. 2010).
Recently, a study treated metastatic breast cancer patients (HER2-positive or
oestrogen receptor-positive) with weekly intravenous NVP-AUY922. For HER2-
positive patients (n=5), the percentage change in SUVmax of lesions assessed by
89Zr-trastuzumab PET scans at baseline and after 3 weeks of treatment, positively
correlated with the percentage change in size of lesions on CT scans at baseline
and after 8 weeks of treatment. Thus, early changes on
89Zr-trastuzumab PET
could potentially predict treatment response (Gaykema, Schroder et al. 2014).
Copper-64 (
64Cu, half-life 12.8 h) conjugated with 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) to trastuzumab for PET imaging was used to
assess eight patients with HER2-positive metastatic disease, the patients had not
received anti-HER2 therapy for ≥ 4 months. An initial 
18F-FDG-PET/CT scan was52
performed to localise tumour sites, defining the axial coverage for
64Cu-DOTA
trastuzumab PET scanning, to overcome the constraints of the short half-life of
64Cu.
Two patients received 5 mg
64Cu-DOTA trastuzumab but following the publication by
Dijkers et al. all subsequent patients received 45 mg non-radiolabelled trastuzumab
immediately before
64Cu-DOTA trastuzumab to reduce non-specific liver uptake
(Dijkers, Oude Munnink et al. 2010; Mortimer, Bading et al. 2013).
64Cu-DOTA trastuzumab had a sensitivity of 89% for all CT detected tumour lesions
at 2 days post-administration, compared to 93% for
18F-FDG-PET. Inter-patient and
intra-patient heterogeneity of
64Cu-DOTA trastuzumab tumour uptake was observed,
if this reflected genuine differences in HER2 tumour expression then it could have a
role in selecting patients for anti-HER2 therapy. Non-radiolabelled trastuzumab
reduced liver uptake by 75-80% and increased blood pooling, enabling visualisation
of all liver lesions at 2 days post-administration. In the absence of patients with
HER2-negative disease, the specificity of
64Cu-DOTA trastuzumab imaging is
unknown and based on this study alone it has no advantage over
18F-FDG-PET
(Mortimer, Bading et al. 2013). Furthermore, the long half-life of trastuzumab limits
the ability of
64Cu-DOTA trastuzumab to identify lesions in areas with high blood
activity such as the mediastinum (Mortimer, Bading et al. 2013; Tamura, Kurihara et
al. 2013).
1.3.4 Antibody fragments
Radiolabelled fragment antigen binding (Fab) regions of trastuzumab have been
developed for HER2 imaging, since their lower molecular weight is associated with a
shorter circulatory half-life, which results in the faster clearance of background
radiation. Potentially, this enables both scanning at earlier time points when tumour
uptake levels are highest and shorter intervals between scans (Figure 1.2).53
Single photon emission computed tomography with antibody fragments
Among six patients with HER2-positive in situ or invasive ductal carcinoma who
received
111In-DTPA-trastuzumab Fab (50 kDa) prior to breast-conserving surgery,
SPECT scans failed to identify any of the breast tumours. The excised tumours had
low counts of radiation. Although the resection margins had higher radiation counts,
this did not correlate with the presence of tumour at the margins. Thus,
111In-DTPA-
trastuzumab Fab was not reliable in the detection of HER2-positive in situ or
invasive ductal carcinoma at the resection margin (Holloway, Scollard et al. 2013).
To improve the biodistribution and tumour uptake of Fab, Dennis et al. assessed a
bifunctional molecule, AB.Fab4D5 which can simultaneously bind to HER2 and
albumin. Histological assessment revealed tumour AB.Fab4D deposition in HER2-
positive tumour bearing mice from 2 to 24 h. By contrast, the trastuzumab derived
Fab, Fab4D5 had only transient tumour uptake at 2 h, while trastuzumab only
achieved significant tumour uptake at 24 h. On SPECT/CT scans of HER2-positive
tumour bearing mouse xenografts,
111In-AB.Fab4D5 achieved higher tumour uptake
at most time points over 48 h than either
111In-Fab4D5 or
111In-trastuzumab. As
expected, the association between AB.Fab4D5 and albumin reduced its renal
secretion compared to Fab4D5. Despite this encouraging pre-clinical study there
have been no recent updates (Dennis, Jin et al. 2007).
Positron emission tomography with antibody fragments
A F(ab’)2 fragment of trastuzumab (~110 kDa) conjugated with DOTA has been
radiolabelled with gallium-68 (
68Ga; half-life 1.14 h) for PET imaging. In pre-clinical
studies, microPET imaging with
68Ga-DOTA-F(ab’)2-trastuzumab identified
decreases in HER2 tumour expression 24 h after administration of an Hsp90
inhibitor (Smith-Jones, Solit et al. 2004). Furthermore, in mice bearing HER2-
positive human breast tumours (BT474),
68Ga-DOTA-F(ab’)2-trastuzumab PET
imaging identified HER2 down-regulation associated with Hsp90 inhibition prior to
changes in glycolysis seen on
18F-FDG-PET scanning (Smith-Jones, Solit et al.
2004; Smith-Jones, Solit et al. 2006).54
Beylergil et al. performed
68Ga-DOTA-F(ab’)2-trastuzumab PET scans on 15 patients
with metastatic HER2-positive (n=8) and HER2-negative (n=7) breast cancer who
had avid disease on
18F-FDG-PET scanning. The study population included
trastuzumab-naïve patients (n=8), patients receiving concomitant trastuzumab (n=3)
and patients who had previously received trastuzumab (n=4) (Table 1.3). There
were no significant adverse events related to
68Ga-DOTA-F(ab’)2-trastuzumab.
Although the half-life of the radioligand was short, 3.6 ± 0.9 h, there was high
background radiation uptake in the liver, blood and kidneys (Beylergil, Morris et al.
2013). Among the eight HER2-positive patients, four patients had no visible lesions
on
68Ga-DOTA-F(ab’)2-trastuzumab PET scans and
68Ga-DOTA-F(ab’)2-trastuzumab
PET imaging failed to identify all lesions among the other four patients. The
radioligand failed to identify any tumours in four of the five patients who were HER2-
positive  and  either  trastuzumab-naïve  or  had  not  received  trastuzumab  for  ≥  2 
months. There was no tumour uptake among the assessed HER2-negative patients.
It is likely that the short half-life of
68Ga (1.14 h) is not compatible with DOTA-F(ab’)2-
trastuzumab (half-life ~4h) and a radioisotope which enables imaging at later time
points is required. Based on these results this approach lacks sensitivity for routine
clinical use, even among patients who are not receiving concomitant trastuzumab.
(Beylergil, Morris et al. 2013).
1.3.5 Anti-HER2 Diabody
Diabodies are non-covalent single chain fragment variable (scFv) dimers, which can
be formed by producing scFv molecules with amino acid chain linkers between their
variable light (VL) and variable heavy (VH) chains (Figure 1.2). The VH from one
molecule associates with the VL from another molecule and vice versa, this creates
a functional scFv capable of binding to two antigens simultaneously (Perisic, Webb
et al. 1994).
C6.5 diabody for single photon emission computed tomography and positron
emission tomography
The C6.5 diabody (C6.5db) is derived from the human anti-HER2 scFV, C6.5
(Adams, Schier et al. 1998). C6.5db specifically targets HER2 and its linkers
between VL and VH chains are five amino acids in length. It has a low molecular55
weight (52 kDa), resulting in first pass renal clearance and short half-life of 6.4 h in
circulation (Robinson, Shaller et al. 2008). C6.5db can be produced in Pichia
pastoris (P. pastoris) or Escherichia coli (E. coli), P-C6.5db and E-C6.5db,
respectively (Miller, Doss et al. 2012).
E-C6.5db radiolabelled with iodine-124 (
124I, half-life 4.2 days) identified HER2-
positive SKOV3 tumours in mouse xenografts on PET scanning from 4 h post-
administration. At 24 and 48 h the tumour-to-blood ratios for
124I-E-C6.5db were 6.7
and 13.4, respectively. By contrast, for mice bearing HER2-negative MDA-MB-468
tumours, the tumour and blood levels of
124I-E-C6.5db were equivalent (Robinson,
Doss et al. 2005).
125I-E-C6.5db tumour uptake has been shown to vary with HER2
expression levels, in xenografts with SKOV3 (1 X 10
6 HER2/cell, IHC 3+) and MDA-
MB-231 (2.3 X 10
4 HER2/cell, IHC 0) tumours, the uptake was 1.91% ID/g and
0.31% ID/g at 24 h post-infusion, respectively (Reddy, Shaller et al. 2011).
Both direct iodination of the tyrosine residues (non-residualising) and water soluble
Bolton-Hunter reagent sulfosuccinimidyl-3-(4-hydroxyphenyl)propionate (SHPP,
partially residualising) methods were used for
124I radiolabelling.
124I-E-C6.5 and
124I-
E-SHPP-C6.5 degraded after binding and internalisation of HER2, leading to low
tumour retention of radioiodine and accumulation in normal tissues that expressed
the sodium-iodide symporter e.g. thyroid, salivary glands and stomach, which could
obscure tumour uptake (Robinson, Doss et al. 2005).
Expression of recombinant proteins in P. pastoris can result in glycosylation with
branched mannose sugar structures.
125I-P-C6.5db is glycosylated and this resulted
in faster systemic clearance and lower tumour uptake compared to
125I-E-C6.5db
which is not glycosylated. In SKOV3 tumour bearing xenografts,
125I-P-C6.5db and
125I-E-C6.5db had similar tumour-to-blood ratios at 48 h post-infusion, 36.7 and 29.5
respectively, as
125I-P-C6.5db serum levels were significantly lower than
125I-E-
C6.5db. PET imaging of mice bearing HER2-positive tumours with
124I-P-C6.5db and
124I-E-C6.5db, demonstrated high background liver, bladder, thyroid and stomach
uptake.
124I-P-C6.5bd had greater liver uptake between 24 and 120 h than
124I-E-
C6.5db due to its glycosylation status (Miller, Doss et al. 2012).56
In vitro, pertuzumab and C6.5db compete with each other for HER2 binding, while
trastuzumab and C6.5db appear to be able to bind to the HER2 receptor
simultaneously. Yet, in SKOV3 and BT474 xenografts mice pre-treated with
trastuzumab prior to
125I-E-C6.5db injection, there was decreased HER2-positive
tumour uptake compared to rituximab (anti-CD20 IgG) pre-treated controls at 24 h
post injection (42% decrease for SKOV3 and 60% decrease for BT474 tumour
xenografts vs. rituximab pre-treatment). This decrease in
125I-E-C6.5db tumour
uptake did not correlate with a change in gross tumour size or loss of HER2
expression on IHC post-trastuzumab (Reddy, Shaller et al. 2011). Since the C6.5db
is unable to bind to HER2 in the presence of trastuzumab and pertuzumab, it has
not been developed for clinical application.
Anti-HER2 diabody derived from trastuzumab for positron emission
tomography
An anti-HER2 diabody derived from trastuzumab was radiolabelled with fluorine-18
(
18F, half-life 109.7 min) by reaction with its lysine residues, using N-succinimidyl-4-
[
18F]fluorobenzoate ([
18F]SFB). In mouse xenografts, the mean uptake for HER2-
positive breast tumours (MCF-7) was only 2.87% ID/g and 1.0% ID/g for HER2-
negative rat glioma tumours (C6) at 6 h post administration. There was high
background uptake in the kidneys and bladder. At 6 h post administration, the
tumour-to-blood ratios was only 1.7 and tumour-to-liver ratio was 5.5. On microPET
scanning, there was uptake in HER2-positive and HER2-negative tumours at 4 h but
higher uptake in the HER2-positive tumour. The low HER2-positive tumour uptake
and or retention are likely to limit
18[F]SFB-anti-HER2 diabody clinical development
(Olafsen, Sirk et al. 2012).
1.3.6 Nanobodies
Nanobodies arise from Camelidae antibodies and are the smallest naturally derived
antigen binding fragments. They contain a functional heavy chain without an
associated light chain and their molecular weight is approximately 15 kDa (Figure
1.2). The anti-HER2 nanobody, 2Rs15d specifically binds to HER2 recombinant
protein and HER2 expressing cells with low nanomolar affinities. Furthermore,57
2Rs15d does not compete with trastuzumab and pertuzumab for HER2 binding
(Vaneycken, Devoogdt et al. 2011) .
Nanobodies for single photon emission computed tomography imaging
SPECT imaging of mice xenografts with HER2 expressing tumours (SKOV3) by
99mTc-2Rs15d-His6, which incorporates a hexahistidine tag (His6) for radiolabelling,
demonstrated rapid renal clearance resulting in low blood levels (0.26±0.03% ID/g at
1.5 h post infusion). The pharmacokinetics was in keeping with other low molecular
weight hydrophilic proteins. There was low accumulation in non-target organs
except the kidneys (154.7±17.7% ID/g at 1.5 h post infusion). The normal liver
uptake was reasonably low at 1.5 h post infusion, 0.72±0.14% ID/g. The tumour
uptake was 4.19±0.47% ID/g at 1.5 h post injection resulting in a tumour-to-blood
ratio of 16.4±3.6 (Vaneycken, Devoogdt et al. 2011; Xavier, Vaneycken et al. 2013).
Nanobodies for positron emission tomography imaging
The HER2 nanonbodies, 2Rs15d and 2Rs15d-His6 were conjugated via 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA) for
68Ga radiolabelling. At 1 h post
administration to rat tumour xenografts, both
68Ga-NOTA-2Rs15d-His6 and
68Ga-
NOTA-2Rs15d had moderate HER2-positive tumour uptake (SKOV3) 3.13±0.06%
ID/g and 4.34±0.90% ID/g, respectively, yet had low uptake in HER2-negative
tumours (MDA-MB-435D). In SKOV3 tumour bearing rats,
68Ga-NOTA-2Rs15d had
considerably lower kidney uptake than
68Ga-NOTA-2Rs15d-His6; 45.00±11.42%
ID/g vs. 116.67±1.83% ID/g but similar uptake in the liver and other assessed
organs. In urine, only intact
68Ga-NOTA-nanobody was detected confirming good
stability. Absence of the C-terminal His6 tag lowers renal retention, possibly due to
the charge effects exerted by imidazole groups within the histidine residues. On
PET/CT scanning of rat xenografts with
68Ga-NOTA-2Rs15d, there was high uptake
in SKOV3 tumours but no uptake in MDA-MB-435D tumours at 1 h post
administration. Besides, high uptake in the kidneys and bladder, uptake in other
normal organs was low.
68Ga-NOTA-2Rs15d is currently being developed for clinical
imaging (Xavier, Vaneycken et al. 2013).58
Nanobodies for radio-immunotherapy
2Rs15d-His6 radiolabelled with the lutetium-177 (
177Lu) using bifunctional chelators
is being developed for HER2-positive breast cancer radio-immunotherapy. Pre-
clinical studies demonstrated high uptake in HER2 expressing tumours with low
background activity except for high kidney uptake. 2Rs15d-His6 radiolabelled with
177Lu via a DTPA based chelator was able to achieve high tumour-to-blood ratios in
SKOV3 mouse xenografts, which peaked at 1264±53 24 h post-infusion, while
tumour uptake in HER2-negative mouse xenografts was negligible (D'Huyvetter,
Aerts et al. 2012). This approach can only be developed for clinical application if
renal uptake can be minimised.
1.3.7 Affibody molecules targeting HER2
Affibody molecules are small (6-7 kDa) non-immunoglobulin binding proteins which
provide an alternative to antibody-based constructs. They are based on a 58 amino
acid Z-domain scaffold, that are derived from the B domain of staphylococcal
surface protein A (Nilsson, Moks et al. 1987; Orlova, Magnusson et al. 2006). They
form a three-helix bundle protein which lack cysteines (Figure 1.3). Large
combinatorial libraries of affibody molecules have been generated by randomising
13 amino acids within the ligand binding domain and phage display is used to select
affibody molecules which bind to desired target proteins (Nord, Gunneriusson et al.
1997). The affibody molecule ZHER2:342, specifically binds to HER2 with picomolar
affinity (KD = 22 pmol/L) and was developed for HER2 imaging (Orlova, Magnusson
et al. 2006). ZHER2:342 can be site specifically radiolabelled for imaging without
affecting in vivo HER2 tumour binding and HER2 binding is not compromised by the
presence of trastuzumab (Orlova, Tolmachev et al. 2007).59
Figure 1.3 Three-helix affibody molecule and two-helix protein scaffold (blue helices
are involved in HER2 receptor binding).
1.3.7.1 Pre-clinical development of affibody molecule based positron emission
tomography
To compare the potential of ZHER2:342 and trastuzumab for HER2 PET imaging, they
were radiolabelled with
124I using p-iodobenzoate (PIB) as a linker. In some
experiments
125I-PIB was used as an analogue for
124I-PIB. Both
125I-PIB-
trastuzumab and
125I-PIB-ZHER2:342 specifically bound to HER2 expressing cells in
vitro and specifically identified HER2 expressing tumours in vivo.
125I-PIB-
trastuzumab was rapidly taken up by HER2 expressing cells, while
125I-PIB-ZHER2:342
remained on the cell surface for longer and consequently was degraded at a slower
rate. In mouse xenografts with HER2-positive tumours,
125I-PIB-trastuzumab had
higher tumour uptake than
124I-PIB-ZHER2:342 over 72 h but
124I-PIB-ZHER2:342 achieved
higher tumour-to-normal tissue ratios at most time points in the blood, liver and
lungs due to faster blood clearance. Pre-administration of non-radiolabelled
trastuzumab did not alter
124I-PIB-ZHER2:342 HER2-positive tumour uptake in vivo,
while pre-administration of non-radiolabelled ZHER2:342 reduced
124I-PIB-ZHER2:342
tumour uptake; confirming receptor-specific tumour uptake. On PET scanning,
124I-
PIB-ZHER2:342 achieved superior tumour-to-normal tissue contrast at 6 h than
124I-PIB-
trastuzumab could achieve at 72 h post administration (Orlova, Wallberg et al.
2009). This study demonstrated that for molecular imaging, small high affinity
proteins have advantages over whole antibodies.60
68Ga-DOTA-ZHER2:342 PET and
111In-DOTA-ZHER2:342 SPECT imaging have been
compared pre-clinically. DOTA-ZHER2:342 was efficiently radiolabelled with
68Ga
(>95%) and maintained specific HER2 binding in vitro and in vivo. In mice bearing
HER2-positive tumours (SKOV3),
68Ga-DOTA-ZHER2:342 and
111In-DOTA-ZHER2:342
achieved similar tumour uptake at 2 h, 12.4±3.8% ID/g and 15.2±4.8% ID/g,
respectively. However,
68Ga-DOTA-ZHER2:342 achieved a higher tumour-to-blood ratio
at 2 h than
111In-DOTA-ZHER2:342 (31±13 vs. 17±6) due to faster clearance
(Tolmachev, Velikyan et al. 2010). In SKOV3 xenografts,
68Ga-DOTA-ZHER2:342 PET
scans at 2 h and
111In-DOTA-ZHER2:342 SPECT scans after 24 h demonstrated
specific tumour targeting. Thus,
68Ga-DOTA-ZHER2:342 could potentially enable
convenient same day HER2 PET scanning (Tolmachev, Velikyan et al. 2010).
Cheng et al. assessed a commercially available HER2 targeting affibody, ZHER2:477,in
both its monomeric (ZHER2:477) and dimeric form (ZHER2:477)2. The affibody molecules
were site specifically radiolabelled with the positron emitter,
64Cu at a C-terminal
cysteine via maleimido-mono-amide DOTA. In HER2-positive tumour (SKOV3)
bearing mice,
64Cu-DOTA-ZHER2:477 achieved much higher tumour uptake and higher
tumour-to-blood ratios than its dimeric counterpart. Consequently,
64Cu-DOTA-
ZHER2:477 achieved superior images of SKOV3 tumour bearing mice on PET imaging
due to lower background radiation. In mice bearing both the melanoma tumour,
MDA-MB-435 and HER2-positive ovarian tumour, SKOV3, only the SKOV3 tumours
were visible with the radiolabelled monomeric and dimeric HER2 affibody molecules.
However, pre-treatment of SKOV3 tumour bearing mice with trastuzumab,
prevented visualisation of tumours on
64Cu-DOTA-ZHER2:477 PET scanning over 24 h,
which could limit future clinical application (Cheng, De Jesus et al. 2010).
Following confirmation that the smaller monomeric affibody molecule is superior to
its dimeric counterpart, Ren et al. developed a smaller 2-helix affibody, MUT-DS by
truncating one of the three α-helices which is not involved in receptor recognition 
(Figure 1.3) (Ren, Zhang et al. 2009).
64Cu-DOTA-MUT-DS identified HER2
expressing SKOV3 tumours in mouse xenografts and achieved reasonable tumour-
to-blood and tumour-to-muscle ratios, 3.05 and 3.48 at 1 h post infusion,
respectively. The smaller MUT-DS affibody needs to be compared with the intact61
three helical affibody to determine whether the smaller size translates into improved
clearance and tumour uptake (Ren, Zhang et al. 2009; Ren, Webster et al. 2012).
ZHER2:342 has been radiolabelled with
18F, by conjugation with N-2-(4-
[
18F]fluorobenzamido)ethyl]maleimide ([
18F]FBEM) at a C-terminal cysteine for PET
imaging (Kiesewetter, Kramer-Marek et al. 2008). [
18F]FBEM-ZHER2:342 PET imaging
of mice bearing HER2-positive tumours (SKOV3), demonstrated tumour uptake at
20 min (SUV = 2.4) which was maintained for at least 2 h (SUV = 3.43) post
infusion. Liver and kidney uptake was high for the first hour and gradually fell, so the
optimal time for imaging was 1 h post injection. These imaging results were
confirmed by biodistribution studies (Kramer-Marek, Kiesewetter et al. 2008).
In mouse xenografts, [
18F]FBEM-ZHER2:342 has been used to assess HER2
expression and changes in expression following Hsp90 inhibitor administration. PET
scans with [
18F]FBEM-ZHER2:342 were performed on five different mouse xenograft
models with varying levels of HER2 tumour expression. [
18F]FBEM-ZHER2:342 rapidly
accumulated in HER2-positive tumours and achieved high tumour-to-blood and
tumour-to-muscle ratios within 20 min of administration. The tumour tracer uptake
on PET scanning correlated with Western blotting, ELISA and IHC (HercepTest).
Following Hsp90 inhibition of two HER2-positive mice xenograft models
(MCF7/clone18 and BT474) tracer uptake on PET scanning decreased by 33% and
71% compared to pre-treatment levels, respectively. Although ex vivo analysis of
treated tumours with ELISA and Western blotting confirmed significant HER2 down
regulation, the BT474 tumours maintained a score of 3+ after Hsp90 inhibitor
treatment on the HercepTest. The
18F radiolabelled affibody may have a potential
future role in monitoring changes in HER2 expression following treatment (Kramer-
Marek, Kiesewetter et al. 2009).
1.3.7.2 Pre-clinical development of affibody molecule based single photon
emission computed tomography
Technetium-99m (
99mTc; half-life 6.02 h) is suitable for SPECT imaging due to its
favourable photon energy (140 keV), low cost, low dose burden and wide
availability.
99mTc radiolabelling of the affibody molecule can be performed at an N-
terminal His6 tag (
99mTc-His6-ZHER2:342-C) or at an inserted C-terminal cysteine
residue (
99mTc-ZHER2:342-C). Both methods achieved radiolabelling yields >90%. In62
HER2-positive tumour bearing xenografts,
99mTc-His6-ZHER2:342-C demonstrated rapid
and specific tumour visualisation on SPECT scanning. Furthermore,
99mTc-ZHER2:342-
C has lower background liver uptake which has clear advantage over
99mTc-His6-
ZHER2:342-C for HER2 SPECT imaging (Ahlgren, Wallberg et al. 2009).
1.3.7.3 Clinical assessment of the first generation HER2 binding affibody
molecule
Baum et al. conducted the first clinical study of ZHER2:342-pep2 (ABY-002, peptide
synthesis in a single chemical process) (Table 1.3). Three patients with metastatic
HER2-positive breast cancer who had been recently staged with a CT or
18F-
fluorodeoyglucose (
18F)-FDG PET/CT scan, received
111In-DOTA-ZHER2:342-pep2 for
SPECT imaging and/or
68Ga-DOTA-ZHER2:342-pep2 for PET imaging. The five
administrations (3 patients received
68Ga-DOTA-ZHER2:342-pep2 and 2 patients received
111In-DOTA-ZHER2:342) were well tolerated. Radiolabelled ZHER2:342-pep2 demonstrated
rapid blood clearance; the first half-life of
111In-DOTA-ZHER2:342-pep2 was 4-11 min and
10-14 min for
68Ga-DOTA-ZHER2:342-pep2. This enabled high contrast SPECT and PET
scans 2-3 h post injection (Baum, Prasad et al. 2010).
For one patient,
111In-DOTA-ZHER2:342-pep2 SPECT imaging detected four out of five
metastatic sites identified by
18F-FDG PET/CT, including a latissimus dorsi
metastasis, that was subsequently excised confirming an IHC score of 3+
(HercepTest). A patient receiving concomitant trastuzumab had a
111In-DOTA-
ZHER2:342-pep2 SPECT scan and
68Ga-DOTA-ZHER2:342-pep2 PET scan within 24 h of each
other, both scans identified all five hyper-metabolic areas seen on a
18F-FDG
PET/CT scan, including a sartorius muscle lesion. The sartorius muscle lesion was
reported as inflammatory or metastatic on
18F-FDG PET/CT scanning, a muscle
biopsy confirmed metastatic breast cancer with heterogeneous HER2 expression on
the HercepTest (mean IHC score 2+). For the same patient, the
68Ga-DOTA-
ZHER2:342-pep2 PET scan identified a lesion in the right anterolateral chest wall which
was not seen by any other imaging modality, however it was not biopsied (Baum,
Prasad et al. 2010).
There was high background kidney and liver uptake of the radiolabelled DOTA-
ZHER2:342-pep2, consequently a liver metastasis and a lesion adjacent to the kidney
(possible lymph node or adrenal metastasis) identified by
18F-FDG PET/CT could63
not be visualised with the affibody scan. In addition, a mediastinal lymph node seen
on
18F-FDG PET/CT was not visualised with the radiolabelled affibody (Baum,
Prasad et al. 2010).
1.3.7.4 Effect of tags on the biodistribution of the HER2 binding affibody
molecule
Attempts have been made to reduce affibody molecule normal liver uptake, to
enable visualisation of HER2-positive liver metastases. It is known that chelators at
the N-terminal domain which are positively charged and lipophilic, increase hepato-
biliary excretion (Tran, Engfeldt et al. 2007). Conventionally, ZHER2:342 has an N-
terminal His6 tag (His6-ZHER2:342), which facilitates purification by immobilised metal
ion affinity chromatography (IMAC) and labelling with [
99mTc(CO)3]
+ but is associated
with increased hepatic radioactivity uptake (Hofstrom, Orlova et al. 2011; Hofstrom,
Altai et al. 2013).
ZHER2:342 was produced with an N-terminal negatively charged and hydrophilic
histidine-glutamate (HE)3 tag, to improve biodistribution and maintain purification by
IMAC. (HE)3-ZHER2:342 retained specific binding to HER2 expressing cells.
Biodistribution studies were performed in non-tumour bearing mice with (HE)3-
ZHER2:342, His6-ZHER2:342 and ZHER2:342-His6 site specifically radiolabelled with
111In,
125I
or
99mTc at a C-terminal cysteine. The three constructs had similar normal tissue
biodistribution profiles, except (HE)3-ZHER2:342 had lower liver uptake for
111In and
99mTc radiolabelling.
111In-(HE)3-ZHER2:342 had 5.7-fold lower liver uptake than
111In-
His6-ZHER2:342 and
99mTc-(HE)3-ZHER2:342 had 19-fold lower liver uptake than
99mTc -
ZHER2:342-His6. The three
125I-radiolabelled constructs had similar liver uptake, as the
liver is involved in metabolism and excretion of iodine radionuclides (Hofstrom,
Orlova et al. 2011).
Ten variants of ZHER2:342 with different histidine-based tags, (HX)3, positioned at the
N- and C-terminus that altered charge and lipophilic properties of the affibody
molecules were labelled with [
99mTc(CO)3]
+ and assessed in non-tumour bearing
mice. For ZHER2:342 radiolabelled with [
99mTc(CO)3]
+, liver uptake is enhanced by
positive charge and lipophilic properties. The N-terminal positioning of the (HX)3-
tags appeared to have a greater effect on liver uptake than C-terminal positioning.
The ZHER2:342 with a (HE)3 tag was the only hydrophilic and negatively charged64
construct. (HE)3-ZHER2:342 had lowest uptake in the liver and spleen with similar
uptake in the other assessed organs as the other constructs (Hofstrom, Altai et al.
2013).
Consequently, a second generation affibody molecule, ZHER2:2891-Cys (ABY-025) was
produced by substituting 11 amino acids within the non-HER2 binding surface,
resulting in increased hydrophilicity as well as improved chemical and thermal
stability (Feldwisch, Tolmachev et al. 2010).
111In-DOTA-ABY-025 achieved similar
tumour uptake in HER2-positive (SKOV3) tumour bearing mice as the first
generation affibody molecule assessed in the clinical trial (
111In-DOTA-ZHER2:342-pep2),
11±3% ID/g vs. 14±1% ID/g. However, the second generation affibody molecule with
increased hydrophilicity
111In-DOTA-ABY-025 had similar liver uptake as the first
generation affibody molecule
111In-DOTA-ZHER2:342-pep2, 1.7±0.7% ID/g and 1.7±0.3%
ID/g, respectively (Ahlgren, Orlova et al. 2010).
1.3.7.5 Clinical assessment of the second generation HER2 binding affibody
molecule
In a first in human clinical trial,
111In-DOTA-ABY-025 was safe and well tolerated by
seven patients with metastatic breast cancer, including patients who had had HER2-
positive (n=5) and HER2-negative (n=2) primary disease. The five patients with
HER2-positive primary disease were receiving concomitant trastuzumab at the time
of assessment. On SPECT scanning, HER2-positive tumour uptake increased
between 4 and 24 h, while HER2-negative tumour uptake was generally lower and
decreased between 4 and 24 h. The decay-corrected 24/4h tumour uptake ratio
could discriminate between HER2-negative and HER2-positive lesions.
Furthermore, the discriminatory capacity of this ratio was confirmed by IHC of
biopsied lesions. Interestingly, a patient who had had HER2-positive primary
disease had HER2-negative metastatic disease based on the 24/4h tumour uptake
ratio, this finding correlated with seven biopsies taken from metastatic sites which
were all HER2-negative on IHC (Sorensen, Sandberg et al. 2014).
Despite having high kidney uptake,
111In-DOTA-ABY-025 is able to image HER2-
positive adrenal metastases and can also cross the blood brain barrier to identify
HER2-positive brain metastases.
111In-DOTA-ABY-025 was capable of imaging liver
metastases, by contrast ZHER2:342-pep2(ABY-002) radiolabelled with
68Ga and
111In was65
unable to image liver metastases in the previous clinical trial (Baum, Prasad et al.
2010; Sorensen, Sandberg et al. 2014).
111In-DOTA-ABY-025 SPECT scanning
appears to be safe and capable of assessing HER2 status in patients with advanced
breast cancer but the 24/4h tumour uptake ratio requires scans at 4 and 24 h which
is inconvenient for patients (Sorensen, Sandberg et al. 2014).
The therapeutic potential of HER2-binding affibody molecules is being investigated
with a variant that contains a C-terminal peptide-based chelator for radiolabelling
(ZHER2:V2). HER2 binding affibody molecules are rapidly internalised by the kidneys
and slowly internalised by HER2-positive cells. Affibody molecules radiolabelled with
residualising radio-isotopes have high radioisotope retention in the kidneys, limiting
their therapeutic application. However, for affibody molecules radiolabelled with non-
residualising radio-isotopes, rapid affibody molecule internalisation in the kidneys
leads to rapid clearance of the non-residualising radioisotope in urine. Radiolabelling
ZHER2:V2 with the non-residualising radio-isotope rhenium-188 (
188Re, half-life 17.0 h),
has demonstrated high uptake in HER2-positive tumours, without exceeding toxicity
limits in the kidneys and bone marrow. Thus,
188Re-ZHER2:V2 directed radiotherapy
may be suitable for investigation in patients (Altai, Wallberg et al. 2014).
1.3.8 Designed ankyrin repeat proteins
Designed ankyrin repeat proteins (DARPins) are non-immunoglobulin scaffolds,
composed of naturally occurring ankyrin repeat proteins which are evolutionary
conserved (Bork 1993). DARPins have a range of properties which justify their
investigation for molecular imaging in cancer.
Ankyrin repeat proteins have been identified throughout the cellular compartments,
bound to the cellular membrane and can also be secreted from cells (Sedgwick and
Smerdon 1999). Ankyrin repeat proteins are among the most commonly found
binding proteins within the human genome (Lander, Linton et al. 2001). For
example, ankyrin repeat proteins form part of the human red cell membrane network
and ankyrin-1 gene mutations are the most common cause of the red cell
membrane disorder, hereditary spherocytosis in Europe and the United States (Da
Costa, Galimand et al. 2013).66
1.3.8.1 Structure of designed ankyrin repeat proteins
Each  ankyrin  repeat  usually  consists  of  33  amino  acids,  which  form  a  β-turn 
followed by two anti-parallel α-helices and a loop reaching to bind to the β-turn of 
the next ankyrin repeat (Sedgwick and Smerdon 1999; Kobe and Kajava 2000).
Ankyrin repeat proteins usually consist of four to six repeats (Tamaskovic, Simon et
al. 2012). They mediate protein-protein interactions with a vast range of protein
targets and consequently have a wide variety of biological functions. Each ankyrin
repeat contributes to target binding, which results in high target affinities (Malek,
Huxford et al. 1998; Sedgwick and Smerdon 1999). The scaffold structure of ankyrin
repeats is highly versatile and repeats can be duplicated, deleted and re-arranged to
alter target protein binding (Figure 1.4) (Kobe and Kajava 2000).
Figure 1.4 Template amino acid sequences of the N-terminal capping ankyrin
repeat, designed ankyrin repeat module and C-terminal capping ankyrin repeat,
besides the G3 DARPin amino acid sequences.
The secondary structure components are shown above their respective sequences,
the amino acid sequences forming the α-helices and β turns are emboldened. The 
designed ankyrin repeat modules usually consist of 26 defined framework residues,
6 randomised potential interaction residues (X, any of the 20 natural amino acids,
except cysteine, glycine or proline) and 1 randomised framework residue (Z, usually
asparagine-N, histidine-H or tyrosine-Y). The G3 DARPins amino acid sequence is
shown besides the template sequences. The G3 has four mutations at defined
framework positions which are underlined. Adapted from (Tamaskovic, Simon et al.
2012).67
Consensus design was used to determine the designed ankyrin repeat consensus
sequence. Consensus design is based on the principle that functionally important
residues, including residues which maintain protein folding are usually conserved,
while residues involved in specific target interaction are not conserved (Forrer, Binz
et al. 2004). This process involved the alignment of multiple naturally occurring
ankyrin repeat proteins to produce a designed ankyrin repeat module consisting of
fixed framework residues and randomised potential interaction residues, which were
used as the template to produce DARPins (Binz, Amstutz et al. 2004). Each
designed ankyrin repeat module consists of 26 defined framework residues, 6 non-
conserved randomised target interaction residues and 1 randomised framework
residue (usually either asparagine, histidine or tyrosine) (Figure 1.4). Thus, to
extend the diversity of the combinatorial library, 7 residues can be randomised to
alter the target interaction of the designed ankyrin repeat modules (Binz, Stumpp et
al. 2003).
Hydrophilic N-terminal (N) and C-terminal (C) capping ankyrin repeats are used to
shield the hydrophobic core of the stacked randomised ankyrin proteins (Figure 1.5).
Originally the N-capping and C-capping repeats were based on naturally occurring
proteins (Binz, Stumpp et al. 2003; Kohl, Binz et al. 2003). However, a new C-
capping repeat based on the consensus sequence has been introduced since it
results in greater thermal resistance (Interlandi, Wetzel et al. 2008). The theoretical
diversity of ankyrin repeat modules with seven randomised positions is 7.2 X 10
7 per
module (Binz, Stumpp et al. 2003). Thus, the theoretical diversity of the N2C and
N3C DARPin libraries are (7.2 X 10
7)
2 = 5.2 X10
15 and (7.2 X 10
7)
3 = 3.8 X 10
23,
respectively (Binz, Stumpp et al. 2003).68
Figure 1.5 Schematic representation of DARPin library generation.
Assembly consists of an N-terminal capping ankyrin repeat (blue), varying the
numbers of designed ankyrin repeat modules (white) and a C-terminal capping
ankyrin repeat (black), producing combinatorial DARPin libraries with different
repeat numbers. The structure of an N2C DARPIN e.g. G3 is shown on right side.
Adapted from (Goldstein, Sosabowski et al. 2013).
1.3.8.2 Properties of designed ankyrin repeat proteins
DARPins are cysteine-free and can be expressed in soluble form in the cytoplasm of
E. coli at very high levels (Binz, Stumpp et al. 2003). They are also soluble and
stable under physiological conditions (Binz, Stumpp et al. 2003). They exhibit high
thermo-stability which is greater than naturally occurring ankyrin repeats, which may
be due to extended H-bond networks (Mosavi, Williams et al. 2002; Kohl, Binz et al.
2003). DARPins have a low molecular weight, 14-15 kDa and 17-18 kDa for N2C
and N3C, respectively (Binz, Stumpp et al. 2003). Using ribosome display, DARPins
have been selected which bind to targets with high affinity, up to the picomolar
range (Binz, Amstutz et al. 2004; Zahnd, Wyler et al. 2007).
1.3.8.3 Designed ankyrin repeat proteins targeting HER2
From DARPin libraries, ribosome display was used to select DARPins which bind to
the HER2 ECD. Ribosome display is an in vitro method which enables selection of
polypeptide binders from large libraries. The ribosome display selected DARPins,
then underwent extensive HER2 binding studies (Zahnd, Pecorari et al. 2006). The
G3 DARPin which consists of an N-terminal capping repeat with a His6 tag, two69
internal designed ankyrin repeat modules and a C-terminal capping repeat had the
highest affinity for HER2 (90 pmol/L) assessed by surface plasmon resonance
(SPR) which was maintained when assessed on HER2-positive, BT474 cells (~60-
100 pmol/L) (Zahnd, Wyler et al. 2007; Zahnd, Kawe et al. 2010). The G3 DARPin
has four mutations at framework positions leading to enhanced affinity compared to
the consensus framework variant (Figure 1.4) (Zahnd, Wyler et al. 2007).
The G3 DARPin and trastuzumab bind to adjacent but non-overlapping epitopes of
subdomain 4 of the HER2 ECD so do not compete for HER2 binding; this has been
determined by both structural modelling of the protein-protein interactions and in
vitro investigation (Epa, Dolezal et al. 2013). Pertuzumab binds to subdomain 2 of
the HER2 ECD, so it can bind in the presence of the G3 DARPin.
1.3.8.4 G3 DARPin assessment of HER2 tumour status
The G3 DARPin with an engineered AviTag for enzymatic biotinylation has been
developed for assessment of HER2 protein expression in tissues. Comparison of the
FDA-approved Ventana HER2 IHC and DARPin-histochemistry, correlated by FISH
has been performed on 793 primary breast cancer tissue microarrays. There was a
strong correlation between amplification status measured by FISH with both
DARPin-histochemistry and Ventana IHC (p<0.0001, each). The G3 DARPin and
Ventana antibody detect HER2 amplification status determined by FISH with similar
sensitivities, 98.9% and 96.6%, respectively, however the G3 DARPin has
significantly higher specificity (98.6 vs. 96.2%, p=0.0005) (Theurillat, Dreier et al.
2010).
1.3.8.5 Bispecific DARPin incorporating the G3 DARPin for anti-HER2 therapy
Although the G3 DARPin in isolation exerts no biological effects, attaching the G3
DARPin (binds subdomain 4 of HER2 ECD) with a DARPin that binds to subdomain
1 via a short linker, results in a bispecific DARPin that has greater cytotoxicity than
trastuzumab against HER2-positive breast cancer cell lines in vitro. The bispecific
DARPin binds to two membrane-bound HER2 molecules, distorting them so they
cannot form dimers, thus preventing intracellular signalling (Jost, Schilling et al.
2013).70
1.3.8.6 G3 DARPin single photon emission computed tomography imaging
In non-tumour bearing BALB/c mice, the G3 DARPin had a half-life of less than 3
min and this short half-life was maintained in HER2-positive tumour bearing mice. In
vivo, there may be an additional slow phase of clearance for 5% of the G3 DARPin
which has a half-life of 80-90 min. The G3 DARPin is predominantly eliminated by
the kidney and to a lesser extent by the liver. By contrast, attachment of
polyethylene glycol (PEG) to the DARPin increased hepatic excretion, prolonging its
half-life (Zahnd, Kawe et al. 2010).
In mice bearing HER2 expressing SKOV3 tumours, the G3 DARPin had high levels
of tumour uptake, 9.12±1.77% ID/g at 1 h and 6.46±0.96% ID/g at 24 h post-
administration. Due to rapid systemic clearance high tumour-to-blood ratios were
obtained at 1 h (12.67±3.34), which increased at 48 h (71.78±26.62). The G3
DARPin penetrates the whole tumour mass relatively evenly, with only slightly
increased staining at the tumour rim. However, tumour-to-liver ratios are less than 2
over 48 h, which may limit identification of liver metastases. PEG-G3 DARPin had
slower tumour accumulation and slower clearance from the bloodstream, resulting in
lower tumour-to-blood ratios, 10.77 ± 4.37 at 48 h (Zahnd, Kawe et al. 2010).
A whole body SPECT/CT scan was performed on mice with SKOV3 tumours who
received either
99mTc-G3 DARPin (555 MBq) or
99mTc-PEG-G3 DARPin (555MBq),
directly radiolabeled at the N-terminal His6 tag. Both DARPins demonstrated high
accumulation of radioactivity within the HER2-positive tumours. There was
significantly less radioactivity in the kidneys of the mouse injected with
99mTc-PEG-
G3 DARPin, as PEG increased hepatic excretion rates (Zahnd, Kawe et al. 2010).
The G3 DARPin has not been investigated in human studies. Although the pre-
clinical data is encouraging for the non-PEG format, there are concerns regarding its
background liver uptake.
1.4 Aims
The principal aim of the research was to develop pre-clinical G3 DARPin HER2
SPECT and PET imaging, for subsequent assessment within a first-in-human trial,
which will recruit patients with advanced metastatic HER2-positive breast cancer.71
This work involved testing a series of hypotheses which formed important
milestones in the translation from pre-clinical to clinical investigation of the G3
DARPin.
1. Purified G3 DARPins can be produced with and without histidine based N-
terminal tags by a P. pastoris production platform.
2. N-terminus histidine-based tags affect normal tissue uptake of the G3 DARPin.
3. The G3 DARPin radiolabelled with indium-111 and iodine-123/125 can achieve
high tumour-to-blood and high tumour-to-normal tissue ratios for pre-clinical
HER2 SPECT imaging.
4. The G3 DARPin can be radiolabelled with gallium-68 for pre-clinical HER2 PET
imaging.
5. The unconjugated G3 DARPin is well tolerated by HER2 transgenic and non-
transgenic mice.72
Chapter 2 Materials and Methods73
2.1 Materials
2.1.1 Suppliers
Table 2.1 List of suppliers.
Company name Company address
American Type Culture Collection Manassas, Virginia, United States
Amresco Solon, Ohio, United States
Anachem Luton, United Kingdom
Baxter Berkshire, United Kingdom
Beckman Coulter (UK) High Wycombe, United Kingdom
Becton Dickinson Oxford, United Kingdom
Bioline Reagents London, United Kingdom
Biometra Göttingen, Germany
Bio-Rad Laboratories Hemel Hempstead, Hertfordshire, United
Kingdom
Bioscan Poway, California, United States
Biosera Boussens, France
Charles River Erkrath, Germany
Chematech Dijon, France
Covidien Netherlands
Dako Ely, Cambridgeshire, United Kingdom
DNA Technologies Leuven, Belgium
Eckert & Ziegler Berlin, Germany
Elkay Laboratory Products (UK) Hampshire, United Kingdom
EMP Genetech Ingolstadt, Germany
Eppendorf UK Cambridge, United Kingdom
Fisher Scientific Loughborough, United Kingdom
GE Healthcare Buckinghamshire, United Kingdom
Generon Maidenhead, Berkshire, United Kingdom
Genetic Research Instrumentation Essex, United Kingdom
GenScript Piscataway, New Jersey, United States
GraphPad Software La Jolla, California, United States
Greiner bio-one Frickenhausen, Germany
Harlan Laboratories Wyton, United Kingdom
IBM Armonk, New York, United States
Innovative Research of America Sarasota, Florida, United States
Integrated DNA Technologies Leuven, Belgium
Leica Biosystems Newcastle Newcastle Upon Tyne, United Kingdom
Life Technologies Paisley, United Kingdom
LKB Instruments Mount Waverley, Victoria, Australia
Lucigen Wisconsin, United States
Macrocyclics Dallas, Texas, United States
Marvel Dublin, United Kingdom
Merck Millipore Billerica, Massachusetts, United States
Nalgene Derbyshire, United Kingdom
New England BioLabs Hitchin, Hertfordshire, United Kingdom74
NuSep Wasserburg, Germany
PAA Laboratories Yeovil, Somerset, United Kingdom
Pall Life Science Portsmouth, United Kingdom
PerkinElmer Llantrisant, United Kingdom
Pharmacia United Kingdom
Pioneer Research Chemicals Colchester, Essex, United Kingdom
Proxcys Downstream Biosystems Nieuw-Amsterdam, Netherlands
Promega Southampton, United Kingdom
Qiagen Crawley, West Sussex, United Kingdom
Roche Diagnostics Burgess Hill, United Kingdom
Sartorius Stedim Epsom, Surrey, United Kingdom
Scivis Göttingen, Germany
Sequani Ledbury, Herefordshire, United Kingdom
Siemens Preclinical Solutions Knoxville, Tennessee, United States
Sigma-Aldrich St. Louis, Missouri, United States
Syngene Cambridge, United Kingdom
Teklab County Durham, United Kingdom
The Jackson Laboratory Bar Harbor, Maine, United States
Thermo Scientific Runcorn, Cheshire, United Kingdom
Tree Star Ashland, Oregon, United States
UCL Advanced Diagnostics London, United Kingdom
UCL Cancer Institute London, United Kingdom
Varian Palo Alto, California, United States
Ventana Medical Systems Tucson, Arizona, United States
Waters Corporation Milford, Massachusetts , United States
Whatman Maidstone, Kent, United Kingdom
2.1.2 Buffers, media and solutions
A 0.2 µm 500 ml polyethersulfone (PES) filter unit (Nalgene) was used to filter
sterilise deionised water (dH2O), buffers and solutions as required. The composition
of buffers, media and solution not described in the main text are outlined below.
Table 2.2 Buffers for protein and nucleic acid manipulation (x; times concentration).
Buffers Composition
PCR
dNTP (deoxyribose nucleoside
triphosphates, concentration 10 mM)
-10 μl of each dNTP: 
dATP, dGTP, dCTP & dTTP,
concentration 100 mM (Life
Technologies)
-60 μl dH2O
Master mix for G3 DARPin DNA PCR For 8.5 ml final volume:
-1 ml 10x PCR Buffer (Life Technologies)
-1 ml of dNTPs concentration 10 mM
(Life Technologies).
-6.5 ml dH2O75
Agarose Gel Electrophoresis
Tris-acetate-EDTA (TAE) stock (50x) 2 M Tris-acetate, 0.05 M EDTA:
-242 g Tris Base
-57.1 ml glacial acetic acid
-100 ml of 0.5 M EDTA (pH 8.0) solution
-Made up to 1L with dH2O.
TAE (1x) 0.04 M Tris-acetate, 0.001 M EDTA
DNA loading buffer (10x) For 20 ml volume
-6.25 ml of dH2O
-0.025 g of Xylene cyanol
-0.025 g of Bromophenol Blue
-1.25 ml of 10% SDS
-12.5 ml of glycerol
New England BioLabs 1kb DNA Ladder  40 μl dH2O, 10 μl 6x Blue Loading Dye 
(provided), 10 μl DNA Ladder 
Promega 1kb DNA ladder  40 μl dH2O , 10 μl 6x Blue Loading Dye 
(provided), 10 μl DNA Ladder 
DNA Molecular Weight Marker IX
(Roche)
80 μl dH2O, 10 μl 10x Blue Loading Dye, 
10 μl DNA Ladder 
Bioline HyperLadder I (BioLine) Purchased in ready to use form
Digestion of PCR Product and Plasmid with XbaI and XhoI
NEBuffer 4 (10x) (New England
BioLabs)
50 mM potassium acetate, 20 mM tris-
acetate, 10 mM magnesium acetate, 1
mM dithiothreitol, pH 7.9 at 25 °C
(purchased in this form)
Purified BSA (bovine serum albumin)
(New England BioLabs)
20mM KPO4, 50 mM NaCl, 0.1 mM
EDTA, 5% glycerol, pH 7.0 at 25 °C
(purchased in this form)
XbaI (New England BioLabs) Concentration 100,000 units/ml
XhoI (New England BioLabs) Concentration 100,000 units/ml
Ligation of PCR Product and Plasmid
T4 DNA ligase reaction buffer (10x)
(New England BioLabs)
50 mM Tris-HCl, 10 mM MgCl2, 1 mM
ATP, 10 mM dithiothreitol, pH 7.5 at 25
°C (purchased in this form)
Linearisation of Plasmid/DARPin DNA prior to transformation
NEBuffer 4 (10x) (New England
BioLabs)
50 mM potassium acetate, 20 mM Tris-
acetate, 10 mM magnesium acetate, 1
mM dithiothreitol pH 7.9 at 25 °C
(purchased in this form)
QIAGEN Plasmid Kit
Qiagen Buffer P1 (re-suspension) 50 mM Tris·Cl, pH 8.0, 10 mM EDTA,100
µg/ml RNase A (purchased in this form)
Qiagen Buffer P2 (lysis) 200 mM NaOH, 1% SDS (w/v)
(purchased in this form)
Qiagen Buffer P3 (neutralisation) 3.0 M potassium acetate, pH 5.5
(purchased in this form)
Qiagen Buffer QBT (equilibration) 750 mM NaCl; 50 mM MOPS, pH 7.0;
15% isopropanol (v/v); 0.15% Triton X-
100 (v/v) (purchased in this form)
Qiagen Buffer QC (wash) 1.0 M NaCl, 50 mM MOPS, pH 7.0,15%76
isopropanol (v/v) (purchased in this form)
Qiagen Buffer QF (elution) 1.25 M NaCl, 50 mM Tris-Cl, pH 8.5,15%
isopropanol (v/v) (purchased in this form)
SDS PAGE Electrophoresis
2x SDS-PAGE reducing buffer (final
concentration)
4x has approximately one-third higher
concentration of components to achieve
the same overall concentration with the
protein sample
To make 50 ml, add 2 g SDS (4% w/v), 5
ml ẞ-Mercaptoethanol (10% v/v), 10 ml 
glycerol (20%), 100 mg bromophenol
blue (0.02% w/v), 10 ml 0.5 M Tris pH
6.8 (0.1 M), 25 ml dH2O
2x SDS-PAGE non-reducing buffer
(final concentration)
4x has approximately one-third higher
concentration of components to achieve
the same overall concentration with the
protein sample
To make 50 ml, add 2 g SDS (4% w/v),
10 ml glycerol (20% v/v), 100 mg
bromophenol blue (0.02% w/v), 10 ml 0.5
M Tris pH 6.8 (0.1 M), 30 ml dH2O.
SDS-PAGE running buffer (10x) 10 g SDS, 30.3 g Tris-base, 144 g
glycine and add dH2O to make up to 1L
SDS-PAGE running buffer (1x) 100 ml 10x SDS-PAGE running buffer
and 900 ml dH2O
Final concentration 25mM Tris, 192mM
glycine, 0.1 % (w/v) SDS
Protein Transfer Buffer (10x) 30.3 g Tris-base and 144 g glycine made
up to 1L with dH2O
Protein Transfer Buffer (1x) 100 ml 10x Protein Transfer Buffer, 200
ml methanol, 700 ml dH2O
(Final concentration 25mM Tris-base,
192mM glycine, 20% (v/v) Methanol)
Western blot analysis
Solution to visualise protein bands (final
concentration)
10  mg  3,3′-Diaminobenzidine 
tetrahydrochloride (DAB) hydrate ≥ 96% 
(0.25 mg/ml), 20 µl hydrogen peroxide
(0.5 µl/ml) in 40 ml dH2O
Coomassie staining
Coomassie stain (final concentration) 1.25 g coomassie brilliant blue (0.25%
w/v), 50 ml glacial acetic acid (10% v/v),
150 ml methanol (30% v/v) and 300 ml
dH20.
Destain 200 ml glacial acetic acid (10% v/v), 600
ml methanol (30% v/v) and 1.2 L dH20
Wizard SV Gel and PCR Clean-Up System (Promega)
Membrane Binding Solution 4.5 M guanidine isothiocyanate, 0.5M
potassium acetate (pH 5.0) (purchased
in this form)
Membrane Wash Solution
(after 95% ethanol added)
10 mM potassium acetate (pH 5.0), 80%
ethanol,16.7  μM  EDTA  (pH  8.0) 
(purchased in this form)77
Table 2.3 Media and plates for bacterial growth.
Media Composition
Low Salt LB
Medium (with or
without Zeocin)
Add dH2O to 10 g tryptone (1% w/v), 5 g sodium chloride
(NaCl) (0.5% w/v) and 5 g Yeast Extract (0.5% w/v) so that
volume reaches 1 litre. The pH should be 7. Autoclave. Add
0.25  ml  of  100  mg/ml  Zeocin  (25  μg/ml),  once  the 
temperature has cooled to ~55 °C.
Low Salt LB Agar
Plates with Zeocin
Add dH2O to 10 g tryptone (1% w/v), 5 g sodium chloride
(NaCl) (0.5% w/v), 5 g Yeast Extract (0.5% w/v) and 15 g
agar (1.5% w/v) so that volume reaches 1 litre. Autoclave.
Add  0.25  ml  of  100  mg/ml  Zeocin  (25  μg/ml),  once  the 
temperature has cooled to ~55 °C. Pour into 10 cm petri
plates. Let the plates harden, then invert, and store at 4 °C.
Table 2.4 Media and plates for yeast growth.
Media Composition
Yeast Extract
Peptone Dextrose
Medium (YPD) with
or without Zeocin
Dissolve 10 g yeast extract (1% w/v) and 20 g peptone (2%
w/v) into 900 ml of dH2O. Autoclave. Once solution has
cooled to ~60 °C add 100 ml of 20 % glucose (2 % v/v). Add
1.0 ml of 100 mg/ml Zeocin (100 μg/ml), if required. Store at 
room temperature if no Zeocin in media but at 4 °C and in
dark if contains Zeocin.
YPD with Sorbitol
(YPDS) + Zeocin
Agar Plates
Dissolve 10 g yeast extract (1% w/v), 182.2 g sorbitol (1 M)
and 20 g peptone (2% w/v) in 900 ml of dH2O. Add 20 g of
agar (2% w/v). Autoclave and once cooled to ~60 °C add 100
ml of 20% glucose (2% v/v) and 1.0 ml of 100 mg/ml Zeocin
(100 μg/ml). Stored at 4 °C and in the dark. 
Buffered Glycerol-
complex medium
(BMGY) with Zeocin
Dissolve 10 g of yeast extract (1% w/v), 20 g peptone (2%
w/v) in 700 ml dH2O. Autoclave. Once cooled to room
temperature add:
-100 ml 1 M potassium phosphate buffer, pH 6.0 (100mM),
100 ml 13.4% YNB (1.34% v/v), 2 ml 0.02% Biotin (4X10
-5 %
v/v),100 ml 10% glycerol (1% v/v) and 1.0 ml of 100 mg/ml
Zeocin (100 μg/ml).  
Store at 4 °C and in dark.
Buffered Methanol-
complex medium
(BMMY) with Zeocin
Dissolve 10 g of yeast extract (1% w/v), 20 g peptone (2%
w/v) in 700 ml dH2O. Autoclave. Once cooled to room
temperature add
100 ml 1 M potassium phosphate buffer, pH 6.0 (100mM),
100 ml 13.4% YNB (1.34% v/v), 2 ml 0.02% Biotin (4X10
-5 %
v/v)
100 ml 5% methanol (0.5% v/v). Add 1.0 ml of 100 mg/ml
Zeocin (100 μg/ml). Store at 4 °C. 78
Table 2.5 Media for fermentation of Pichia pastoris.
Media Composition
Yeast extract peptone
dextrose medium
(YEPD, primary culture
medium) with Zeocin
Dissolve 4 g peptone (1.7% w/v), 2 g yeast extract (0.9%
w/v), 3 g glucose (1.3% w/v) into 230 ml dH20, then
autoclave. After autoclaved add 230 µl of 100 mg/ml
Zeocin (100 μg/ml). 
Basic salt medium For 5.3 L final volume, dissolve 5.4 g CaSO4 , 88 g
K2SO4, 70 g MgSO4: 7H2O, 54 g (NH4)2SO4 and 300 ml
glycerol into 5.0 L dH20 and then autoclaved in the
bioreactor.
Sodium
hexametaphosphate
Dissolve 150 g hexametaphosphate in 1 L dH20, then
filter sterilised.
Trace elements
(Amresco)
5.99 g CuSO4.(H2O)5
0.08g NaI
3.0 g MnSO4.H2O,
0.20 g Na2MoO4.(H2O)2
0.50 g CoCl2.(H2O)6
20.04 g ZnCl2.(H2O)5
65.05 g FeSO4.(H2O)7
0.02 g H3BO3
19.2 ml 96.2% H2SO4
0.40 g D-biotin
Add dH2O to make final volume 1L (purchased in this
form)
Secondary culture
medium
300 ml basic salt medium 30 ml sodium
hexametaphosphate, 1.2 ml trace elements, then filter
sterilised.
Fermentation media To 5 L of autoclaved basic salt medium, add 970 ml
hexametaphosphate, 24 ml trace elements and 1 ml anti-
foam.
Limited glycerol feed 300 ml 100 % glycerol, 300 ml water, then autoclaved.
Then add 7 ml trace elements.
Limited methanol feed 2 L methanol and 24 ml trace elements.
Table 2.6 Solutions for the radial flow column.
Solution Composition
0.1 M Copper Sulfate
for EAEAHis6-G3 and
His6-G3
25 g CuS04 . 5H2O in 1 L dH2O and then autoclaved.
0.1 M Nickel (II) sulfate
for EAEA(HE)3-G3,
(HE)3-G3 and cleavable
tag-G3
52.56 g NiS04 . 6H2O in 2 L dH2O and then autoclaved
1 X equilibration/wash
solution for EAEAHis6-
G3, His6-G3 and
cleavable tag-G3
292 g NaCl (0.5 M) and PBS 48 g (0.5x PBS) in 10L
dH2O autoclaved and after cooled to room temperature
add 6.8 g imidazole (10mM).79
1 X equilibration/wash
solution for EAEA(HE)3-
G3 and (HE)3-G3
292 g NaCl (0.5 M) and PBS 48 g (0.5x PBS) in 10L
dH2O autoclaved (no imidazole added).
4 X cell application
solution for EAEAHis6-
G3, His6-G3 and
cleavable tag-G3
584 g NaCl (2 M) and PBS 96 g (2x PBS) in 5L dH2O
autoclaved and after cooled to room temperature add
13.6 g imidazole (40mM).
4X cell application
solution for EAEA(HE)3-
G3 and (HE)3-G3
584 g NaCl (2 M) and PBS 96 g (2x PBS) in 5L dH2O
autoclaved (no imidazole).
20 mM imidazole
solution for EAEAHis6-
G3, His6-G3 and
cleavable tag His6-G3
58.4 g NaCl (0.5 M) and PBS 9.6 g (0.5x PBS) in 2L
dH2O autoclaved and after cooled to room temperature
add 2.72 g imidazole (20mM).
200 mM imidazole
solution to elute all
DARPin from IMAC
column
58.4 g NaCl (0.5 M) and PBS 9.6 g (0.5x PBS) in 2L
dH2O autoclaved and after cooled to room temperature
add 27.2 g imidazole (200mM). Adjusted to pH 7 with 4M
HCl.
Table 2.7 Solutions used in G3 DARPin conjugation with maleimido-mono-amide
DOTA and purification post-conjugation.
Solution Constituents
0.1M Phosphate Buffer,
pH 7
1.17 g Sodium phosphate monobasic (TraceSELECT, ≥ 
99.999% metals basis, anhydrous, Sigma-Aldrich) and
2.16g Sodium phosphate dibasic (TraceSELECT,  ≥ 
99.999% metals basis, anhydrous, Sigma-Aldrich)
dissolved in 250 ml sterile water (Baxter). The solution
was then put through a chelex-100 column (Bio-Rad) and
filter sterilised.
0.2 M Ammonium
Acetate Buffer, pH 7
3.95 g ammonium acetate (TraceSELECT, ≥ 99.9995% 
metals basis, Sigma-Aldrich) dissolved in 250 ml sterile
water (Baxter). The solution was then put through a
chelex-100 column (Bio-Rad) and filter sterilised.
0.2 M Ammonium
Acetate Dialysis Buffer,
pH 6.5 containing
chelex-100
15.416  g  ammonium  acetate  for  molecular  biology  (≥ 
98%, Sigma-Aldrich) and 10g chelex-100 (Bio-Rad) was
dissolved in 1 L sterile water (Baxter). Slowly add 37%
hydrochloric acid until pH reaches 6.5 (approx. 150 µl).80
Table 2.8 Solutions used for instant thin layer chromatography (iTLC) to assess
111In
and
123/125I radiolabelled G3 DARPins.
Solvent Constituents Strips Separation for
indium-111
Separation for
iodine-125 and
iodine-123
0.1 M
ammonium
acetate & 25
mM EDTA
7.7 g
ammonium
acetate and
9.3g EDTA
in 1L dH20
(1.5-2 ml per
test strip)
iTLC-SG
(Varian)
Origin
-
111In-DARPin
-Insoluble
111In
Front
-
111In-EDTA
-
111In-DOTA
(any free
111In
binds to EDTA in
the solution)
Origin
-
123I/
125I- DARPin
Front
-Free
123I/
125I
Ammonia-
ethanol-water
For 8 ml, use
1 ml of 35%
ammonia, 2
ml ethanol, 5
ml dH20
(1.5-2 ml per
test strip)
iTLC-SG
(Varian)
Origin
-Insoluble
111In
Front
-
111In-DARPin
-
111In-EDTA
-
111In-DOTA
-Free
111In (if not
quenched with
EDTA)
Not required
Table 2.9 Solutions used for instant thin layer chromatography (iTLC) to assess
68Ga radiolabelled G3 DARPin.
Solvent Constituents Strips Separation for
Gallium-68
0.1 M citrate
buffer, pH 5
0.672 g of citric acid
anhydrous and 1.911g
of trisodium citrate,
dehydrate 100 ml dH2O
(1 ml per test strip,
control performed
without adding protein to
detect
68Ga-DARPin)
iTLC-SA
(Varian)
Origin
-
68Ga-DARPin
-Insoluble
68Ga
Front
-
68Ga-EDTA
-
68Ga-Chelator
-Free
68Ga
Table 2.10 Solution used for the HotSHOT DNA extraction from mice ear biopsies.
Solution Composition
Alkaline Lysis Buffer (pH
12) 25 mM NaOH
0.2 mM Na2EDTA
For 100 ml: 25 ml of 100 mM NaOH, 0.4 ml of 50 mM
Na2EDTA (pH 8), 74.6 ml of dH2O
Neutralizing Solution (pH
5) 40 mM Tris-HCl
For 100 ml: 630 mg of Tris-HCl, 100 ml of dH2O81
2.1.3 Electrophoresis and Western Blotting Consumables
Agarose gel electrophoresis was performed with horizontal gels slab run on a Hi-Set
mini electrophoresis unit (Anachem). Agarose MP (Roche Diagnostics) was used to
produce the gels. The DNA ladders, DNA Molecular Weight Marker IX (Roche
Diagnostics), 1 kb DNA Ladder (New England BioLabs), 1 kb DNA Step Ladder
(Promega) and Hyperladder I (Bioline Reagents) were selected based on the size of
the DNA samples (Figure 2.1). Gel electrophoresis was powered with the Pharmacia
LKB-GPS 200/400 power pack (Pharmacia). Images were obtained using the
G:BOX gel imaging system (Syngene).
A) B) C D)
Figure 2.1 DNA Ladders: weight of DNA bands are expressed as base pairs:
A) DNA Molecular Weight Marker IX (Roche Diagnostics) ran on a 1% agarose gel.
B) 1 kb DNA Ladder (New England BioLabs, NEB) ran on a 0.8% TAE agarose gel.
C) 1 kb DNA Step Ladder (Promega) ran on a 0.7% agarose gel.
D) Hyperladder I (Bioline Reagents) ran on a 1 % agarose gel.
For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
western blotting, the SeeBlue Plus2 Pre-Stained Standard (Life Technologies) and
Spectra Multicolor Broad Range Protein Ladder (Thermo Scientific) were used
(Figure 2.2). Samples were run on either Novex 16% Tris-Glycine Mini Gels 1.0 mm,82
10 well pre-cast mini gels (Life Technologies) or 4-20% Tris-Glycine 1.0mm, 10 well
pre-cast mini gels (NuSep).
A) B)
Figure 2.2 Molecular weights of the protein bands.
A) SeeBlue Plus2 Pre-Stained Standard, approximate molecular weights on Tris-
Glycine Gel (Life Technologies)
B) Spectra Multicolor Broad Range Protein Ladder, approximate molecular weights
on Tris-Glycine Gel (Thermo Scientific)
The PowerEase 500 power supply (Life Technologies) was used for SDS-PAGE and
protein transfer. SDS-PAGE was performed in the XCell SureLock Mini-Cell
Electrophoresis System (Life Technologies). The immun-blot polyvinylidene
difluoride (PVDF) 0.2 µm membranes (Bio-Rad Laboratories) and XCell Blot II
Module (Life Technologies) were used in the transfer of protein samples from gels to
membranes for western blotting.
2.1.4 Primers for molecular biology techniques, nuclease and proteinase
cleavage sites
All primers were purchased from Integrated DNA Technologies, except AOX1 Sense
and AOX1 Anti-sense which were purchased from Life Technologies. Primers were
purchased in a lyophilised form and dissolved with filtered dH2O. Primers for G3
DARPin DNA PCR were dissolved to either 1 µg/µL (1x concentration) or 10 µg/µL83
(10x concentration) depending on their molecular weights (Table 2.11 and Table
2.12).
Table 2.11 Primers used for the PCR of G3 DARPin DNA.
Primer Sequence (5’ - 3’) Description
EAEAHis6
Sense
5’ ATAGAATTC*TCGAGAAAAGAGAGGCTGAA
GCTCATCACCATCATCACCATGGACCAGGTTC
TGATTTGGGAAAGAAATTGTTGGAAGCTGCTA
GAGCTG 3’
Sense primer for EAEAHis6-
G3 DNA. The sequence
which anneals to ANK-1
plasmid is underlined. A His6
tag (red), glycine-proline
(blue) and lysine ( ) are
introduced. Site cleaved by
nuclease XhoI (*). Translated
amino acid sequences
cleaved by proteinases Kex2
and Ste13 (bold).
EAEA(HE)3
Sense
5’ ATAGAATTC*TCGAGAAAAGAGAGGCTGAA
GCTCATGAGCATGAACACGAAGGACCAGGTT
CTGATTTGGGAAAGAAATTGTTGGAAGCTGCT
AGAGCTG 3’
Sense primer for EAEA(HE)3-
G3 DNA. The sequence
which anneals to the ANK-1
plasmid is underlined. A (HE)3
tag (red), glycine-proline
(blue) and lysine ( ) are
introduced. Site cleaved by
nuclease XhoI (*). Translated
amino acid sequences
cleaved by proteinases Kex2
and Ste13 (bold).
Cleavable
tag Sense
5’ C*TCGAGAAAAGAGAGGCTGAAGCTCATCA
CCATCATCACCATGGAGGTGGCTCTGGATTA
GAGGTATTGTTTCAAGGACCAGGTTCTGATTT
GGGAAAGAAATTGTTGGAAGCTGCTAGAGCT
G 3’
Sense primer for cleavable
tag-G3 DNA. The sequence
which anneals to the ANK-1
plasmid is underlined. A
cleavable His6 tag (red) and
lysine ( ) are introduced. The
site recognised by HRV 3C
protease site including a
glycine-proline (blue). Site
cleaved by nuclease XhoI (*).
Translated amino acid
sequences cleaved by
proteinases Kex2 and Ste13
(bold).
His6 Sense 5’ ATAGAATTC*TCGAGAAAAGACATCACCATC
ATCACCATGGACCAGGTTCTGATTTGG 3'
Please refer to Appendix for plasmid EAEAHis-
3/pPICZαB sequence. 
Sense primer for His6-G3. The
sequence which anneals to
the EAEAHis6-G3 plasmid is
underlined. The His6 tag (red)
and glycine-proline (blue) are
maintained. Site cleaved by
nuclease XhoI (*). Translated
amino acid sequences
cleaved by proteinase Kex2
(bold).
(HE)3
Sense
5’ATAGAATTC*TCGAGAAAAGACATGAGCATG
AACACGAAGGACCAGGTTCTGATTTGG 3’
Sense primer for (HE)3-G3.
The sequence which anneals
to the EAEA(HE)3-G3 plasmid84
Please refer to Appendix for plasmid EAEAHE-
3/pPICZαB sequence. 
is underlined. The (HE)3 tag
(red) and glycine-proline
(blue) are maintained. Site
cleaved by nuclease XhoI (*).
Translated amino acid
sequences cleaved by
proteinase Kex2 (bold).
Truncated
Sense
5 ’ATAGAATTC*TCGAGAAAAGAGAGGCTGA
AGC 3’
Sense primer used for
EAEAHis6-G3, EAEA(HE)3-
G3, cleavable tag-G3. Site
cleaved by nuclease XhoI (*).
Translated amino acid
sequences cleaved by
proteinase Kex2 and Ste13
(bold).
AOX1
Sense
5’ GACTGGTTCCAATTGACAAGC 3’ Sense control for His6-G3 and
(HE)3-G3 PCR. Binds to
pPICZαB sense AOX1 primer 
site
Anti-sense
G3
5’ TAATTAT*CTAGATTATTAGCAACCTCCGTT
AACTTTTGCAAAATTTCAG 3’
Antisense primer used for
EAEAHis6-G3, EAEA(HE)3-
G3, cleavable tag-G3, His6-
G3 and (HE)3-G3 DNA,
introduces a C-terminal
cysteine (red), XbaI nuclease
cleavage site (*) and
incorporates stop codons
(underlined)
AOX1 Anti-
sense
5’ GCAAATGGCATTCTGACATCC 3’ Anti-sense for His6-G3 and
(HE)3-G3. Anti-sense control
for His6-G3 and (HE)3-G3.
Binds to pPICZαB anti-sense 
AOX1 primer site
Table 2.12 Properties of primers used in the production of G3 DARPin DNA.
Primer Melting
temperature
(° C)
Molecular
Weight (Da)
Weight
(mg)
Conc.
(µg/µl)
G3 DARPin DNA
PCR
EAEAHis6Sense 71.7 30,722 3.10 10 EAEAHis6-G3
EAEA(HE)3 Sense 71.2 30,900 3.28 10 EAEA(HE)3-G3
Cleavable tag Sense 71.5 38,584 0.154 1 Cleavable tag-G3
His6 Sense 67.3 17,528.4 0.48 1 His6-G3
(HE)3 Sense 67.4 17,706.6 0.46 1 (HE)3-G3
Truncated Sense 59.5 9,650 0.32 1 EAEAHis6-G3,
EAEA(HE)3-G3,
cleavable tag-G385
AOX1 Sense 54.3 6,430.2 0.21 1 Sense control for
His6-G3 and (HE)3-G3
Anti-sense G3 61.9 15,267 0.61 1 EAEAHis6-G3,
EAEA(HE)3-G3,
cleavable tag-G3,
His6-G3 and (HE)3-G3
AOX1 Anti-sense 54.8 6,390.2 0.21 1 or 10 Anti-sense for His6-
G3 and (HE)3-G3.
Anti-sense control for
His6-G3 and (HE)3-
G3.
Table 2.13 DNA sequences cleaved by restriction endonucleases for G3 DARPin
and pPICZαB DNA digestions. 
Restriction
endonucleases
Source DNA Cleavage
site (*)
DARPin DNA
base position
pPICZαB 
base position
XhoI E. coli 5’ C*TCGAG 3’ N-terminus 1184*1185
XbaI E. coli 5’ T*CTAGA 3’ C-terminus 1275*1276
Table 2.14 Amino acid sequences cleaved by proteinases.
Proteinase Source Protein cleavage site (*)
Kex2 gene product P. pastoris Glu(E)-Lys(K)-Arg(R) * (amino acid)
Ste13 gene product P. pastoris Glu (E)-Ala(A) * (amino acid)
Human rhinovirus
(HRV) 3C
Rhinovirus
(recombinant)
Leu(L)-Glu(E)–Val(V)–Leu(L)-Phe(F)-
Gln(Q) * Gly(G)-Pro(P)
2.1.5 Plasmids
The plasmid ANK-1 was based on the G3 DARPin E. coli DNA sequence (gift from
Professor Andreas Plückthun, University of Zurich), which was optimised for P.
pastoris by GenScript. ANK-1 was used as the DNA template for the PCR
amplification of EAEAHis6-G3, EAEA(HE)3-G3 and cleavable tag-G3 (Figure 2.3).
The plasmids produced during the EAEAHis6-G3 and EAEA(HE)3-G3 development
were used as the templates for His6-G3 and (HE)3-G3, respectively (Appendix).86
Figure 2.3: ANK-1 DNA plasmid optimised for P. pastoris, encodes for a G3 DARPin
which differed from the proposed G3 DARPins in the following respects.
1) C-terminal His6 tag rather than N-terminal tag
2) No cysteine rather than a solitary C-terminal cysteine
3) Alanine (A) rather than a Lysine (K) at residue 17 (A17K)
4) Add Glycine (G) Proline (P) between N-terminal tag and GDSDL
ctcgagaagagagaagctgaagctatggctggttctgatttgggaaaggctttgttggaa
L E K R E A E A M A G S D L G K A L L E
gctgctagagctggtcaagatgatgaagttagaattttgatggctaacggtgctgatgtt
A A R A G Q D D E V R I L M A N G A D V
aacgctaaggatgaatacggtttgactccattgtacttggctactgctcatggtcatttg
N A K D E Y G L T P L Y L A T A H G H L
gaaattgttgaagttttgttgaagaatggagctgatgttaacgctgttgatgctattggt
E I V E V L L K N G A D V N A V D A I G
tttactccattgcatttggctgcttttattggtcatttggaaattgctgaagttttgttg
F T P L H L A A F I G H L E I A E V L L
aagcatggtgccgacgttaacgctcaggataagtttggaaagactgcttttgatatttct
K H G A D V N A Q D K F G K T A F D I S
attggtaacggtaacgaagatttggctgaaattttgcaaaagttgaaccatcatcatcat
I G N G N E D L A E I L Q K L N H H H H
catcattaataatctagagcggccgc
H H - - S R A A87
2.2 Methods
2.2.1  Production of ligated pPICZαB plasmid and G3 DARPin DNA
2.2.1.1 Polymerase chain reaction of G3 DARPin DNA
The G3 DARPin PCRs were prepared in a similar way to each other (Table 2.15),
except different primers and different primer concentrations were used for each
construct (Table 2.16). The DNA templates used for His6-G3 and (HE)3-G3 were
generated during the PCR for EAEAHis6-G3 and EAEA(HE)3-G3, respectively
(Appendix). For His6-G3 and (HE)3-G3, a control PCR was performed with alcohol
oxidase 1 (AOX1) Sense and AOX1 Anti-sense primers which would be expected to
produce a larger DNA fragment than G3 DARPin DNA alone, as it would also
incorporate pPICZαB DNA. 
Table 2.15 G3 DARPin polymerase chain reactions.
Constituent Volume (µl) Final reaction
concentration
PCR Master Mix 42.5 50.5 nM of each dNTP
Sense primer (concentration 0.1, 1.0 or 10 µg/µl) 1 0.002, 0.02 or 0.2 µg /µl
Anti-sense primer (concentration 1.0 or 10
µg/µl)
1 0.02 or 0.2 µg /µl
Taq polymerase: ampliTaq DNA Polymerase, 5
U/μl (Roche Diagnostics) 
1 0.1 U/µl
Template DNA 1 0.16-0.24 µg/µl
Filtered dH2O 3.5
Total volume 5088
Table 2.16 Primers and templates used for each G3 DARPin PCR.
DARPin PCR (no.
of cycles)
Template DNA
(final conc.)
Sense primer
(final conc.)
Anti-sense primer
(final conc.)
EAEAHis6-
G3
Short
PCR (40)
ANK-1 (0.2 µg/µl) EAEAHis6 Sense
(0.002 µg/µl) for
cycles 1-10
Truncated Sense
(0.02 µg/µl) for
cycles 11-40
Anti-sense G3
(0.02 µg/µl) for
cycles 1-40
Long PCR
(30)
ANK-1 (0.2 µg/µl) EAEAHis6 Sense
(0.02 µg/µl) for
cycles 1-30
Anti-sense G3
(0.02 µg/µl) for
cycles 1-30
EAEA(HE)3-
G3
Short
PCR (40)
ANK-1 (0.2 µg/µl) EAEA(HE)3 Sense
(0.002 µg/µl) for
cycles 1-10
Truncated Sense
(0.02 µg/µl) for
cycles 11-40
Anti-sense G3
(0.02 µg/µl) for
cycles 1-40
Long PCR
(30)
ANK-1 (0.2 µg/µl) EAEA(HE)3 Sense
(0.02 µg/µl) for
cycles 1-30
Anti-sense G3
(0.02 µg/µl) for
cycles 1-30
Cleavable
tag-G3
Short
PCR (40)
ANK-1 (0.2 µg/µl) Cleavable tag
Sense (0.002 µg
/µl) for cycles 1-10
Truncated Sense
(0.02 µg/µl) for
cycles 11-40
Anti-sense G3
(0.02 µg/µl) for
cycles 1-40
Long PCR
(30)
ANK-1 (0.2 µg/µl) Cleavable tag
Sense (0.02 µg/µl)
for cycles 1-30
Anti-sense G3
(0.02 µ /µl) for
cycles 1-30
His6-G3  His-1 (30)  pPICZαB/EAEAHis3 
(0.16 µg/µl)
His6 Sense (0.02
µg /µl) for cycles 1-
30
Anti-sense G3
(0.02 µg/µl) for
cycles 1-30
His-2 (30)  pPICZαB/EAEAHis3 
(0.16 µg/µl)
His6 Sense (0.02
µg /µl) for cycles 1-
30
AOX1 Anti-sense
(0.02 µg/µl) for
cycles 1-30
Control
(30)
pPICZαB/EAEAHis3 
(0.16 µg/µl)
AOX1 Sense
(0.2 µg/µl) for
cycles 1-30
AOX1 Anti-sense
(0.2 µg/µl) for
cycles 1-30
(HE)3-G3  HE-1 (30)  pPICZαB/EAEAHE3 
(0.24 µg/µl)
(HE)3 Sense (0.02
µg /µl) for cycles 1-
30
Anti-sense G3
(0.02 µg/µl) for
cycles 1-30
HE-2 (30)  pPICZαB/EAEAHE3 
(0.24 µg/µl)
(HE)3 Sense (0.02
µg /µl) for cycles 1-
30
AOX1 Anti-sense
(0.02 µg/µl) for
cycles 1-30
Control
(30)
pPICZαB/EAEAHE3 
(0.24 µg/µl)
AOX1 Sense
(0.2 µg/µl) for
cycles 1-30
AOX1 Anti-sense
(0.2 µg/µl) for
cycles 1-3089
The same PCR cycle conditions were used for all G3 DARPin PCRs, which were
performed with the Personal Cycler (Biometra) (Table 2.17).
Table 2.17 PCR conditions used for EAEAHis6-G3, EAEA(HE)3-G3, cleavable tag-
G3, His6-G3 and (HE)3-G3 DARPins.
PCR steps Conditions
Initialisation 95 °C for 3 min
PCR cycles (n = 30-40) 95 °C for 60 sec (denaturation)
60 °C for 60 sec (annealing)
72 °C for 90 sec (elongation)
Final elongation 72 °C for 10 min
Final hold 4 °C (5 min – 24 h)
2.2.1.2 Agarose gel electrophoresis of G3 DARPin PCR products
Agarose gels were formed by dissolving 0.75 g (1.5% w/v) or 1.0 g (2% w/v) of
agarose (Sigma-Aldrich) in 50 ml Tris-acetate-EDTA (TAE) 1x buffer with microwave
heating for 2 min. After cooling to 50-55 °C, 5 µl ethidium bromide (concentration 10
mg/ml, Sigma-Aldrich) was added to the gel solution, the gel was then poured into
the electrophoresis unit with the appropriate sized well comb and allowed to set.
After setting, TAE 1x buffer was poured over the gel.
Conventionally, the DNA ladder (10 µl) was applied to the first well of the agarose
gel. DNA 10x loading buffer (5 µl) was added to the PCR samples and the entire
PCR sample was applied to an individual well. The electrophoresis was performed
at 50 millivolts (mV). Bands were visualised with the UVP transilluminator (Genetic
Research Instrumentation) and the desired bands were excised from the gel with a
scalpel.
2.2.1.3 Purification of G3 DARPin DNA from agarose gel bands
DNA was purified from excised agarose gel bands using the Wizard SV Gel and
PCR Clean-Up System (Promega) by centrifugation, according to the
manufacturer’s instructions. Each DNA gel band was placed into a 1.5 ml
microcentrifuge tube and weighed. Membrane Binding Solution (10 µl/mg of gel)
was applied to the gel, which was subsequently vortexed and incubated at 50-65 °C
until the gel dissolved. An equal volume of Membrane Binding Solution was added
to the dissolved gel.90
The dissolved gel was transferred to a SV Minicolumn and incubated at room
temperature (RT) for 1 min. The SV Minicolumn was placed into a Collection Tube
for centrifugation. The dissolved gel was centrifuged at 16,000 × g for 1 min (RT),
the flow through was discarded. To wash the DNA, 700 μl Membrane Wash Solution 
was added to the sample and centrifuged at 16,000 × g for 1 min (RT), the flow
through was discarded and a second wash was performed with 500 μl Membrane 
Wash Solution in same way as described. Finally, the Collection Tube was
centrifuged for 1 min at 16,000 × g (RT) to allow any residual ethanol to evaporate.
The Minicolumn was transferred to a clean 1.5 ml microcentrifuge tube and
nuclease-free water (50 µl) was added, it was incubated for 1 min at RT and then
centrifuged at 16,000 x g for 1 min (RT). The flow through containing DNA was
stored at -20 °C.
2.2.1.4 Amplification and extraction of pPICZαB plasmid DNA  
Electroporation of electro-competent bacterial cells
Electrocompetent TOP10F´ cells (E. coli, Life Technologies) were electroporated
with  Pme  I-linearised  pPICZαB  plasmid  (gift  from  Dr  Kim  Vigor,  UCL  Cancer 
Institute).
Pme I-linearised pPICZαB plasmid (1 µl) was added to TOP10F´ cells (100 µl) which 
had been thawed on ice, the mixture was then transferred into a 0.2 cm Gene
Pulser/ MicroPulser cuvette (Bio-Rad Laboratories) which had been pre-chilled on
ice. The cells were pulsed once using the pre-set ‘Eco2’ setting on the MicroPulser
electroporator (Bio-Rad Laboratories) at 2500 Volts (V) for 5 ms. Ice cold Low Salt
Luria Bertani (LB) media (1 ml) was added to the cuvette and incubated at 37 °C for
1 h with no shaking. Electroporated cells were spread onto Low Salt LB plates
containing Zeocin (25 µg/ml) in 50 and 100 µl aliquots and incubated at 37 °C for 24
h.
The following day, two colonies were selected and transferred into separate sterile
250 ml conical flasks containing 50 ml of Low Salt LB with Zeocin (25 µg/ml). The
flasks were incubated at 37 °C, shaking at 200 revolutions per min (rpm) overnight
in the New Brunswick / Innova 4230 Refrigerated Benchtop Incubator Shaker
(Eppendorf UK).91
pPICZαB plasmid DNA extraction 
pPICZαB plasmid was  extracted from TOP10F’ cells using the QIAGEN Plasmid 
Midi Extraction Kit (Qiagen), according to the manufacturer’s instructions.
To lyse the electroporated TOP10F´cells, 25 ml from the two overnight cultures were
centrifuged at 6,000 x g for 15 min (4 °C) in separate 50 ml conical polypropylene
tubes. The pellets were retained, then the final 25 ml of the overnight cultures was
added to the pellets and centrifuged at 6,000 x g for 15 min (4 °C). The supernatant
was discarded and the two pellets were re-suspended in 4 ml of Qiagen Buffer P1,
followed by adding 4 ml Qiagen Buffer P2, inverting 4-6 times and incubating for 5
min at RT. Subsequently, 4 ml of chilled Qiagen Buffer P3 was added, inverted 4-6
times and incubated on ice for 15 min.
The pPICZαB plasmid was removed from the sample by centrifuging at 20,000 x g
(4 °C) for 30 min and retaining the supernatant. The supernatant was re-centrifuged
for 15 min at 20,000 x g (4 °C) and supernatant retained.
Two Qiagen-tip 100 columns were equilibrated with 4 ml of Buffer QBT and the
supernatant containing the pPICZαB plasmid DNA was applied to the columns. The 
Qiagen-tip columns were washed twice with 10 ml Qiagen Buffer QC. The DNA was
eluted from the columns with 5 ml Qiagen Buffer QF into two clean 15 ml centrifuge
tubes.
To precipitate the DNA, 3.5 ml of isopropanol was added to the eluted DNA, the two
samples were centrifuged at 15,000 x g for 30 min (4 °C) and the supernatant was
discarded. To wash the pellet, 2 ml of 70% ethanol was added, then centrifuged at
15,000 x g for 10 min (4 °C) and supernatant discarded. After air drying for 5-10 min
the pellet of plasmid DNA was re-dissolved in 50 µl of dH2O. The nucleic acid
concentration of the two samples was assed using the NanoDrop 1000
Spectrophotometer (Thermo Scientific); finally it was stored at -20 °C.
2.2.1.5 Digestion of G3 DARPin and pPICZαB Plasmid DNA 
Purified G3 DARPin DNA (50 µl) and pPICZαB plasmid DNA (3 µl) were digested 
separately with 5 µl XbaI (500 Units, concentration 100,000 Units/ml), 5 µl XhoI (500
Units, concentration 100,000 Units/ml), 10 µl NE Buffer 4 (10x concentration), 10 µl92
Bovine serum albumin (BSA, 10x concentration) and dH2O (17 µl) (Figure 2.4 and
Table 2.13). The digestions were incubated at 37 °C for 2.5 h.
The  digested  pPICZαB  plasmid  was  run  on  an  agarose  gel  electrophoresis  (1% 
agarose gel and Promega 1 kb DNA ladder used). The digested G3 DARPin DNA
was not run on an agarose gel electrophoresis.
Figure 2.4 DNA sites cleaved by XbaI and XhoI, nucleic acids retained by DARPin
(green) and plasmid (black).
A) XhoI recognition site (˅ /˄) at N-terminus
5’…C˅TCGAG…3’
3’…GAGCT˄C…5’
B) XbaI recognition site (˅ /˄) at C-terminus
5’… T˅CTAGA…3’
3’… AGATC˄T…5’
pPICZαB plasmid DNA was purified from the agarose gel using the Wizard SV Gel 
and PCR Clean-Up System (Promega), as previously described. Digested G3
DARPin DNA was also purified using the Wizard SV Gel and PCR Clean-Up System
(Promega) to remove XbaI and XhoI, initially 100 µl of Membrane Binding Solution
was added to digested G3 DARPin DNA (100 µl) and purification was completed as
outlined  previously.  The  digested  pPICZαB  plasmid  and  G3  DARPin  DNA  were 
stored at -20 °C.
2.2.1.6 Ligation of PCR Product and pPICZαB plasmid 
All ligation buffers and enzymes were purchased from New England BioLabs.
Digested DARPin DNA (1 µl) and pPICZαB plasmid DNA (1 µl) were added to 40 µl 
dH2O, followed by 5 µl T4 Ligase Reaction Buffer (10x) and 3 µl of ice cold T4
Ligase (1,200 cohesive end units, concentration 400,000 cohesive end units/ml).
Control ligations omitted digested G3 DARPin DNA. The ligation mixtures were
incubated for 10 min at RT.
2.2.1.7 Phenol-Chloroform extraction of DNA from Ligation Mixture
Ligation and control mixtures (50 µl) were placed in separate 1.5 ml microcentrifuge
tubes and 50 µl phenol solution (Sigma-Aldrich) was added to them, the mixtures93
were centrifuged for 10 min at 16,000 x g (RT). The upper layer was transferred into
a new 1.5 ml microcentrifuge tube and an equal volume (~50 µl) of
Phenol:Chloroform:Isoamyl Alcohol 25:24:1 saturated with 10 mM Tris, pH 8.0, 1
mM EDTA (Sigma-Aldrich) was added. Once an emulsion formed, it was centrifuged
for 10 min at 16,000 x g (RT). The upper aqueous phase containing DNA was
transferred into a new 1.5 ml microcentrifuge tube and treated with 1/10
th volume of
3 M sodium acetate (pH 6), 2.5 times volume of absolute ethanol (≥ 99.5%) and 1 µl 
glycogen. The extraction mixture was incubated either at -20 °C overnight or at -80
°C for 1-2 h, then centrifuged at 16,000 x g for 10 min (RT) and the supernatant was
discarded. The DNA containing pellet was washed with 195 µl of 70% ethanol and
centrifuged at 16,000 x g for 10 min (RT). The supernatant was discarded and DNA
pellet was air dried. The pellet was solubilised in 10 µl of dH2O and stored at -20 °C.
2.2.1.8 Bacterial transformations of ligated pPICZαB/DARPin DNA  
Electrocompetent TOP10F´ cells (E. coli, Life Technologies) or electrocompetent
TG1 Cells (E. coli, Lucigen Corporation) were used for the bacterial transformations.
Ligated pPICZαB/DARPin DNA (2 µl) was added to thawed bacteria (50 µl) and the 
samples were transferred into 0.2 cm Gene Pulser/ MicroPulser cuvettes (Bio-Rad
Laboratories), which had been pre-chilled on ice. The cells were pulsed at 2500 V
for 5 ms using the Bio-Rad MicroPulser electroporator (Eco2 setting). Low salt LB
without Zeocin (1 ml) was added and the cuvettes were incubated for 1 h at 37 °C.
Subsequently, 50-200 µl of the media were plated onto Low Salt LB/ Zeocin (25
µg/ml) plates and incubated overnight at 37 °C.
The following day up to seven colonies were selected from each plate using sterile
pipette tips. The pipette tip carrying an individual colony was mixed in 10 µl of dH2O,
to PCR screen colonies for G3 DARPin DNA inserts. Finally, the pipette tip was
mixed with 5 ml Low Salt LB media containing Zeocin (25 µg/ml) in a sterile 50 ml
conical polypropylene tube. The inoculated media were stored at 4 °C and would
later be used to obtain ligations of pPICZαB/DARPin DNA from positive colonies. 
2.2.1.9 PCR Colony Screening
The PCR mixture was prepared with 85 µl PCR Master Mix, 5 µl Truncated Sense
primer (1 µg/µl), 5 µl Anti-sense G3 primer (1 µg/µl), 10 µl dH2O and 1 µl ampliTaq94
DNA Polymerase (5 U/μl, Roche Diagnostics). Each colony was screened by taking 
1 µl of dH2O exposed to the colony and adding 10 µl PCR reaction mixture.
The PCR cycling was performed using the same equipment and conditions as used
for the initial DARPin DNA PCR (Table 2.17) and 30 cycles were performed.
Subsequently, 2 µl of 10x DNA loading buffer was added to the reactions and
samples were run on a 1.5% agarose gel with a NEB 1 kb DNA ladder (New
England BioLabs) or DNA Molecular Weight Marker IX (Roche Diagnostics).
2.2.1.10  Plasmid Extraction of ligated pPICZαB/DARPin DNA 
Transformed clones containing G3 DARPin DNA inserts were selected for an
overnight culture. Low Salt LB media (100 µl) which had been inoculated with the
selected clones was added to sterile 250 ml conical flask containing 50 ml Low Salt
LB Media with Zeocin (25 µg/ml). The inoculated media were incubated overnight at
37 °C and shaking at 225 rpm using the New Brunswick / Innova 4230 Refrigerated
Benchtop Incubator Shaker (Eppendorf UK).
The ligated pPICZαB/DARPin DNA was extracted from the bacterial cells using the 
QIAGEN Plasmid Midi Extraction Kit (Qiagen), as described previously. The DNA
was sequenced by the DNA Sequencing Service at the UCL Cancer Institute, using
the AOX1 Sense and AOX1 Anti-sense primers (Life Technologies).
2.2.2 Pichia pastoris expression of G3 DARPin protein
2.2.2.1 Linearisation of pPICZαB plasmid/DARPin DNA ligations 
Ligations of pPICZαB/DARPin DNA inserts were linearised with Pme I (enzyme and 
buffers from New England BioLabs) at the AOX1 promoter region of pPICZαB for 
transformation into X-33 (P. pastoris) yeast genomes (Figure 2.5).
Ligated pPICZαB/DARPin DNA (10 µg of nucleic acid) were digested with 3 µl Pme I 
(30 units, concentration 10,000 units/ml), 10 µl of 10x NEBuffer 4, 10 µl of 10x
Purified BSA and reactions were made up to 100 µl volume with dH2O. Controls
were performed with ligated pPICZαB/DARPin DNA (10 µg of nucleic acid) in dH2O
only or pGAPZαB/DARPin DNA ligations treated in the same way as their pPICZαB 
counterparts (pGAPZαB is not linearised by Pme I). 95
Reactions were incubated at 37 °C for 3 h. To assess the linearisation efficiency a 5
µl sample was removed from each reaction and diluted in 20 µl of dH2O, then run on
an agarose gel electrophoresis, 1% or 2% agarose gels with a 1 kb DNA step ladder
(Promega) or HyperLadder I (Bioline) were used.
5’… GTTT˅AAAC…3’
3’…CAAA˄TTTG…5’
Figure 2.5 Pme I Recognition Site (˅ /˄) in the 5’ AOX1 promoter region of pPICZαB 
plasmid (base 413/414).
2.2.2.2 Phenol-Chloroform  Extraction  of  linearised  pPICZαB  plasmid/DARPin 
DNA
After linearisation, phenol-chloroform extraction was performed to purify and extract
DNA, as previously outlined.
2.2.2.3 Expansion of electrocompetent X-33 cells
Electrocompetent X-33 cells (Life Technologies) were used to inoculate 5 ml of
Yeast Extract Peptone Dextrose (YPD) media in a sterile 50 ml conical
polypropylene tube, by placing a sterile pipette tip in a vial of frozen X-33 cells (-80
°C) and then mixing the tip with YPD media. The inoculated media was incubated
overnight at 30 °C and shaking at 225 rpm within the New Brunswick / Innova 4230
Refrigerated Benchtop Incubator Shaker (Eppendorf UK). The following day, 100 µl
of the overnight culture was used to inoculate 250 ml YPD media within a sterile 2 L
glass conical flask, the flask was incubated at 30 °C and 225 rpm until the optical
density measured at 600 nm (OD600) reached 1.3-1.5 (~16 h post inoculation).
The X-33 culture was centrifuged at 1,500 x g for 5 min (4 °C), the supernatant was
discarded and subsequent centrifugations were performed in the same way. The
pellet was resuspended in 250 ml ice cold sterile dH2O, re-centrifuged and the
supernatant was discarded. The pellet was resuspended in 20 ml ice cold sterile 1 M
sorbitol, re-centrifuged and supernatant was discarded. Finally, the X-33 cell pellet
was resuspended in 1-2 ml ice cold sterile 1 M sorbitol, stored on ice and used the
same day for electroporation.96
2.2.2.4 Electroporation of X-33 cells with linearised pPICZαB plasmid/ DARPin 
DNA
X-33  cells  (80  µl)  were  added  to  linearised  pPICZαB/DARPin  DNA  (10  µl)  and 
placed on ice for 1 min. Cells were transferred into a pre-chilled 0.2 cm Gene
Pulser/ MicroPulser cuvette (Bio-Rad Laboratories) and pulsed with the ‘Pic’ setting
on the MicroPulser electroporator (Bio-Rad Laboratories) at 2000 V for 5 ms.
Immediately after electroporation, 1 ml sterile ice cold 1 M sorbitol was added to the
cuvette and incubated at 30 °C for 2 h with no shaking. The transformed cells were
spread onto YPDS (Yeast Extract Peptone Dextrose Sorbitol) plates containing 100
µg/ml of Zeocin in 50-200 µl aliquots and incubated for 72 h at 30 °C without
shaking.
2.2.2.5 Protein expression in X-33 yeast cells
X-33 colonies (4-6) of each construct were selected from the YPDS/Zeocin plates.
Each selected colony was used to inoculate separate sterile 50 ml conical
polypropylene tubes containing 5 ml of Buffered Glycerol-complex medium (BMGY)
with Zeocin 100 μg/ml, then incubated at 30 °C and 225 rpm overnight. At the same 
time,  YPDS  containing  Zeocin  100  μg/ml  plates  were  streaked  with  inoculated 
media and incubated at 30 °C without shaking, these plates would be used to
prepare the seed lots, once protein expression was confirmed.
Once the OD600 reached 2.5 (~16 h post inoculation), the overnight culture was
centrifuged for 5 min at 3,000 x g (RT). The supernatant was discarded and pellets
were re-suspended in Buffered Methanol-complex medium (BMMY) with Zeocin 100
μg/ml to achieve a final OD600 equivalent to 1 (~25 ml). The BMMY containing the
electroporated cells were transferred into a sterile 250 ml conical flask, then
incubated at 30 °C and 225 rpm for 72 h. At 24, 48 and 72 h incubation, 250 µl of
the media was removed and centrifuged at 5,000 rpm for 5 min and the supernatant
was mixed with SDS-PAGE reducing buffer and stored at -80 °C. After the samples
were taken at 24 and 48 h, 100% Methanol was added to the media, at a volume
equivalent to 25 µl/5ml BMMY (~125 µl) to stimulate continued G3 DARPin protein
expression through methanol induced AOX1 gene activation.97
2.2.2.6 SDS-PAGE
Protein samples were mixed with 4x SDS-PAGE (3 protein: 1 buffer volumes) or 2x
SDS-PAGE (1:1) loading buffer. Samples in reducing buffer were denatured by
heating for 3 min at 75 °C in a Personal Cycler (Biometra), while samples in non-
reducing buffer were not heated.
Up to two gels were fixed in the electrophoresis unit by locking the gel tension
wedge, then the unit was filled with 1x SDS-PAGE Running Buffer to cover the
gel(s). The samples were loaded using a micropipette; the protein standard was
usually loaded into lane 1. Subsequently, samples were loaded. The gels were run
at a constant 35 mA (125 V, 5.0 W) for 1 h 30 min. Afterwards the gel(s) were
removed from their cassette(s), then the lower (below the dye) and upper (well
dividers) aspect of the gels were cut off.
2.2.2.7 Western blot analysis
The electrophoresis gels were transferred to PVDF membranes which had been
pre-soaked in methanol for 20 sec, followed by 1x Protein Transfer Buffer. For each
transfer 20 pieces of blotting paper (Whatman) and six sponges were pre-soaked in
1x Protein Transfer Buffer. The deep half of the transfer module was loaded in the
following order, three sponges, ten pieces of blotting paper, agarose gel, PVDF
membrane, ten pieces of blotting paper and three sponges. Two gels could be
transferred simultaneously with blotting paper placed between the separate gel-
membrane transfers. The chamber was filled with 1x Protein Transfer Buffer and run
at 125 mA (25 V, 17 W) for 1 h 30 min.
Following protein transfer, the membrane was placed in 5% (w/v) dried milk powder
(Marvel) made up with PBS for 1 h on a shaker. It was washed three times in 0.1%
Tween-20/PBS (v/v), followed by three PBS washes. The membrane was placed in
25 ml of 1% milk/PBS (w/v) containing the primary antibody for 1 h shaking (Table
2.18). The Tween-20/PBS and PBS washes were repeated, prior to incubating with
the secondary antibody in 25 ml of 1% milk/PBS (w/v) for 1 h shaking (Table 2.18).
Afterwards the final Tween/PBS and PBS washes were repeated. The protein bands
were  visualised  by  incubating  the  membrane  in  3,3′-Diaminobenzidine 
tetrahydrochloride (DAB) and hydrogen peroxide solution. Once the bands became98
visible the reaction was stopped by rinsing the membrane in dH2O and then air
dried.
Table 2.18 Primary and secondary antibodies used for western blot analysis of G3
DARPin proteins.
Antibody steps His6-based G3 and
Cleavable tag-G3
(HE)3-based G3
Primary antibody
in 1% milk (w/v) with
PBS (25 ml)
25 µl (0.1 % v/v) mouse
tetra-His antibody, BSA-free
(Qiagen)
12.5 µl (0.05% v/v) rabbit
anti-DARPin (Gift from
Professor Plückthun,
University of Zurich)
Secondary antibody
in 1% milk (w/v) with
PBS (25ml)
25 µl (0.1% v/v) ECL anti-
mouse IgG2 horse radish
peroxidase linked F(ab’)2
fragment from sheep (GE
Healthcare)
25 µl (0.1% v/v) goat anti-
rabbit IgG (whole molecule)–
peroxidase antibody (Sigma-
Aldrich)
2.2.2.8 Coomassie staining
Following SDS-PAGE, the gel was placed in coomassie stain for 1 h. The
coomassie stain was poured off and the gel was rinsed in destain until the bands
were visible. The gel was then washed in dH2O for 15 min, followed by soaking in
Gel Dry Drying Solution (Life Technologies). The gel was placed in a gel drying rack
between two cellophane sheets (Sigma-Aldrich) which had been pre-soaked with
Gel Dry Drying Solution 1X. The gel was placed upright and dried overnight.
2.2.2.9 Seed lot preparation
A single X-33 colony confirmed to produce G3 DARPin protein by western blotting
analysis and or coomassie staining was selected from the YPDS/Zeocin plates
prepared during the protein test expression. The seed lot was prepared in a laminar
flow hood. A sterile plastic loop was used to transfer the selected colony from the
plate to a sterile 250 ml conical flask containing 50 ml YPD with Zeocin 100 μg/ml. 
The colony was grown overnight at 30 °C and 250 rpm shaking. Once the OD600
reached 15-20, the culture was transferred into a 50 ml conical polypropylene tube
and centrifuged at 3,000 rpm for 5 min (RT). The supernatant was discarded and the
pellet of G3 DARPin producing X-33 cells were resuspended in YPD/Glucose 15%,
to achieve a final OD600 equivalent to 1 (~15-20 ml), the suspension was dispensed
in 1 ml aliquots into Nunc CryoTubes (Sigma-Aldrich) and stored at -80 °C.99
2.2.3 Production of G3 DARPin protein
2.2.3.1 Fermentation of X-33 cells
Fermentation was carried out by Mr Gaurav Bhavsar and Dr Berend Tolner, with
assistance from Dr Robert Goldstein (All participants are based at the UCL Cancer
Institute).
Fermentation involves generating a large biomass of P. pastoris cells during a
limited glycerol feed. DARPin protein production is initiated during methanol feeding
through the methanol-inducible AOX1 promoter gene within the pPICZαB plasmid. 
The α-factor signal sequence within the pPICZαB plasmid stimulates secretion of G3 
DARPin protein from P. pastoris into the media.
The New Brunswick BioFlo 3000 autoclavable 10 L benchtop bioreactor with
BioCommand supervisory software (Eppendorf) was used for the fermentations.
Each DARPin was broadly produced by the same method but there were some
variations to optimise individual yields (Table 2.19). Samples were taken from the
bioreactor at different stages of the fermentation process, stored in 4x SDS-PAGE
reducing buffer at -80 °C until analysed.
Step 1- Primary Culture:
A 2 L baffle flask containing 230 ml of YEPD was autoclaved, when cooled Zeocin
was added. A seed lot vial (1 ml) was thawed in a laminar flow hood, the
YPED/Zeocin-100 μg/ml media was inoculated with the entire vial and incubated at 
30 °C (200 rpm) until the OD600 reached 12 (Table 2.19).
Step 2- Secondary Culture:
The secondary culture media (volume 331.2 ml) within a sterile 2 L baffle flask was
inoculated with 1 ml of the primary culture in a laminar flow hood. The secondary
culture was incubated at 30 °C (200 rpm) until the OD600 reached 5 (Table 2.19).
The 10 L bioreactor was filled with 5.3 L of basic salt media and autoclaved, then
970 ml hexametaphosphate, 24 ml trace elements and 1 ml anti-foam (Sigma-
Aldrich) was added. The bioreactor was maintained at 30 °C and pH 5 with 100%
ammonium hydroxide and 10% orthophosphoric acid. The bioreactor dissolved
oxygen probe was set at 30%. The entire secondary culture (332.2 ml) was
transferred to the bioreactor and agitated at 500-1000 rpm.100
After approximately 22-24 h, all the glycerol in the media is consumed under aerobic
conditions by the yeast. At this point, there is no demand for oxygen, the oxygen
levels rapidly rise (oxygen spike) until the bioreactor reduces the dissolved oxygen
back to the 30% default setting.
Table 2.19 Variations between the different G3 DARPin production processes.
Production
stages
Cleavable
tag-G3
DARPin
EAEAHis6-
G3 DARPin
His6-G3
DARPin
EAEA(HE)3-
G3 DARPin
(HE)3-G3
DARPin
Fermentation
Primary
culture
until OD600of
12 reached
(h)
12 – 24
Secondary
culture until
OD600of 5
reached (h)
14 – 19
Time from
bioreactor
inoculation to
oxygen spike
(h)
22 – 24
Limited
glycerol feed
in bioreactor
(h)
4 4 4 4 4
Limited
methanol feed
in bioreactor
(h)
0 (10 ml
methanol
given during
glycerol
feed)
23 22 1 2
Harvest
IMAC Column Nickel (II)
sulfate
hexahydrate
Copper
sulphate
pentahydrate
Copper
sulphate
pentahydrate
Nickel (II)
sulfate
hexahydrate
Nickel (II)
sulfate
hexahydrate
Imidazole
wash of radial
flow column
prior to
harvesting
Yes Yes Yes No No
Purification
Concentration,
dialysis and
FPLC steps
Yes Yes Yes Yes Yes
Dialysis fluid PBS with 10
mM DTT
PBS PBS with 10
mM DTT
PBS PBS with 10
mM DTT
FPLC elution
fluid
Eluted into
PBS
Eluted into
PBS
Eluted into
PBS
Eluted into
PBS
Eluted into
PBS101
Step 3- Biomass generation (limited glycerol feed)
At the time of the oxygen spike, a limited glycerol feed (volume 607 ml) was
commenced and the bioreactor pH was set at 6.5. The limited glycerol feed
commenced at 100 ml/h and reduced at pre-determined time points and
discontinued at 4 h (Table 2.20). After 1 h of the limited glycerol feed, 10 ml 100%
methanol was injected into the bioreactor to induce the AOX gene, facilitating
transition from biomass generation into methanol-induced G3 DARPin protein
production.
Step 4- Protein generation (limited methanol feed)
The limited methanol feed was commenced immediately after the limited glycerol
feed and the methanol flow rate increased incrementally until it reached 45 ml/h, this
rate was maintained until harvesting (Table 2.20). The length of the limited methanol
feed was altered for each DARPin construct to optimise yields, by balancing DARPin
production against DARPin breakdown due to P. pastoris proteases. For example,
the cleavable tag-G3 DARPin had no limited methanol feed to prevent premature
His6tag cleavage (Table 2.19).
Table 2.20 Limited glycerol feed for biomass generation and limited methanol feed
for protein generation.
Time post oxygen
spike (h)
Limited glycerol feed flow
rate (ml/h)
Limited methanol feed flow rate
(ml/h)
0 100 0
0.5 100 0
1.0 100 0 (10 ml methanol injected)
1.5 100 0
2.0 80 0
2.5 60 0
3.0 40 0
3.5 20 0
4.0 0 10
6.0 0 20
8.0 0 30
10.0 (until
harvest)
0 45
2.2.3.2 Harvest
G3 DARPins were captured using a XC15 MD62 Radial Flow IMAC column
(Proxcys Downstream Biosystems). Harvesting was tailored for each G3 DARPin.102
IMAC purification is based on the principle that proteins with histidine based tags
have an affinity for certain metal ions that can be immobilised on chromatographic
media ensuring specific capture. Elution from the column is then achieved by
increasing the imidazole concentration, as imidazole is a histidine analogue which
competes with histidine for column binding (Bornhorst and Falke 2000). Low
concentration imidazole buffer washes are commonly used prior to protein elution, to
limit non-specific protein binding. However, prior developmental work performed by
our Group had demonstrated that low concentration imidazole column washes
increased (HE)3-DARPins losses from the IMAC columns (non-published).
Prior to harvesting the radial flow column was prepared by:
1) Neutralising the column with 8 L of dH2O.
2) Charging the column with metal ions (Table 2.19):
 EAEAHis6-G3 and His6-G3: 1 L autoclaved 0.1M copper sulfate pentahydrate
was applied to the column and excess copper removed with 3 L dH2O.
 EAEA(HE)3-G3, (HE)3-G3 and cleavable tag-G3: column was charged with 1 L
autoclaved 0.1M nickel (II) sulfate hexahydrate and excess nickel was removed
with 3 L dH2O. A nickel charged IMAC column was used, as it had been
efficient in purifying the (HE)3-tagged affibody molecule (Tolmachev, Hofstrom
et al. 2010).
3) De-gassing the column by applying short pulses of electricity from the feed
pump.
4) Equilibrating the column with 1X equilibration/ wash solution:
 EAEAHis6-G3, His6-G3 and cleavable tag-G3 wash solution contained 10 mM
imidazole.
 EAEA(HE)3-G3 and (HE)3-G3 did not contain imidazole.
5) Equilibrated columns stored at 4 °C until used.
At the time of harvesting the bioreactor temperature was reduced from 30 °C to 20
°C. Then 1.5 L of biomass from the bioreactor was added to the 2 L dilution vessel
with a stirrer and 0.5 L 4X cell application solution (imidazole free for EAEA(HE)3-G3
and (HE)3-G3) was added to the vessel and the biomass was applied to the IMAC
column. This was repeated several times to process the entire biomass. The rate of
the limited methanol feed (if in process) was reduced by 2 increments, so that the103
amount of methanol feed in proportion to cells in the bioreactor remained fairly
constant.
After all of the biomass had been applied to the column, the cell debris was washed
from the column with 1X equilibration/ wash solution with or without 10mM imidazole
(5L). The matrix of the column was then washed with 20mM imidazole solution but
this step was omitted for EAEA(HE)3-G3 and (HE)3-G3.
The DARPins were eluted from the column with 1 L of high concentration imidazole
solution (200 mM) and collected in 20 fractions within 50 ml conical polypropylene
tubes. Fractions with the highest protein concentrations determined by the optical
density measured at 280 nm (OD280) were pooled. The pooled fractions were filtered
with a 0.2 µm PES 500 ml filter (Nalgene).
2.2.3.3 Concentration and dialysis
The harvested sample was concentrated using a Labscale TFF system with Pellicon
XL 50 cassettes (BioMax 5 kDa filter) (Merck Millipore) which had been washed with
dH2O and then equilibrated with 200 mM imidazole, the stirrer speed was set at 1.5
rpm. When the sample volume reached 20-25 ml, the stirrer was stopped and the
OD280 was assessed.
For dialysis, the DARPin sample volume was exchanged five to ten times (125-250
ml) against filtered PBS with or without 10 mM dithiothreitol (DTT), using the same
system and filters as used for concentration (Table 2.19).
2.2.3.4 Fast protein liquid chromatography
DARPin samples were purified with the AKTA fast protein liquid chromatography
(FPLC) system (GE Healthcare) using a Preparative Superdex 75 column (500 ml
bed volume, pre-packed with Superdex 75 prep grade) (GE Healthcare). DARPin
samples were run through the column at 1.5 ml/min in filtered PBS (pressure ≤ 0.3 
MPa) and fractions (1ml) containing the monomer DARPin were collected in
microcentrifuge tubes and stored at -80 °C. Samples were stored in filtered PBS
with 10 mM DTT and filtered PBS alone.
Purified DARPin samples were analysed by coomassie staining and or FPLC using
the Analytical Superdex 75 column (125 ml bed volume, pre-packed with Superdex104
75  prep  grade)  (GE  Healthcare)  at  1  ml/min  (pressure  ≤  0.3  MPa).  The  protein 
standards were run on the Analytical Superdex 75 Column to determine the
estimated elution volume for the G3 DARPins.
2.2.4 Cleavage of His6 tag from cleavable tag-G3
The recombinant type 14 3C protease from the human rhinovirus (HRV 3C) (Merck
Millipore), is a purified His6 tag fusion protein which is active at 4 °C (MW 22 kDa).
HRV 3C was used to remove the His6 tag from the cleavable tag-G3. The protease
recognises the HRV 3C cleavage site, Leu(L)-Glu(E)–Val(V)–Leu(L)-Phe(F)-Gln(Q)
* Gly(G)-Pro(P). This work was performed with assistance from Ms Maria Livanos
(UCL Cancer Institute, London).
2.2.4.1 Optimisation cleavage study
The optimisation study assessed a range of conditions, including duration of
cleavage, type of cleavage solution and HRV 3C protease concentration. A unit (U)
of HRV 3C Protease is defined as the amount of enzyme that will cleave >95% of
100 μg HRV 3C Cleavage Control Protein in Cleavage Buffer at 4 °C over 16 h.  
For most assessed cleavage reactions, 2 U of HRV 3C protease was used to treat
26.1 µg of cleavable tag-G3 (~76 U/mg) and the final reaction concentration was
maintained at 40 U/ml. The final protease reaction concentration was varied in High
Salt Cleavage Buffer to assess the concentration; 0.4, 0.8, 4 and 40 U/ml (Table
2.21).
Three different buffers were assessed, including PBS (155 mM NaCl, pH 7.4),
Cleavage Buffer (150mM NaCl, 50mM Tris-HCl, pH 7.5, Merck Millipore) and High
Salt Cleavage Buffer (800 mM NaCl, 50mM Tris-HCl, pH 7.5). The cleavable tag-G3
DARPin in PBS with 10 mM DTT was dialysed at 4 °C with 1 L of the appropriate
buffer using Slide-A-Lyzer Dialysis Cassettes with 3,500 Da molecular weight cut off
(MWCO) membranes and 0.5-3.0 ml capacity (Thermo Scientific). The buffer was
changed three times over 24 h.
All test cleavage reactions were performed at 4 °C with 26.1 µg of cleavable tag-G3
DARPin (Table 2.21); samples were taken for analysis and stored in 4x SDS-PAGE
reducing buffer. Each reaction was assessed by coomassie staining and western
blotting using the antibodies as previously outlined (Table 2.18).105
Table 2.21 Cleavage reactions assessed in optimisation cleavage study.
Solution Volume (µl)
10X HRV Protease 3C Cleavage Buffer 4
Buffer containing cleavable tag-G3 (DARPin
mass in each reaction)
45
(26.1µg)
HRV 3C Protease (concentration 2 U/µl) 1
(2 U/reaction)
Total Volume 50
2.2.4.2 Bulk cleavage
The most efficient conditions (HRV 3C Protease concentration, duration and buffer)
were used for the bulk cleavage of cleavable tag-G3 (2.25 mg, concentration 0.75
mg/ml) to form untagged-G3.
2.2.4.3 Reverse purification of the untagged-G3 (subtractive IMAC)
Separation of the His6 tagged HRV 3C Protease and cleaved His6 tag from the
untagged-G3 DARPin was performed by subtractive IMAC. A HisPur Ni-NTA column
(4 ml, Thermo Scientific) was packed with HisPur Ni-NTA Resin (Nickel) and
washed with three column volumes of dH20. The column was then equilibrated with
four column volumes of the selected buffer containing 10 mM DTT.
The cleavage reaction was applied to the column. The column was washed with two
column volumes of the selected buffer containing 10 mM DTT and 1 ml aliquots of
flow through were collected (untagged-G3). Two column volumes of elution buffer
(250mM Imidazole) were then applied to the column and 1 ml aliquots of flow
through were collected (HRV 3C protease and cleaved His6 tag). The fractions were
analysed by western blotting and coomassie staining as performed during the
optimization study.
2.2.5 Matrix-assisted laser desorption/ionization (MALDI) Mass Spectrometry
The molecular weights of the G3 DARPins were assessed using the Waters
Micromass MALDI micro MX mass spectrometer (Waters Corporation). The matrix
was prepared by dissolving 10 mg of sinapic acid powder (Sigma-Aldrich) into 1 ml
of 50% (v/v) acetonitrile. For analysis, 1 µl of matrix solution was placed onto the
five-spot clusters of the mass spectrometry plate.106
Cytochrome C (12,360 Da) was used for calibration prior to DARPin analysis. Stock
cytochrome C was prepared by diluting 1 mg cytochrome C (Sigma-Aldrich) into 1
ml of 50% (v/v) acetonitrile (Sigma-Aldrich). Cytochrome C was mixed with an equal
volume of 0.1% formic acid for analysis and 1 µl of this solution was placed in the
central spot of the 5 spot cluster(s).
For sample analysis, a zip-tip pipette tip (Sigma-Aldrich) was pre-equilibrated by
drawing up and expelling 0.1% (v/v) formic acid six times and then 100% (v/v)
acetonitrile six times. The G3 DARPin sample was then drawn up and expelled six
times. Finally, 3 µl of 0.1% formic acid was drawn up and placed into a
microcentrifuge tube, and then 3 µl acetonitrile was drawn up and added to the
same tube, using the same zip-tip pipette tip throughout for one sample. Sinapic
acid solution (6 µl) was added to the sample tube and vortexed for 30 sec. Samples
(1 µl) were analysed in duplicate and calibrated with cytochrome C.
2.2.6 Conjugation of the G3 DARPins
For site specific
111In and
68Ga radiolabelling, G3 DARPins were conjugated with
maleimide-DOTA (mal-DOTA) (Macrocyclics), mal-NOTA (Chematech) or mal-
CP256 (YM103, gift from King’s College London) at the C-terminal cysteine. For
conjugation, all solutions were treated with chelex-100 chelating ion exchange resin
(Bio-Rad Laboratories) and all size exclusion columns were pre-packed with
Sephadex G-25.
Ethylenediaminetetraacetic acid (EDTA) was added to the G3 DARPins (in PBS with
10 mM DTT) to a final concentration of 1 mM and left at RT for 30 min. Any
remaining disulphide bonds were reduced with 5 mM Bond-Breaker Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) solution, neutral pH (Thermo Fisher
Scientific) for 2 h 30 min at RT. Subsequently, the G3 DARPins were buffer-
exchanged using PD-10 size exclusion columns (GE Healthcare) into 0.1 M sodium
phosphate buffer, pH 7. The G3 DARPins were then mixed with a 4-fold molar
excess of mal-DOTA, mal-NOTA or YM103 at RT under constant gentle agitation for
72 h.
The DARPin conjugates were purified from unconjugated bifunctional chelator using
PD-10 size exclusion columns (GE Healthcare), pre-equilibrated and eluted with 0.2
M ammonium acetate buffer, pH 7. The G3 DARPins were further purified by107
centrifugation in a 2 ml Vivaspin with a 5,000 MWCO PES membrane (Sartorius
Stedim). After each spin the filtered solution was replaced with 0.2 M ammonium
acetate buffer, pH 7. Finally, the conjugated DARPins were dialysed at 4 °C against
0.2 M ammonium acetate pH 6.5 containing chelex-100 using a GeBAflex Maxi
dialysis tube with a 3,500 Da MWCO membrane (Generon) over 72 h, the dialysis
buffer was changed every 24 h. The conjugation efficiency was assessed by MALDI
mass spectrometry. For example DOTA conjugation increases the G3 DARPin
molecular weight by 526 Da.
2.2.7 G3 DARPin HER2 binding
2.2.7.1 Affinity and binding kinetics assessed by Surface Plasmon Resonance
Conjugated and unconjugated G3 DARPin kinetics and affinities were measured by
Surface Plasmon Resonance (SPR) using ProteOn XPR36 (Bio-Rad Laboratories)
with recombinant human HER2 extracellular domain (ECD, residues 1-631 of the
mature protein) (EMP Genetech). This was performed by Dr Gabriela Nagy-
Davidescu (University of Zurich).
Initially, HER2 ECD was biotinylated in vitro using EZ-Link Sulfo-NHS-SS-Biotin (six-
fold molar excess of the biotinylating reagent relative to the target protein). Excess
biotin was removed by a PD-10 size exclusion column (GE Healthcare) and dialysis
against PBS.
For affinity determinations samples were assessed in duplicate. Two ligand
channels of a Neutravidin Sensor Chip (ProteOn NLC) were coated with 900
resonance units of the biotinylated HER ECD. Five different concentrations of G3
DARPins (0.316 nM; 1 nM; 3.16 nM; 10 nM; 31.6 nM) were injected in parallel at a
buffer flow rate of 100 µl/min in PBS containing 0.005% Tween-20, allowing 240 sec
for association and 3600 sec for dissociation. Evaluation of the data was performed
using the ProteOn Manager software (Bio-Rad Laboratories), to calculate the Ka (on
rate or association), Kd (off rate or dissociation) and KD (binding affinity).
2.2.7.2 Flow cytometry analysis of G3 DARPin binding to HER2-positive and
HER2-negative cells
For analysis, DOTA conjugated G3 DARPins were labelled with cold indium chloride
(Sigma-Aldrich) in 0.05 M HCl solution and unconjugated G3 DARPins were labelled108
with cold sodium iodide (Sigma-Aldrich) in 0.1 M sodium hydroxide, using the same
conditions required for
111In and
123/125I radiolabelling reactions, respectively (see
below). NOTA conjugated G3 DARPins were treated with 0.2 M acetate buffer at a
range of different pH conditions, to assess NOTA-G3 DARPin compatibility for
68Ga
labelling at these conditions (Table 2.22). All assessed G3 DARPins were
neutralised to physiological pH with PBS to a final concentration of 10 µg/ml, prior to
flow cytometry assessment.
HER2-positive BT474 (American Type Culture Collection), HER2-positive OE-19
(Sigma-Aldrich) cells and HER2-negative MDA-MB-468 (American Type Culture
Collection) cells were individually prepared by removal of media and incubation with
5 ml of 0.2% EDTA for 10 min. The cells were then transferred to centrifuge tubes
(Elkay Laboratory Products) and centrifuged (4 °C, 4 min, 1000 rpm). The EDTA
containing supernatant was removed and 5 ml of fresh media was added. Cells
were counted and diluted to 1 million/ml with media, and 1 ml was used for each test
condition. After washing the cell pellets with cold PBS (2 ml), 200 µl of DARPin
(concentration 10 µg/ml) was added and incubated for 1 h at 4 °C, to minimise
HER2 internalisation.
Cells were washed with cold PBS (2 ml) and incubated with 200 µl of mouse anti-
DARPin (0.1% v/v in Dulbecco’s-PBS) (K. Chester, UCL Cancer Institute,
unpublished) for 1 h at 4 °C, then centrifuged as previously outlined and cell pellets
retained. Subsequently, the cells were washed with cold PBS (2 ml) and incubated
with 200 µl of Alexa Fluor 488 goat anti-mouse IgG (0.1% v/v in Dulbecco’s-PBS)
(Life Technologies) for 30 min at 4 °C, then centrifuged as outlined and cell pellets
retained. After two further washing steps with cold PBS (2 ml), the cells were
suspended in 500 µl of cold PBS. Negative control cell samples were not subjected
to G3 DARPins but were treated with Dulbecco’s-PBS alone or with anti-DARPin
antibody followed by Alexa Fluor 488 antibody.
Samples were analysed on a CyAn ADP High-Performance Flow Cytometer (Becton
Dickinson); cells were gated according to side scattering, forward scattering and
pulse width, to ensure that only single cells were analysed (Figure 2.6). A total of
10,000 cell events were recorded per sample and data was analysed using FlowJo
software (version 7; Tree Star).109
Figure 2.6 Stages required for flow cytometry.
2.2.8 Radiolabelling of the G3 DARPins
For in vivo assessment the radiochemical purity of radiolabelled G3 DARPins were
>95%. Higher specific activities (SA) were required for the imaging studies (~ 30-60
MBq/nmol) than biodistribution studies (~1-2 MBq/nmol).
2.2.8.1 Radiolabelling with Indium-111
For
111In radiolabelling, DOTA conjugated G3 DARPins in 0.2 M ammonium acetate
pH 6.5 (5-60 µg) were mixed with
111InCl3 (10-30 MBq, Covidien) and incubated for 2
h at 37 °C. The reactions were stopped by adding EDTA to a final concentration of 5
mM and purified by elution into PBS with a NAP-5 column (GE Healthcare). The
radiochemical purity of the
111In-G3 DARPins was determined by instant thin layer
chromatography (iTLC) using the solvents 0.1 M ammonium acetate with 25 mM
EDTA and 35% ammonia (v/v):ethanol:water (1:2:5) with iTLC- silica gel (SG) strips
(Varian) (Table 2.8). If insoluble material was detected on iTLC, the reactions were
filtered with 0.2 µm sterile syringe filters with a supor membrane (Pall Life Science).110
2.2.8.2 Radiolabelling with Iodine-125
Non-conjugated G3 DARPins in PBS (30-60 µg) were mixed with iodine-125 (
125I,
PerkinElmer, 10 MBq) in pre-coated Pierce iodination tubes (Thermo Scientific) for
10 min at RT. The reactions were stopped by adding sodium metabisulfite to a final
concentration of 1 µM, and then purified by elution into PBS with a NAP-5 column.
The radiochemical purity of the
125I-G3 DARPins were determined by iTLC with
iTLC-SG (Varian) strips using the solvent 0.1 M ammonium acetate with 25 mM
EDTA (Table 2.8).
2.2.8.3 Radiolabelling with Iodine-123
Iodine-123 in 0.05 M NaOH, pH 10 (
123I, GE Healthcare) (15-20 MBq) was added to
pre-coated Pierce iodination tubes (Thermo Scientific), followed by 100 µl of Tris
Iodination Buffer (25 mM Tris-HCl, pH 7.5, 0.4 M NaCl). The non-conjugated
DARPin in PBS (5 µg) was added to the tube. The reaction was performed for 10
min at RT and stopped by adding sodium metabisulfite to a final concentration of 1
µM. The radiochemical purity was assessed by the same iTLC method used for
125I-
G3 DARPins (Table 2.8) and a purification step was not required. An equivalent
molar amount of ‘cold’ potassium iodide (3.4 X10
-10 mol) was co-administered with
123I-G3 DARPin, to minimise normal tissue uptake of 'free'
123I (formed by de-
iodination in vivo).
2.2.8.4 Radiolabelling with Gallium-68
Assessment of optimal pH conditions for Gallium-68 radiolabelling of NOTA-
G3 DARPin
NOTA-G3 DARPin was radiolabelled at a range of different pH conditions (pH 3.6 to
7.7) at RT, to determine the optimal pH for
68Ga radiolabelling. The test
radiolabelling reactions were performed by adding 200 µl of acetate buffer to 20 µl
68Ga (0.1 MBq/µl) eluted in 0.1 M HCl from an IGG100
68Ge/
68Ga Generator (Eckert
& Ziegler) (Table 2.22). Subsequently, NOTA-G3 DARPin in 0.2 M ammonium
acetate pH 6.5 (10 µg, concentration 1 mg/ml) was incubated with the buffered
68Ga
(pH 3.6 to 7.7).
68Ga radiolabelling efficiency was assessed by iTLC using 0.1 M
citrate buffer, pH 5 with iTLC-salicylic acid (SA) strips (Varian).111
Table 2.22 Composition of 0.2 M acetate buffers used for
68Ga-NOTA-DARPin
radiolabelling.
0.2 M acetate buffer 0.2 sodium acetate (Vol. %) 0.2 M acetic acid (Vol. %)
pH 7.7 100 % 0 %
pH 6.5 95 % 5 %
pH 5.5 80 % 20 %
pH 4.6 49 % 51 %
pH 3.6 8 % 92 %
Gallium-68 radiolabelling of NOTA-G3 and YM103-G3 DARPin
NOTA-G3 DARPin in 0.2 M ammonium acetate pH 6.5 (10-30 µg) was mixed with
0.2 M ammonium acetate buffer pH 5 at a volume equivalent to the intended volume
of
68Ga. Subsequently,
68Ga eluted from the IGG100
68Ge/
68Ga Generator (Eckert &
Ziegler) in 0.1 M HCl was added to the buffered NOTA-G3 DARPin and incubated at
RT for 10 min. The pH of the radiolabelling reaction was pH 4.6.
YM103-G3 DARPin in 0.2 M ammonium acetate pH 6.5 (20-30 µg) was mixed with
0.2 M ammonium acetate buffer pH 5 at a volume equivalent to the intended volume
of
68Ga. Subsequently,
68Ga eluted from the IGG100
68Ge/
68Ga Generator (Eckert &
Ziegler) in 0.1 M HCl was added to the buffered YM103-G3 DARPin and incubated
at RT for 10 min. The pH of the radiolabelling reaction was pH 4.6, as Dr Maggie
Cooper (King’s College London) had determined this was the optimal pH for
68Ga
radiolabelling of YM103-G3 DARPin.
For
68Ga-NOTA-G3 and
68Ga-YM103-G3, iTLC was performed using the solvent 0.1
M citrate buffer, pH 5 with iTLC-SA strips (Varian) (Table 2.9). Insoluble material
was detected on iTLC by assessing a control reaction performed with the same
conditions but without adding G3 DARPin.
It was not necessary to add EDTA to the reactions for biodistribution studies as a
high radiochemical purity was achieved. However, EDTA was added to the reactions
prepared for imaging studies, to a final concentration of 5 mM, since their
radiochemical purity was not as high.112
2.2.9 Biodistribution studies
All animal studies were ethically reviewed and carried out in accordance with the UK
Animals (Scientific Procedures) Act 1986 and UK Home Office regulations and local
regulations.
2.2.9.1 Biodistribution studies in non-tumour and HER2-positive tumour
bearing mice
DARPins were administered in 200 µl aliquots of PBS/0.1% BSA. For
111In-G3 and
125I-G3 DARPin studies mice were sacrificed at 4 h (n=4) and 24 h (n=4). While for
68Ga-G3 DARPin studies mice were sacrificed at 1 h (n=4).
For non-tumour studies, female BALB/c mice aged 6-11 weeks (Charles River,
mean weight 19 g), received an intravenous dose of 0.3 MBq of
111In-G3 DARPin
(2.2 µg [SA 2.0 MBq/nmol] to 4.3 µg [SA 1 MBq/nmol]) or
125I-labelled G3 DARPin
(2.8 µg [SA 1.6 MBq/nmol] to 4.3 µg [SA 1 MBq/nmol]). Based on the results of the
studies in BALB/c mice with His6-, (HE)3- and untagged-G3 DARPins, the construct
with the lowest normal tissue uptake (optimal G3 DARPin) was selected for
assessment in tumour bearing mice.
For tumour studies, a single 60 day release 0.72 mg 17ẞ-estradiol pellet (Innovative 
Research of America) was inserted into the scruff of female SCID-beige mice aged
6-8 weeks (Charles River). The following day, the mice were inoculated by sub-
cutaneous injection with BT474 cells (7.5 X 10
6 cells) (American Type Culture
Collection) in PBS mixed with equivalent volumes of Basement Membrane Matrix
that was growth factor reduced and lactate dehydrogenase-elevating virus free
(Becton Dickinson). At 5-7 weeks post inoculation (mean mouse weight 24 g), the
tumours reached 25-100 mm
2 and each mouse received 0.3 MBq of
111In-G3
DARPin (2 µg [SA 2.2 MBq/nmol]), 0.3 MBq of
125I-G3 DARPin (3 µg [SA 1.5
MBq/nmol]) or 1 MBq of
68Ga-G3 DARPin (2.5 µg [SA 5.7 MBq/nmol]) intravenously.
In a trastuzumab blocking study, three female SCID-beige mice with BT474 tumours
received intravenous trastuzumab (14.2 mg/kg or 350 µg/mouse) (Roche
Diagnostics) 24 h prior to intravenous
111In-G3 DARPin. The controls were three
BT474 tumour bearing SCID-beige mice who only received intravenous
111In-G3
DARPin. The mice were all sacrificed at 4 h post-administration of 0.3 MBq
111In-G3
DARPin (1.9 µg [SA 2.3 MBq/nmol] per mouse).113
Blood, selected organs and tumour (if present) were removed and radioactivity was
measured in an LKB Wallac Gamma Counter 1282 Compugamma (LKB
Instruments). Uptake was expressed as a mean ± SD of the percentage injected
radioactive dose per gram of tissue (% ID/g).
To assess the HER2 tumour status, BT474 tumours were excised from four
untreated SCID-beige mice, fixed in 10% formalin, embedded in paraffin and freshly
cut  (3 μm)  for  tissue  slides.  Tissue  slides  were  deparaffinised  in  xylene  and 
gradually rehydrated in graded alcohols and water. Epitope retrieval and
immunohistochemical reactions were performed using the HercepTest (Dako)
according to the manufacturer’s instructions. The HER2-positive (3+ on IHC) human
breast carcinoma cell line SK-BR-3 was used as the positive control. The negative
control substituted the primary antibody, rabbit anti-human HER2 with normal rabbit
immunoglobulins but used the same secondary antibody (goat anti-rabbit linked with
HRP) for assessment of SK-BR-3 tumour cells. The IHC was performed with help
from Mr Mohammed Rashid (UCL Cancer Institute).
2.2.9.2 Statistical analysis of normal tissue uptake in non-tumour bearing mice
An independent samples t-test was performed with SPSS Statistics 21 (IBM), to
compare tissue uptake between the different radiolabelled G3 DARPins, a p value <
0.05 was considered statistically significant.
2.2.10 microSPECT/CT imaging of HER2-positive tumour xenografts
For imaging, the optimal G3 DARPin was radiolabelled directly with
123I and via
DOTA for
111In.
125I was substituted with
123I for SPECT imaging, as it has a shorter-
half (~13 h vs. ~59 days) and higher gamma energy emission (159 keV vs. 35.5
keV).
Female SCID-beige mice bearing BT474 tumours were injected intravenously with
either 10.5 MBq of
123I-G3 (2.1 MBq/µg [SA 30.1 MBq/nmol]) or 8.4 MBq of
111In-G3
(4 MBq/µg [SA 58 MBq/nmol]) in 200 µl PBS/0.1% BSA.
Imaging was performed under isoflurane anaesthesia (2% at 1 L/min) at 4 h post
injection using a microSPECT/CT animal scanner (Bioscan) equipped with a heated
bed. Helical SPECT images were acquired in 20 projections over 30-40 min using a
four-headed camera with 4×9 (1.4 mm) pinhole collimators. The CT images were114
acquired in 180 projections with 1000 ms exposure time using a 45 peak kilovoltage
(kVP) over 6 min for anatomical reference. Radionuclide images were reconstructed
using HiSPECT (Scivis) iterative reconstruction software and fused with CT images
using proprietary InVivoScope (Bioscan) software.
2.2.11 PET/CT imaging of mice bearing HER2-positive tumour xenografts
Female SCID-beige mice bearing BT474 tumours were injected intravenously with
4.5 MBq of the optimal
68Ga-G3 DARPin (3.0 µg [SA 14.4 MBq/nmol]) in 200 µl
PBS/0.1% BSA, for PET imaging studies.
Mice were scanned under anaesthesia (2% isoflurane in air, 1 L/min) on an animal
Inveon PET/CT scanner (Siemens Preclinical Solutions). Mice were placed on the
animal bed and then wrapped with SpaceDrape thermal protective material to
reduce heat loss. Initially, a PET emission scan was acquired from 30 to 120 min
post-administration and was followed by a CT scan (spatial resolution 108 µm, 80
kV, 500 µA) for anatomical reference. Scans were reconstructed using Inveon
Acquisition Workplace software (version 1.5; Siemens Preclinical Solutions) with the
following parameters: matrix, 128 x 128 x 159; pixel size, 0.776 x 0.776 x 0.796
mm
3;  and  β-value  of  1.5  mm  with  uniform  resolution.  Scans  were  analysed  with 
Inveon Research Workplace software (version 4.0, Siemens Preclinical Solutions),
to quantify volume of interest (VOI) in MBq.
2.2.12 Affinity of selected radiolabelled G3 DARPin for HER2-positive cells
A saturation assay with BT474 cells was performed to evaluate the binding affinity of
111In and
125I radiolabelled G3 DARPins assessed in tumour bearing mice. This
involves measuring the binding equilibrium by performing a titration of radiolabelled
DARPin while keeping the amount of HER2 receptors constant.
BT474 cells were seeded at a density of 1 x 10
6 per well in Cellstar 6-well plates
(Greiner bio-one) and grown to confluence over 24 h. The confluent cells were
incubated in triplicate with 0.1 to 20 nM radiolabelled DARPin in Dulbecco's Modified
Eagle Medium (DMEM) media with high glucose (4.5 g/L) containing 1% Foetal Calf
Serum (Biosera) and 0.1% sodium azide (to minimize internalization) for 1 h 30 min
at 37 °C. Non-specific binding was determined by a parallel series of radiolabelled
G3 DARPins with 1,000 nM non-radiolabelled G3 DARPin assessed in triplicate.115
The assays were stopped by removing the media containing radiolabelled G3
DARPin and washing the cells twice with ice cold media and once with ice cold PBS.
The cells were lysed with 1 M sodium hydroxide and collected. The wells were
washed twice with PBS and the washes were pooled with the cell lysate for analysis.
The radioactivity was counted for 1 min in a LKB Wallac Gamma Counter 1282
Compugamma (LKB Instruments). The protein concentration per million cells was
assessed from wells containing untreated BT474 cells using the DC (detergent
compatible) colorimetric protein assay (Bio-Rad Laboratories) as per the
manufacturer’s instructions.
The total binding curve was determined from the samples with the increasing
concentrations of radiolabelled DARPin in absence of cold DARPin (measures
combined specific binding to receptor and non-specific binding). The non-specific
binding curve was determined from the increasing concentration of radiolabelled
DARPin in presence of cold DARPin (measures non-receptor radioligand binding).
Finally, the specific receptor binding is determined from the total binding minus the
non-specific binding (Figure 2.7). The affinity and BMax (maximum binding capacity)
was calculated by nonlinear regression using Prism software (GraphPad Software).
Figure 2.7 Analysis of cell saturation binding assay.116
2.2.13 In vitro stability of selected radiolabelled DARPin
The stability of the
111In-G3 DARPin administered to HER2-positive tumour bearing
mice was assessed in PBS or in human serum:PBS (1:1). The human serum was
isolated from whole blood collected in a BD Vacutainer SST gel tubes (Becton
Dickinson) by centrifugation at 1,000 x g for 10 min. Serum stability was assessed at
37 °C, while stability in PBS was assessed at 4 °, 20 ° and 37 °C for 24 h post
radiolabelling by iTLC. After incubation, the stability of the
111In-G3 DARPin was
assessed by SDS-PAGE using non-reducing conditions, followed by
autoradiography using a Cyclone Storage Phosphor System (PerkinElmer).
2.2.14 Genotyping HER2 transgenic mice
Hemizygous B6.Cg-Tg(Wap-ERBB2)229Wzw/J transgenic mice (The Jackson
Laboratory) which express human HER2 in their mammary glands and cerebellum
under the control of the mouse whey acidic protein (WAP) promoter were used for
pre-clinical toxicity assessment (Piechocki, Ho et al. 2003). A cohort of wild and
HER2 transgenic mice were bred and genotyped by The Jackson Laboratory; their
HER2 status was verified at UCL.
Ear punch biopsies were taken from The Jackson Laboratory bred mice and a
negative control mouse (C57 Black; C57BL/6J). DNA was extracted from the ear
biopsies using the HotSHOT genomic DNA isolation protocol. Initially, 75 µl of
Alkaline Lysis Buffer was added to the biopsies within 1.5 ml microcentrifuge tube,
followed by heating at 95 °C for 40 min. After 1 h of cooling, 75 µl of Neutralisation
Buffer was added and the biopsies were centrifuged at 4,000 rpm for 4 min (Table
2.10). PCR was performed on samples of the supernatant.
The lyophilised primers (Integrated DNA Technologies) were dissolved with filtered
dH2O to make a stock solution of 10 µM (Table 2.23). The mouse interleukin-2 (IL-2)
gene was used as an internal control, to confirm that there was sufficient DNA in the
sampled supernatant for assessment. Negative controls were performed by
substituting DNA-containing supernatant with dH2O.117
Table 2.23 Human HER2 transgene and mouse IL-2 gene primers used for mouse
genotyping.
Primer name Sequence (5’-3’) Melting
temperature (°C)
Molecular
weight (Da)
HER2 transgene
Sense
5’ GAGCCGCGAGCACCCA 3’ 61.8 4,861.2
HER2 transgene
Anti-sense
5’ GGTGGGCAGGTAGGTGAGTTCC 3’ 61.8 6,887.5
Mouse IL-2
Sense
5’ CTAGGCCACAGAATTGAAAGATCT 3’ 54.7 7,369.9
Mouse IL-2 Anti-
sense
5’ GTAGGTGGAAATTCTAGCATCATCC 3’ 55.2 7,681.0
The IL-2 primers were efficient at 1 µM concentration and HER2 transgene primers
were efficient at 0.25 µM concentration (Table 2.24). The conditions for the IL-2 and
HER2 PCRs were identical and performed in the GeneAmp PCR System 2700
(Life Technologies) (Table 2.25).
Table 2.24 PCR of the human HER2 transgene and mouse IL-2 gene.
Constituent Volume (µl) Final reaction concentration
De-ionised water 14.5 µl (HER2)
or 11.5 µl (IL-2)
Dream Taq Buffer 10x contains 20
mM MgCl2(Thermo Scientific)
2 µl 1X
dNTPs (10 mM) 0.4 µl 0.2 mM
Sense primer (10 µM) 0.5 µl (HER2)
or 2 µl (IL-2)
0.25 µM (HER2) or 1 µM (IL-
2)
Anti-sense primer (10 µM) 0.5 µl (HER2)
or 2 µl (IL-2)
0.25 µM (HER2) or 1 µM (IL-
2)
Dream Taq polymerase (5 U/µl)
(Thermo Scientific)
0.1 µl 0.5 U/reaction
Supernatant with extracted DNA 2 µl
Total volume 20 µl
Table 2.25 HER2 transgene and IL-2 PCR conditions.
Stage Temperature (°C) Time Cycles
Initialisation 94 3 min 1
Denature 94 30 sec
30 Anneal 66 45 sec
Elongate 72 45 sec
Final elongation 72 2 min 1
Hold 5 Until discontinued118
After the PCR, DNA 10x loading buffer (2 µl) was added to the PCR samples and
the samples were applied to the wells of 1.5% agarose gels. To confirm the
presence of the human HER2 gene and mouse IL-2 gene the DNA from the agarose
gel bands of selected mice were extracted and purified with the Wizard SV Gel and
PCR Clean-Up System (Promega), as previously outlined. The extracted and
purified DNA was sequenced by the DNA Sequencing Service at the UCL Cancer
Institute.
2.2.15 Breeding HER2 transgenic mice
The homozygous variant is fatal in utero, while the hemizygous variant is viable, so
wild and hemizygous mice were bred with each other (Piechocki, Ho et al. 2003). All
newborn mice were genotyped when they were weaned and breeding pairs were
assigned based on their genotype.
2.2.16 Endotoxin removal from (HE)3-G3 DARPin prior to mouse
administration
Endotoxins were removed from the G3 DARPins with the Pierce High-Capacity
Endotoxin Removal Resin (Thermo Scientific) according to the manufacturer’s
instructions. A column with 1 ml resin volume was used; it is capable of removing
endotoxins from 2-10 ml samples. All consumables and solutions used were
endotoxin-free. This was performed by Miss Maria Livanos and Miss Leah Ensell
(UCL Cancer Institute).
Briefly, degassed resin slurry (50% slurry in 20% ethanol) was applied to the column
(1 ml volume). The column was washed with five column volumes of 0.2 M sodium
hydroxide. Then the column was washed with five column volumes of 2 M sodium
chloride, followed by five column volumes of endotoxin-free ultrapure water. The
column was equilibrated with five column volumes of Dulbecco’s-PBS without
calcium and magnesium (PAA Laboratories).
(HE)3-G3 DARPin in PBS was applied to the column and eluted in one column
volume of Dulbecco’s-PBS without calcium and magnesium (PAA Laboratories), the
sample was applied and eluted from the same column five times. After the fifth
elution, 10 mM BioUltra DTT (Sigma-Aldrich) was added to the sample to prevent
dimerisation and stored at -80 °C.119
Prior to mice administration, the (HE)3-G3 DARPin in PBS with DTT was buffer
exchanged using a PD-10 column (GE Healthcare) into Dulbecco’s-PBS without
calcium and magnesium (PAA Laboratories). This was collected as three separate
aliquots.
2.2.17 Analysis of (HE)3-G3 DARPin prior to mice administration for toxicity
assessment
2.2.17.1 Endotoxin levels
Endotoxin levels were assessed after endotoxin removal, using the Pierce LAL
Chromogenic Endotoxin Quantification Kit (Thermo Scientific), according to the
manufacturer’s instructions.
2.2.17.2 Dimerisation status
(HE)3-G3 DARPin in 4x non-reducing buffer was assessed by SDS-PAGE and
coomassie staining, as well as FPLC using the Analytical Superdex 75 column (125
ml bed volume, pre-packed with Superdex 75 prep grade) (GE Healthcare) at 1
ml/min (pressure ≤ 0.3 MPa). 
2.2.18 Pre-clinical toxicity study
2.2.18.1 Mouse (HE)3-G3 DARPin dosing
Mice received unconjugated (HE)3-G3 DARPin at 50 or 100 times the human
equivalent dose (HED) in Dulbecco’s PBS. According to the U.S. Department of
Health and Human Services Food and Drug Administration (FDA) Center for Drug
Evaluation and Research (CDER) two methods can be used to convert mouse
doses into human doses (U.S. Department of Health and Human Services 2005). In
this situation, the mouse dose was calculated from the planned human trial dose,
500 µg.
1) Conversion based on body surface area for mice weighing 11-34 g
Mouse dose (mg/kg) = Human dose (mg/kg) multiplied by 12.3.
Human dose is 500 µg, formula assumes human body weight is 60 kg, so human
dose is 8.33 X10
-3 mg/kg.
Mouse dose 0.10 mg/kg is the HED (8.33 X10
-3 mg/kg multiplied by 12.3)
Mouse dose 10 mg/kg is 100 times the HED120
2) Conversion based on body surface area for mice weighing more than 34 g
HED (mg/kg) = mouse dose in mg/kg x (animal weight in kg/human weight in kg)
0.33
e.g. 50 g mouse and formula assumes human weight 60 kg
8.33 X10
-3mg/kg = mouse dose x (0.050/60)
0.33
Mouse dose of 0.087 mg/kg is the HED
Mouse dose of 8.7 mg/kg is 100 times the HED
The assessed HER2 transgenic and wild type mice weighed between 35 and 51 g,
while the assessed CD-1 mice weighed between 33 and 36 g. Thus, mice received
9-10 mg/kg intravenously to achieve 100 times the HED or 4.5-5 mg/kg for 50 times
the HED.
2.2.18.2 Toxicity study in HER2 transgenic and wild type mice
Four HER2 transgenic and eight wild type B6.Cg-Tg(Wap-ERBB2)229Wzw/J mice
received 100 times the HED of (HE)3-G3 DARPin intravenously. Control HER2
transgenic (n=3) and control wild type mice (n=7) received Dulbecco’s PBS
intravenously. The mice were euthanised at 24 h post-administration and blood
sampling was performed under terminal anaesthesia to assess haematology and
clinical chemistry. Histological analysis was performed on the liver, heart, kidneys,
spleen, brain, adrenals and mammary glands. The six older control mice only had
their livers’ and blood biochemistry assessed (Table 2.26).
Table 2.26 Trasngenic (T) and wild (W) type mice received 100 X HED of (HE)3-G3
DARPin in Dulbecco’s-PBS. Control (C) mice received Dulbecco’s-PBS.
Mouse Sex Age
(months)
Genotype Dose Histology Biochemistry Haematology
C1 F 3 Wild PBS 7 organs Yes Yes
C2 F 3 Wild PBS 7 organs Yes Yes
C3 M 3 Wild PBS 7 organs Yes Yes
C4 M 3 Wild PBS 7 organs Yes Yes
C5 M 12 HER2 PBS Liver Yes No
C6 M 12 Wild PBS Liver Yes No
C7 M 11 HER2 PBS Liver Yes No
C8 M 9 Wild Untreated* Liver Yes No
C9 M 9 Wild PBS Liver Yes No
C10 M 9 HER2 PBS Liver Yes No
W1 F 6 Wild 100X HED 7 organs Yes Yes
W2 F 6 Wild 100X HED 7 organs Yes Yes121
W3 F 6 Wild 100X HED 7 organs Yes Yes
W4 M 6 Wild 100X HED 7 organs Yes Yes
W5 M 5 Wild 100X HED 7 organs Yes Yes
W6 M 5 Wild 100X HED 7 organs Yes Yes
W7 M 5 Wild 100X HED 7 organs Yes Yes
W8 F 5 Wild 100X HED 7 organs Yes Yes
T1 F 9 HER2 100X HED 7 organs Yes Yes
T2 F 9 HER2 100X HED 7 organs Yes Yes
T3 M 9 HER2 100X HED 7 organs Yes Yes
T4 M 9 HER2 100X HED 7 organs Yes Yes
*unable to cannulate tail vein, 7 organs include heart, kidneys, spleen, brain,
adrenals, mammary glands and liver.
2.2.18.3 CD-1 mice liver toxicity study
To determine whether (HE)3-G3 DARPin causes liver damage, CD-1 mice were
assessed as their normal phenotype is better characterised than the transgenic
mice. Male CD-1 mice were treated with 100 times the HED (n=6), 50 times the
HED (n=6) or Dulbecco’s-PBS (n=6). At 24 h post administration the mice were
euthanised and their livers’ were removed for histological analysis (Table 2.27).
Table 2.27 Male CD-1 mice treated at 100X HED and 50X HED of (HE)3-G3
DARPin. Control (C) CD-1 mice received Dulbecco’s-PBS.
Mouse Sex Age (months) Dose Histology
C1 M 2 PBS Liver
C2 M 2 PBS Liver
C3 M 2 PBS Liver
C4 M 2 PBS Liver
C5 M 2 PBS Liver
C6 M 2 PBS Liver
50.1 M 2 50X HED Liver
50.2 M 2 50X HED Liver
50.3 M 2 50X HED Liver
50.4 M 2 50X HED Liver
50.5 M 2 50X HED Liver
50.6 M 2 50X HED Liver
100.1 M 2 100X HED Liver
100.2 M 2 100X HED Liver
100.3 M 2 100X HED Liver
100.4 M 2 100X HED Liver
100.5 M 2 100X HED Liver
100.6 M 2 100X HED Liver122
2.2.18.4 Blood and histological analysis
Biochemistry samples were collected in BD plasma separation tubes containing
lithium heparin (Becton Dickinson). Immediately after collection samples were
inverted 10 times, they were centrifuged within 2 h of collection at 1,300 X g for 15
min in a fixed angle centrifuge. The plasma was collected and stored at -80 °C until
analysis.
Haematology samples were collected in 0.5 ml EDTA containing tubes (Teklab); the
samples were inverted 10 times after collection and stored at 4 °C until analysis.
Deceased mice were stored in 10% neutral buffered formalin within 500 ml plastic
pots (Pioneer Research Chemicals) until dissection for histological assessment.
All blood and tissue samples were analysed by Sequani. The analysis was
performed to Good Laboratory Practice (GLP) standards but was not performed in
audited laboratories, so was technically non-GLP compliant.
2.2.18.5 HER2 status of the livers from HER2 transgenic and wild type
mice
The HER2 status of livers’ from transgenic (n=1) and wild type (n=1) mice were
assessed, to determine whether (HE)3-G3 DARPin could bind to HER2 in the liver.
This work was performed by UCL Advanced Diagnostics.
HER2 immunohistochemistry
HER2 IHC was performed with the Bond Polymer Refine Detection (Leica
Biosystems Newcastle), which utilises a primary rabbit antibody targeting human
HER2 and secondary goat anti-rabbit-HRP antibody. DAB was used to visualise the
antibody complexes bound to the human HER2 receptors. There is a good
concordance between the Bond HER2 IHC and the FDA approved HercepTest
which utilises a rabbit anti-human HER2 (O'Grady, Allen et al. 2010).
Human breast cancer tissue microarrays (TMAs) were used as positive and
negative controls. In addition, negative controls using only the secondary antibody
were performed on each assessed mouse liver.123
Chromogenic in situ hybridisation (CISH)
The INFORM HER2 Dual ISH DNA Probe Cocktail (Ventana Medical Systems)
which contains a HER2 DNA probe (labelled with the hapten dinitrophenyl or DNP)
and a chromosome 17 centromere DNA probe (labelled with the hapten digoxigenin
or DIG) was used for CISH analysis. The DNA probes are added first, followed by
the primary antibody and secondary antibody conjugated with an enzyme. The black
HER2 signal is catalysed by HRP from silver and the red chromosome 17
centromere signal is catalysed by alkaline phosphatase from naphthol, fast red.
For single-probe assessment the HER2 gene is amplified when ≥ 6.0 signals/cell 
and for dual-probe ISH the HER2 gene is amplified if the HER2/Ch17 ratio is ≥ 2.0. 
(Wolff, Hammond et al. 2013).124
Chapter 3 Production of G3 DARPins with
different N-terminus domains125
3.1 Introduction
The G3 DARPin has high affinity for the HER-2 receptor assessed by SPR (90
pmol/L) and cell binding analysis (~60-100 pmol/L with BT474 cells) (Zahnd, Wyler
et al. 2007; Zahnd, Kawe et al. 2010). The structure of the G3 DARPin includes an
N-terminal capping repeat, two internal repeats and a C-terminal capping repeat.
Based on structural modelling, the G3 DARPin and trastuzumab bind to adjacent
and non-overlapping epitopes of subdomain 4 of the HER2 ECD, by contrast
pertuzumab binds to subdomain 2 (Epa, Dolezal et al. 2013). Thus, G3 DARPin
should be able to bind in the presence of trastuzumab and pertuzumab.
Development of the G3 DARPin for HER2 molecular imaging depends on
minimising normal tissue uptake to achieve high tumour-to-normal tissue ratios. To
date, only G3 DARPins with a His6 tag used for technetium radiolabelling have been
assessed in vivo.
99mTc-His6-G3-DARPin was associated with high HER2-positive
tumour uptake (> 8 % ID/g over 24 h) and HER2-positive tumours could be seen on
microSPECT/CT scanning. However,
99mTc-His6-G3-DARPin had low tumour-to-liver
ratios (< 2 for 48 h post-administration), which could prevent the identification of liver
metastases on imaging (Zahnd, Kawe et al. 2010).
Exchanging the His6 tag of an anti-HER2 affibody molecule for a negatively charged
(HE)3 tag reduced background liver uptake, while also enabling tag-mediated
purification by IMAC (Tolmachev, Hofstrom et al. 2010; Hofstrom, Orlova et al.
2011). The effect of altering or removing the G3 DARPin N-terminus histidine-based
tag on normal tissue uptake is unknown (Zahnd, Kawe et al. 2010). The G3 DARPin
N-terminus does not participate in HER2 binding, so alteration of the N-terminus tag
would not be expected to alter HER2 binding affinity and kinetics (Zahnd, Wyler et
al. 2007; Epa, Dolezal et al. 2013). Thus, it is necessary to produce different
variants of the G3 DARPin for subsequent in vivo comparison.
The P. pastoris production platform was selected for G3 DARPin production as it
has several advantages compared to mammalian cell lines and the E. coli platform.
Compared to mammalian cell lines, P. pastoris has a shorter fermentation time,
faster transition from gene synthesis to protein production, cheaper production costs
and use of media without animal derived products thus minimising the potential for126
viral contamination. Recombinant protein is secreted from P. pastoris cells directly
into the media, under the control of the α-factor signal sequence within the pPICZαB 
plasmid, by contrast recombinant protein is not secreted by E. coli cells. P. pastoris
cells are capable of performing post-translation modifications to proteins, including
proteolysis by Ste13 and Kex2 proteases, this does not occur in E. coli (Table 3.1).
Downstream processing of recombinant proteins produced by P. pastoris is easier
than processing of recombinant proteins produced by E. coli, as only low
concentrations of P. pastoris host cell proteins are released into the media. The
recombinant histidine-based tagged proteins secreted by P. pastoris can be isolated
via IMAC (Tolner B 2012).
Table 3.1 Amino acid sequences cleaved by P. pastoris Kex2 and Ste13
proteinases.
Proteinase Protein cleavage site(*)
Kex2 gene product Glu(E)-Lys(K)-Arg(R) * (amino acid)
Ste13 gene product Glu (E)-Ala(A) * (amino acid)
Aim:
To test the hypothesis that; purified G3 DARPins can be produced with and without
histidine based N-terminal tags by a P. pastoris production platform.
Objectives:
To produce three variants of the G3 DARPin which only differ from each other at
their N-terminus and have a unique C-terminal cysteine for site specific
radiolabelling, using the P. pastoris expression system (Figure 3.1) (Tolner, Smith et
al. 2006).
1) His6-G3
2) (HE)3-G3
3) Untagged-G3 DARPins127
Structure of proposed G3 DARPin variants
The cleavable tag-G3 with a cleavable His6 was the precursor for the untagged-G3.
Initially, the G3 DARPins were designed with LEKREAEA residues preceding their
tags, which can potentially be cleaved by the combined action of the P. pastoris
Kex2 and Ste13 proteinases (Table 3.1), so all G3 DARPin proteins would
commence at their histidine based tags (Figure 3.1 and Figure 3.2). This meant that
all DARPins could be purified by IMAC and the untagged-G3 could be formed post
purification by His6 tag cleavage (Figure 3.1). The cleavable tag-G3 contained the
residues LEVLFQ/GP which forms the site recognised by HRV 3C protease and
results in GP being retained, so for consistency purposes all DARPins incorporated
a GP sequence at the N-terminus (Figure 3.1).
Pre-cleavage HHHHHHGGGSGLEVLFQGPGSDLGKKLLEAARAGQDDEVRILMANGAD
Untagged G3 GPGSDLGKKLLEAARAGQDDEVRILMANGAD
His6-G3 HHHHHHGPGSDLGKKLLEAARAGQDDEVRILMANGAD
(HE)3-G3 HEHEHEGPGSDLGKKLLEAARAGQDDEVRILMANGAD
Pre-cleavage VNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAF
Untagged G3 VNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAF
His6-G3 VNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAF
(HE)3-G3 VNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAF
Pre-cleavage IGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKLNGGC
Untagged G3 IGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKLNGGC
His6-G3 IGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKLNGGC
(HE)3-G3 IGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKLNGGC
Figure 3.1 Desired amino acid sequences of His6-G3, (HE)3-G3 and untagged-G3
DARPins.
All constructs have a C-terminal gly-gly-cys tag for maleimide labelling and glycine-
proline (GP) residues. The two Tyr that can be labelled with iodine are highlighted
(yellow), the first and last residues of the G3 DARPin are emboldened and the
common residues are underlined
EAEAHis6-G3 and EAEA(HE)3-G3 refers to the G3 DARPins which had LEKREAEA
residues preceding their histidine based tags prior to the action of Kex2 and Ste13
P. pastoris proteinases. While His6-G3 and (HE)3-G3 refers to G3 DARPins which
only had LEKR preceding their histidine based tags prior to the action of Kex2
(Figure 3.2).128
A) EAEAHis6-G3
Kex2 Ste13 Ste13
C*TC GAG AAA AGA GAG GCT GAA GCT cat cac cat cat cac cat GGA CCA
L E K R E A E A H H H H H H G P
ggttctgatttgggaaagaaattgttggaa
G S D L G K K L L E
gctgctagagctggtcaagatgatgaagttagaattttgatggctaacggtgctgatgtt
A A R A G Q D D E V R I L M A N G A D V
aacgctaaggatgaatacggtttgactccattgtacttggctactgctcatggtcatttg
N A K D E Y G L T P L Y L A T A H G H L
gaaattgttgaagttttgttgaagaatggagctgatgttaacgctgttgatgctattggt
E I V E V L L K N G A D V N A V D A I G
tttactccattgcatttggctgcttttattggtcatttggaaattgctgaagttttgttg
F T P L H L A A F I G H L E I A E V L L
aagcatggtgccgacgttaacgctcaggataagtttggaaagactgcttttgatatttct
K H G A D V N A Q D K F G K T A F D I S
attggtaacggtaacgaagatttggctgaaattttgcaaaagttgaacGGAGGTTGC
I G N G N E D L A E I L Q K L N G G C
TAATAAt^ctagataatta
- -
B) EAEA(HE)3-G3
Kex2 Ste13 Ste13
C*TC GAG AAA AGA GAG GCT GAA GCT cat gag cat gaa cac gaa GGA CCA
L E K R E A E A H E H E H E G P
ggttct. . . . . . . . . . . . GGAGGTTGCTAATAAt^ctagataatta
G S . . . . . . . . . . . . G G C - -
C) Cleavable tag-G3
Kex2 Ste13 Ste13
C*TC GAG AAA AGA GAG GCT GAA GCT cat cac cat cat cac cat
L E K R E A E A H H H H H H
CGG AGG TGG CTC TGG TTA GAG GTA TTG TTT CAA / GGA CCA
G G G S G L E V L F Q / G P
ggttct. . . . . . . . . . . . GGAGGTTGCTAATAAt^ctagataatta
G S . . . . . . . . . . . . G G C - -
D) His6-G3
Kex2
C*TC GAG AAA AGA cat cac cat cat cac cat GGA CCA
L E K R H H H H H H G P
ggttct. . . . . . . . . . . . GGAGGTTGCTAATAAt^ctagataatta
G S . . . . . . . . . . . . G G C - -
E) (HE)3-G3
Kex2
C*TC GAG AAA AGA cat gag cat gaa cac gaa gga cca
L E K R H E H E H E G P
ggttct. . . . . . . . . . . . GGAGGTTGCTAATAAt^ctagataatta
G S . . . . . . . . . . . . G G C - -
Figure 3.2 Desired nucleic acid and amino acid sequences of EAEAHis6-G3,
EAEA(HE)3-G3, cleavable tag, His6-G3 and (HE)3-G3.
Proteinase site of products from Kex2 and Ste13 genes highlighted, XhoI (*) and (^)
XbaI endonuclease sites, site recognised by HRV 3C (underlined and cleavage site
denoted by /) and stop codons (-). N-terminus tag and C-terminus shown in red. The
complete G3 DARPin sequence is only shown for EAEAHis6-G3 and was identical
for all constructs, (.) omission of common amino acid and nucleic acid sequences.129
3.2 Results
3.2.1 PCR of G3 DARPin DNA
DNA encoding EAEAHis6-G3, EAEA(HE)3-G3 and cleavable tag-G3 were derived
from PCR of the ANK-1 DNA plasmid (please refer to Materials and Methods). A
short PCR (utilising the conventional sized Sense primer and Truncated Sense
primer) and long PCR (only utilising the conventional sized Sense primer) were
performed for each construct. For EAEAHis6-G3, EAEA(HE)3-G3 and cleavable tag-
G3 both the short and long PCR methods were successful in amplifying G3 DARPin
DNA (Figure 3.3). For consistency purposes, DNA from the short PCR process was
used for the subsequent G3 DARPin production.
Figure 3.3 Agarose gels (2%) showing G3 DARPin PCR products using ANK-1.
A) EAEAHis6-G3: Short used EAEAHis6 Sense and Truncated Sense with Anti-
Sense G3. Long used EAEAHis6 Sense with Anti-Sense G3
B) EAEA(HE)3-G3: Short used EAEA(HE)3 Sense and Truncated Sense with Anti-
Sense G3. Long used EAEA(HE)3 Sense with Anti-Sense G3
C) Cleavable tag-G3: Short used Cleavble tag Sense and Truncated Sense with
Anti-Sense G3. Long used Cleavable tag Sense with Anti-Sense G3130
PCR of the DNA ligations, pPICZαB/EAEAHis3 and pPICZαB/EAEAHE3 were used 
to produce His6-G3 and (HE)3-G3 DNA, respectively (Appendix). These PCRs all
used the conventional sized Sense primers but assessed different Anti-Sense
primers. These included the Anti-sense G3 (His-1 and HE-1 PCRs) and AOX1 Anti-
sense (His-2 and HE-2 PCRs). PCR with the AOX1 Anti-sense primer produced
larger DNA fragments than PCR with the Anti-sense G3 primer, as the former also
amplified sections of the pPICZαB DNA at the 3’ end. This was not problematic, as 
the pPICZαB DNA could be removed by the action of XbaI restriction endonuclease 
prior to ligation.
The control PCR with AOX1 Sense and AOX1 Anti-sense primers produced the
largest DNA construct as it amplifies a long sequence of pPICZαB DNA between the 
AOX1 priming sites and the incorporated G3 DARPin DNA (Figure 3.4). His-2 and
HE-2 DNA were selected for subsequent development, as their DNA bands were
clearly defined and presumed less likely to contain contaminants.
Figure 3.4 Agarose gels (2 %) showing His6-G3 and (HE)3-G3 DARPin DNA PCR
products.
A) His6-G3 PCR using pPICZαB/His3 template. His-1 used His6 Sense and Anti-
sense G3. His-2 used His6 Sense and AOX1 Anti-sense
B) (HE)3-G3 PCR using pPICZαB/HE3 template. HE-1 used (HE)3 Sense and Anti-
sense G3. HE-2 used (HE)3 Sense and AOX1 Anti-sense
Control PCRs used AOX1 Sense and AOX1 Anti-sense primers131
3.2.2  Amplification of pPICZαB plasmid 
The overnight cultures of the two colonies of pPICZαB-electroporated TOP10F´ cells 
yielded 1910.5 ng/µl and 1355.9 ng/µl of pPICZαB plasmid DNA.  
3.2.3  XbaI and XhoI digested pPICZαB plasmid 
pPICZαB plasmid (3597 bp) was digested by XbaI and XhoI, then purified from the 
agarose gel (Figure 3.5), for subsequent ligation with XbaI and XhoI digested and
purified G3 DARPin DNA.
Figure 3.5 Agarose gel (1 %) showing XbaI and XhoI digested pPICZαB plasmid, 1 
kb DNA Ladder (Promega) used.
3.2.4 Overnight culture of electroporated TOP10F´ and TG1 cells
For  bacteria  electroporated  with  ligated  pPICZαB/DARPin  DNA,  EAEAHis6-G3
(TOP10F’ cells), EAEA(HE)3-G3 (TOP10F’ cells), cleavable tag-G3 (TG1 cells),
His6-G3 (TG1 cells) and (HE)3-G3 (TG1 cells) had 50-200 colonies per Low Salt LB
plate. The pPICZαB DNA contains the Zeocin resistance (Sh ble) gene, enabling the
bacterial cells electroporated with pPICZαB/DARPin DNA to grow on Low Salt LB/ 
Zeocin (25 µg/ml) plates.132
3.2.5 PCR screening of electroporated TOP10F’ and TG1 colonies
G3 DARPin DNA contains approximately 450 base pairs (bp). Among the five
screened colonies of TOP10F’ which were electroporated with ligated
PICZαB/EAEAHis6-G3 DNA, four colonies contained G3 DARPin DNA. Colony
EAEAHis-3 was selected for DNA sequencing (Figure 3.6). For EAEA(HE)3-G3, two
TOP10F’ colonies electroporated with PICZαB/EAEA(HE)3-G3 DNA contained G3
DARPin DNA and both colonies (EAEAHE-1 and -3) were selected for DNA
sequencing (Figure   3.7). For bacterial electroporated with PICZαB/cleavable tag-G3 
DNA, nine of the twenty screened TG1 colonies contained DNA encoding the G3
DARPin. The colony no tag 9 was selected for DNA sequencing (Figure 3.8). Among
colonies of TG1 electroporated with PICZαB/His6-G3 DNA, colonies His-5 and -9
contained G3 DARPin DNA and were selected for DNA sequencing (Figure 3.9).
Among  the  nine  TG1  colonies  electroporated  with  PICZαB/(HE)3-G3 DNA, three
colonies contained G3 DARPin DNA. Colonies HE-3 and -4 were selected for DNA
sequencing (Figure 3.10)
Figure 3.6 Agarose gel (1.5 %) showing the PCR colony screening to determine
which colonies of electroporated TOP10F’ cells contained EAEAHis6-G3 DNA.
Figure 3.7 Agarose gel (1.5 %) of the PCR colony screening to determine which
colonies of electroporated TOP10F’ cells contained EAEA(HE)3-G3 DNA.133
Figure 3.8 Agarose gel (1.5 %) of the PCR colony screening to determine which
colonies of electroporated TG1 cells contained cleavable tag-G3 DNA (only colonies
8-10 shown).
Figure 3.9 Agarose gel (1.5 %) showing the PCR colony screening to determine
whether colonies of electroporated TG1 cells encoded His6-G3 DNA.
Figure 3.10 Agarose gel (1.5 %) showing the PCR colony screening to determine
whether colonies of electroporated TG1 cells had DNA encoding (HE)3-G3.
3.2.6  Sequencing of ligated pPICZαB/ G3 DARPin DNA 
For each G3 DARPin construct, at least one pPICZαB/DARPin ligation expressed by 
transformed bacteria contained the appropriate G3 DARPin DNA sequence (Table
3.2).134
Table 3.2 DNA sequencing of results pPICZαB/G3 DARPin DNA ligations.  
DNA Construct Nucleic acid concentration (ng/µl) DNA Sequencing Results
pPICZαB/EAEAHis-3  784.2  EAEAHis6-G3 DNA
pPICZαB/EAEAHE-1  1369.9  EAEA(HE)3-G3 DNA
pPICZαB/EAEAHE-3  1204.5  EAEA(HE)3-G3 DNA
pPICZαB/No tag-9  1889.4  Cleavable tag-G3 DNA 
pPICZαB/His-5  2323.9  His6-G3 DNA
pPICZαB/His-9  758.0  His6-G3 DNA
pPICZαB/HE-3  2458.5  (HE)3-G3 DNA
pPICZαB/HE-4  1764.3  (HE)3-G3 DNA
3.2.7  Linearisation of pPICZαB plasmids containing G3 DARPin DNA 
Ligations of pPICZαB/DARPin DNA were linearised with the Pme I enzyme at the 5’ 
AOX1 promoter region of pPICZαB for transformation into X-33 (P. pastoris) (Figure
2.5). Linear DNA fragments travel slower on agarose gels than their non-linear
(coiled) counterparts. Agarose gel electrophoresis confirmed Pme I linearisation of
the pPICZαB/DARPin DNA ligations of each construct. The controls were Pme I 
untreated  or  pGAPZαB  counterparts  treated  with  Pme  I  (Pme  I  cannot  linearise 
pGAPZαB).  There  was  possible  cross-contamination  of  pPICZαB/cleavable  tag, 
pPICZαB/His and pPICZαB/HE controls by Pme I treated counterparts (Figure   3.11). 135
Figure 3.11 Agarose gels (2%) of Pme I linearised pPICZαB/DARPin DNA ligations.  
A) pPICZαB/EAEAHis, B) pPICZαB/EAEAHE, C) pPICZαB/No tag, D) pPICZαB/His 
and  E)  pPICZαB/HE.  Controls  non-Pme  I  treated  pPICZαB/DARPin  (B,C,D,E)  or 
Pme I treated pGAPZαB/DARPin counterparts (A).  136
3.2.8 Protein expression by X-33 cells
After 72 h incubation, there were approximately fifty colonies of X-33 cells
transformed with pPICZαB/EAEAHis-3 DNA. Among the four selected colonies, two 
colonies expressed 14-15 kDa proteins with a His6 tag (data not shown). The X-33
cells  transformed  with  pPICZαB/EAEAHE-1  DNA  did  not  have  any  colonies. 
However, X-33 cells transformed with pPICZαB/EAEAHE-3 DNA had approximately 
fifty colonies and all five selected colonies expressed DARPins with the appropriate
molecular weight (14-15 kDa), as determined by western blotting using anti-DARPin
antibodies. The tetra-His antibody (Qiagen) was able to detect the dimer form of
EAEA(HE)3-G3 but was unable to detect the monomer form (Figure 3.12).
Figure 3.12 Western blots demonstrating EAEA(HE)3-G3 DARPin protein expression
by X-33 colonies transformed with pPICZαB/EAEAHE-3 DNA at 48 h incubation.  
4x SDS-PAGE reducing buffer and 16% Tris-Glycine gel used. Control SMV CB5 is
an anti-CEA diabody, its component parts have a His6tag.
A) Rabbit anti-DARPin primary and goat anti-rabbit secondary.
B) Mouse tetra-His antibody primary and sheep anti-mouse secondary.137
X-33 cells transformed with pPICZαB/cleavable tag-9 DNA produced 15 colonies. 
Among the three selected colonies, only one colony expressed protein of the
appropriate molecular weight (14-15 kDa). There was possibly premature cleavage
of the His6 tag at 48 h of incubation, as a second smaller protein was identified at
this time point which was not been detected at 24 h (Figure 3.13).
Figure 3.13 SDS-PAGE on 16% Tris-Glycine gel stained with coomassie blue
analysing protein expressed by X-33 colonies transformed with pPICZαB/cleavable 
tag 9 DNA.
Samples were processed with 4x SDS-PAGE reducing buffer.
After 72 h of incubation, there were no colonies of X-33 cells transformed with
pPICZαB/His-9  DNA.  However,  there  were  approximately  thirty  colonies  of  X-33 
cells transformed with pPICZαB/His-5 DNA and among the six selected colonies, 
two colonies expressed protein with a His6 tag with the appropriate molecular weight
(14-15 KDa) at 48 h incubation (data not shown).
X-33 cells transformed with pPICZαB/HE-3 DNA and pPICZαB/HE-4 DNA produced 
colonies and their selected colonies expressed DARPins with the appropriate
molecular weight (14-15 KDa) at 48 h incubation (data not shown).138
3.2.9 Yields of purified G3 DARPin protein from fermentations
Yields of purified G3 DARPin ranged from 18 to 85 mg per fermentation and
subsequent purification (Table 3.3).
Table 3.3 Yields of purified G3 DARPin protein from a single fermentation.
Cleavable tag-
G3 DARPin
EAEAHis6-G3
DARPin
His6-G3
DARPin
EAEA(HE)3-
G3 DARPin
(HE)3-G3
DARPin
Yield (mg) 18 46 32 36 85
The G3 DARPin produced by the fermentations was assessed by SDS-PAGE,
FPLC and mass spectrometry. Initially, protein standards were assessed on the
Analytical Superdex 75 FPLC Column to determine the appropriate elution volume
for the G3 DARPin (14-15 kDa) (Figure 3.14).
Figure 3.14 Protein standards (Bio-Rad Laboratories) run on the Analytical
Superdex 75 FPLC Column (125 ml bed volume, pre-packed with Superdex 75 prep
grade).139
3.2.10 Analysis of EAEAHis6-G3 fermentation, harvest and purification
During concentration and dialysis negligible amounts of EAEAHis6-G3 DARPin were
lost in the flow through and breakdown products > 5kDa were retained owing to the
MWCO (5 kDa) of the tangential flow filter (TFF) (Figure 3.15).
Figure 3.15 Stages of fermentation, harvest and purification of EAEAHis6-G3,
assessed by SDS-PAGE on 16% Tris-Glycine gel stained with coomassie blue,
samples were processed with 2x SDS-PAGE reducing buffer.
EAEAHis6-G3DARPin was eluted from the FPLC in several different forms including
monomer and dimer. Pool 1 (aliquots 29-39) related to the monomer confirmed by
coomassie staining (Figure 3.16 and Figure 3.17). Pool 1 was eluted at 90-100 ml
on the Analytical Superdex 75 column, relating to the approximate molecular weight
(14-15 kDa) (Figure 3.14 and Figure 3.16).140
Figure 3.16 FPLC trace of EAEAHis6-G3 DARPin. Red line relates to conductivity
and blue line relates to UV.
A) Preparative Superdex 75 column. Aliquots 29-39 (inclusive) related to the
monomer (Pool 1). Aliquots collected denoted by ^.
B) Pool 1 on Analytical Superdex 75 column.
Figure 3.17 SDS-PAGE on 16% Tris-Glycine gel stained with coomassie blue,
samples processed with 2x SDS-PAGE non-reducing (NR) buffer. EAEAHis6-G3
DARPin samples *2, *14 and *33 from the Preparative Superdex 75 FPLC column.141
The molecular weight of His6-G3 DARPin is 14,536.3 Da. However, MALDI mass
spectrometry confirmed that the glutamic acid (E) and alanine (A) residues
preceding the His6 tag were not efficiently cleaved by Ste13 resulting in EAEAHis6
(14,936.7 Da) and EAHis6 (14,736.5 Da) and the measured mass was between
these values, 14,869 Da (Figure 3.18). Thus, it was necessary to produce a His6-G3
which did not contain EAEA preceding the His6 tag, to ensure that the G3 DARPin
commenced at the His6 tag.
Figure 3.18 MALDI Mass spectrometry of EAEAHis6-G3 DARPin, confirming that
there was inefficient cleavage of the N-terminus glutamic acid (E) and alanine (A)
residues.
3.2.11 Analysis of EAEA(HE)3-G3 fermentation, harvest and purification
There were only small losses of EAEA(HE)3-G3 DARPin from the IMAC radial flow
bed during biomass application (10 L) and column washing with non-imidazole
solution. Therefore, most of the DARPin was eluted with 200 mM imidazole, as
intended (Figure 3.19). Breakdown products > 5 kDa were retained during
concentration and dialysis, owing to the TFF filter size (MWCO 5 kDa) (Figure 3.19).142
Figure 3.19 SDS-PAGE on 16% Tris-Glycine gel stained with coomassie blue of
EAEA(HE)3-G3, samples were processed with 4x SDS-PAGE reducing buffer.
A) Stages of fermentation, harvest and purification of EAEA(HE)3-G3.
B) Minimal loss of EAEA(HE)3-G3 from the radial flow IMAC column during biomass
application (10L) and column wash, prior to elution with 200 mM imidazole solution.
EAEA(HE)3-G3 was eluted at three different points from the Preparative Superdex
75 FPLC column (Figure 3.20). Pool 1 (aliquots 18-21) related to the dimer and Pool143
2 (aliquot 30-33) related to the monomer. Samples from three different points of
FPLC elution were ~14-15 kDa when processed with SDS-reducing buffer for
coomassie staining (Figure 3.19). On the Analytical Superdex 75 FPLC column, pool
2 was eluted at 85-95 ml confirming it was close to the anticipated molecular weight
of the monomer G3 DARPin (14-15 kDa) (Figure 3.20 and Figure 3.14).
Figure 3.20 FPLC traces of EAEA(HE)3-G3 DARPin. Red line relates to conductivity
and blue line relates to UV.
A) Preparative Superdex 75 column. Aliquots 18-21 (inclusive) related to the dimer
and aliquots 30-33 (inclusive) related to the monomer.
B) Analytical Superdex 75 column of Pool 2.
The molecular weight of (HE)3-G3 DARPin which starts at the (HE)3 tag is 14,512.2
Da. However, on mass spectrometry the molecular weight was 14,846.4 Da,
consistent with inefficient Ste13 cleavage resulting in EAEA(HE)3-G3 (14,912.6 Da)
and EA(HE)3-G3 (14,712.4 Da) production (Figure 3.21). Thus, it was necessary to144
omit the EAEA residues preceding the (HE)3 tag, to produce the (HE)3-G3 DARPin
commencing at the (HE)3tag.
Figure 3.21 MALDI Mass spectrometry of EAEA(HE)3-G3 DARPin, confirming there
was inefficient cleavage of N-terminus glutamic acid (E) and alanine (A) residues.
3.2.12 Analysis of His6-G3 fermentation, harvest and purification
There was increased His6-G3 protein production throughout the limited glycerol feed
(oxygen spike to 4 h post oxygen spike) and limited methanol feed (22 h duration)
(Figure 3.22). The His6-G3 was captured with the radial flow column, retained during
dialysis and concentration, for subsequent FPLC purification.
Figure 3.22 Fermentation, harvest and purification of His6-G3 DARPin assessed by
SDS-PAGE on 16% Tris-Glycine gel stained with coomassie blue, samples were
processed with 4x SDS-PAGE reducing buffer.145
The His6-G3 DARPin was dialysed into PBS containing 10 mM DTT and then
applied to the Preparative Superdex 75 FPLC column. Comparison of the FPLC
traces of His6-G3 and EAEAHis6-G3 (dialysed into PBS alone), demonstrates that
DTT increases the relative proportion of monomer G3 DARPin (Figure 3.16 and
Figure 3.23). Fractions 16-20 related to the monomer and were retained (Figure
3.23). Evaluation on the Analytical Superdex 75 FPLC column revealed that the
monomer pool was eluted at 95-100 ml which related to the anticipated molecular
weight 14-15 kDa (Figure 3.23 and Figure 3.14).
Figure 3.23 FPLC traces of His6-G3 DARPin. Red line relates to conductivity and
blue line relates to UV.
A) His6-G3 DARPin in PBS with 10 mM DTT applied to the Preparative Superdex 75
column. Aliquots 16-20 (inclusive) related to the monomer. Aliquots collected
denoted by ^. The presence of DTT increases the proportion of monomer.
B) Monomer pool applied to the Analytical Superdex 75 column.146
The His6-G3 DARPin had no EAEA at the N-terminus so did not rely on Ste13
cleavage. The molecular weight on MALDI mass spectrometry was 14,447 Da which
was closer to the anticipated weight (14,536.3 Da) than EAEAHis6-G3 (14,869 Da)
(Figure 3.24).
Figure 3.24 MALDI mass spectrometry of His6-G3, the molecular weight was close
to the anticipated molecular weight (14,536.3 Da).
3.2.13 Analysis of (HE)3-G3 fermentation, harvest and purification
There was increased (HE)3-G3 protein production from the oxygen spike to the
harvest (at 2h of limited methanol feed or 6 h post-oxygen spike) (Figure 3.25).
Breakdown products were retained during the concentration and dialysis, as
observed previously. At the time of harvesting, there were some losses in the flow
through from the IMAC column but minimal losses from the column during the
imidazole-free wash (data not shown).147
Figure 3.25 Fermentation, harvest and purification of (HE)3-G3 DARPin assessed by
SDS-PAGE on 16% Tris-Glycine gel stained with coomassie blue, samples were
processed with 4x SDS-PAGE reducing buffer.
(HE)3-G3 DARPin in PBS with 10 mM DTT was eluted on the Preparative Superdex
75 FPLC column, the presence of DTT ensured that the majority of (HE)3-G3
DARPin was eluted in monomer form (fractions 31-37) (Figure 3.26). On the
Analytical Superdex 75 column the monomer pool was eluted at 85-95 ml which
relates to the anticipated molecular weight, 14-15 kDa. A small protein fragment (at
140-150 ml equates to ~1 KDa molecular weight) was detected on the Analytical
Column, which is likely to be a breakdown product. This product may have been
retained during dialysis/concentration or formed spontaneously post-
dialysis/concentration as the TFF MWCO was 5 kDa (Figure 3.26 and Figure 3.14).148
Figure 3.26 FPLC traces of (HE)3-G3 DARPin. Red line relates to conductivity and
blue line relates to UV.
A) Preparative Superdex 75 column. Aliquots 31-37 (inclusive) related to the
monomer and were stored at -80 °C. Aliquots collected denoted by ^.
B) Analytical Superdex 75 column of (HE)3-G3 DARPin monomer pool.
The anticipated molecular weight of (HE)3-G3 DARPin which starts at the (HE)3 tag
is 14,512.2 Da. The molecular weight of (HE)3-G3 DARPin on MALDI mass
spectrometry was 14511.7 Da, as production did not rely on Ste13 cleavage of
EAEA residues (Figure 3.27).149
Figure 3.27 MALDI mass spectrometry of (HE)3-G3 DARPin. The molecular weight
was close to the anticipated molecular weight (14,512.2 Da).
3.2.14 Analysis of cleavable tag-G3 Fermentation, Harvest and Purification
The cleavable tag-G3 was harvested at 4 h post oxygen spike. During the harvest,
there were substantial DARPin losses in the column flow through but only small
losses when the column was washed with low concentration imidazole solution.
Western blotting confirmed that the cleavable tag-G3 DARPin lost in the flow
through and eluted from the FPLC retained its His6 tag (Figure 3.28).150
Figure 3.28 Analysis of the fermentation, harvest and purification of cleavable tag-
G3 DARPin. Samples run on 16% Tris-Glycine gel and processed with 4x SDS-
PAGE reducing buffer.
A) Coomassie blue stained gel.
B) Western blot demonstrating that the cleavable tag-G3 DARPin lost in the flow
through had a His6 tag (arrowed). The dialysed-concentrated and FPLC eluted
DARPin had a His6 tag (circled). Primary mouse anti-His, secondary sheep anti-
mouse.151
The cleavable tag-G3 DARPin was predominantly eluted in monomer form, as it had
been dialysed in PBS containing 10 mM DTT prior to FPLC purification (Figure
3.29).
Figure 3.29 FPLC trace of cleavable tag-G3 DARPin run on a Preparative Superdex
75 column. Aliquots 5-10 (inclusive) formed the pool of monomer DARPin.
The molecular weight of the cleavable tag-G3 DARPin commencing at the His6 tag
(prior to cleavage) is 15,581.5 Da. However, due to inefficient Ste13 activity, the
cleavable tag-G3 had a molecular weight of 15,934 Da (Figure 3.30). The molecular
weights of the variants with an EAEA-cleavableHis6 tag G3 and EA-cleavableHis6
tag G3 at the N-terminus are 15,981.8 and 15,781.7 Da, respectively. However,
cleavage by human rhinovirus 3C protease would ensure that the untagged-G3
DARPin would commence at the appropriate amino acid residue, glycine (G). Thus,
it was not necessary to produce a cleavable tag-G3 without EAEA residues at the N-
terminus.152
Figure 3.30 MALDI mass spectrometry of cleavable tag-G3
3.2.15 Cleavage of the cleavable tag-G3 DARPin
3.2.15.1 Optimisation of cleavage conditions
Removal of the His6 tag from the cleavable tag-G3 was assessed in PBS, Cleavage
Buffer and High Salt Cleavage Buffer by HRV 3C protease at 4 °C (concentration 40
U/ml or ~76 U/mg of cleavable tag-G3 DARPin). Cleavage in High Salt Cleavage
Buffer was efficient over 18 h, as there was no detectable His6 tagged protein. By
comparison, there was incomplete cleavage of the cleavable tag-G3 in the PBS and
Cleavage Buffer at 18 h, as there was detectable His6-tagged protein on western
blotting. Thus, cleavage in High Salt Cleavage Buffer was selected for further
assessment (Figure 3.31).153
Figure 3.31 Analysis of His6 tag cleavage of the cleavable tag-G3 DARPin in PBS,
Cleavage Buffer (CB) and High Salt Cleavage Buffer (HS-CB) for 18 h with 40 U/ml
HRV 3C Protease (22 kDa).
All samples were processed with 4x SDS-PAGE reducing buffer and run on a 16%
Tris-Glycine gel. Control was an untreated cleavable tag-G3 DARPin.
A) SDS-PAGE gel stained with coomassie blue.
B) Western blot demonstrating His6 tag loss form cleavable tag-G3 DARPin in HS-
CB (primary antibody mouse anti-His, secondary antibody sheep anti-mouse).154
In High Salt Cleavage Buffer at 4 °C, cleavage of the His6 tag from the cleavable
tag-G3  with  HRV  3C  Protease  was  less  efficient  at  ≤  4  U/ml  than  at  40  U/ml 
concentration. At 40 U/ml (equivalent to 76 U/mg of cleavable tag-G3DARPin)
cleavage could be completed within 2 h (Figure 3.32).
Figure 3.32 Effect of different HRV 3C Protease concentrations (0.4-40 U/ml) on
cleavage in High Salt Cleavage Buffer, tested at 2, 6 and 18 hours (4 °C).
SDS-PAGE on 16% Tris-Glycine gel stained with coomassie blue, samples were
processed with 4x SDS-PAGE reducing buffer. Control untreated cleavable tag-G3
DARPin.
3.2.15.2 Bulk cleavage
Based on the optimisation study, the cleavable tag-G3 was dialysed into High Salt
Cleavage Buffer containing 10 mM DTT and the bulk cleavage was performed over
2 h with HRV 3C protease at concentration 76 U/mg of DARPin (4 °C). A reverse
purification step of the untagged-G3 (subtractive IMAC) separated the untagged-G3
(eluted in High Salt Cleavage Buffer with 10 mM DTT wash) from the HRV 3C
protease (eluted in 250 mM Imidazole in the final step), as the HRV 3C protease has
a His6 tag. The untagged-G3 in the flow through was retained and stored (Figure
3.33).155
Figure 3.33 Bulk conjugation demonstrating untagged-G3 in the flow through (FT2)
of High Salt Cleavage Buffer (HS-CB) with 10 mM DTT which was retained and
HRV 3C protease in the final elution (E) in 250 mM imidazole.
Samples were processed with 4x SDS-PAGE reducing buffer on 16% Tris-Glycine
gel. A) Staining with coomassie blue. B) Western blot (primary antibody mouse anti-
His, secondary antibody sheep anti-mouse).156
3.3 Discussion
The aim of the work presented in this Chapter was to produce purified G3 DARPins
with and without histidine based N-terminal tags using a P. pastoris production
platform. His6-G3, (HE)3-G3 and untagged-G3 DARPins which only differed at the N-
terminus by the presence or absence of their tags were successfully produced.
It was not possible to produce His6-G3 and (HE)3-G3 DARPins from the template
which incorporated LEKREAEA preceding the histidine based tags, since the Ste13
gene product was inefficient in EA cleavage. The Kex2 gene product efficiently
removed LEKR residues, so the DARPins commenced with the residues EAEAH.. or
EAH.. (Sasagawa, Matsui et al. 2011).
The EA and EAEA extensions form part of the pro-sequence of the Saccharomyces
cerevisiae α-factor secretion signal which precedes the recombinant protein DNA. 
The α-factor secretion signal allows efficient secretion of proteins from P. pastoris, it
consists of a pre-sequence (19 amino acids) and pro-sequence (66 amino acids).
The EA repeats are located at the C-terminus of the pro-sequence (Kurjan and
Herskowitz 1982). The pre-sequence is the signal peptide that facilitates protein
secretion across the cytoplasmic membrane into the media and is removed by a
signal peptidase system (Raemaekers, de Muro et al. 1999). The pro-sequence acts
as an intra-molecular chaperone and guides protein folding, the pro-sequence can
be cleaved from the mature protein through auto-proteolysis performed by Kex2 and
Ste13 (He, Huang et al. 2012).
Interestingly, the recombinant small protein 1 (Sm1) expressed in P. pastoris has a
larger molecular mass than native Sm1 produced by the fungus Trichoderma virens.
This difference arises, as the N-terminus of P. pastoris produced Sm1 is extended
by the presence of EAEAYV residues, due to inefficient Ste13 protease activity
downstream of the Kex2 cleavage site (Buensanteai, Mukherjee et al. 2010).
It was necessary to produce pPICZαB/G3 DARPin DNA which did not encode EAEA 
but relied solely on the removal of the α-factor secretion signal pro-sequence by
Kex2 cleavage of LEKR residues. This change to the pro-sequence of the α-factor 
secretion signal did not affect Kex2 functioning and DARPin secretion from the
cytoplasm into the media (reflected by the fermentation yields). Removal of EAEA157
ensured that the G3 DARPin sequences commenced at the histidine based tags
(Table 3.3).
Although the cleavable tag-G3 DARPin also had EAEA residues at the N-terminus, it
was not necessary to produce an alternative construct, as the action of HRV 3C
protease ensured all residues preceding the GP were removed. Subsequently,
subtractive IMAC was able to isolate the untagged-G3 from the His6 tagged HRV 3C
protease.
In conclusion, three variants of the G3 DARPin were successfully produced using
the P. pastoris expression system which could be used to assess the influence of N-
terminal histidine based tag on normal tissue biodistribution. The Ste13 gene
product is inefficient in cleavage of Glutamate (E)-Alanine (A) repeats from the C-
terminus of the α-factor secretion signal and in their absence the G3 DARPin can 
still be efficiently secreted from P. pastoris.158
Chapter 4 Indium-111 and iodine-125
radiolabelled G3 DARPins in non-tumour
bearing mice159
4.1 Introduction
In Chapter 3, (HE)3-G3, His6-G3 and untagged-G3 DARPins which only differed
from each other by the presence or composition of their N-terminal histidine tags
were successfully produced using the P. pastoris production platform. They were
designed to be site-specifically radiolabelled via a bifunctional chelator at their
unique C-terminal cysteine or directly with radioiodine at one or both of their two
tyrosine residues.
Comparative assessment of the (HE)3-G3, His6-G3 and untagged-G3 DARPins in
mice, could determine the influence of the N-terminus histidine-based tags on
normal tissue biodistribution. Differences in the biodistribution profiles would be
easier to assess with radio-isotopes that have a long half-life, thus
111In (half-life
~2.8 days) and
125I (half-life ~60 days) were selected. Both residualising (
111In) and
non-residualising (
125I) radio-isotopes were assessed as they have different cellular
fates, which can also affect tumour-to-normal tissue ratios.
Previously, only G3 DARPins with a His6 tag for [
99mTc(CO)3]
+-radiolabelling had
been assessed in vivo. It was necessary to investigate the influence of the histidine-
based tag on normal liver uptake, as [
99mTc(CO)3]
+-His6-G3 had relatively high liver
uptake (7.27 ± 1.04% ID/g at 4 h) and low tumour-to-liver ratios (< 2:1 over 48 h),
despite achieving reasonably high HER2-positive tumour uptake (8.02 ± 2.85% ID/g
at 4 h) in SKOV3-tumour bearing mice (Zahnd, Kawe et al. 2010). Thus, G3 DARPin
normal liver uptake could compromise the ability to identify HER2-positive liver
metastases on imaging (Zahnd, Kawe et al. 2010).
For the HER2 binding affibody molecule, ZHER2:342, the histidine-based tag amino
acid configuration and position (N or C-terminus) effected normal tissue
biodistribution. [
99mTc(CO)3]
+-(HE)3-ZHER2:342 (N-terminus tag) had lower liver uptake
than counterparts with different histidine-based tags (Hofstrom, Altai et al. 2013).
The influence of the N-terminus histidine based tag on G3 DARPin normal tissue
uptake is unknown (Zahnd, Kawe et al. 2010). A G3 DARPin with low normal tissue
uptake could facilitate high tumour-to-normal tissue ratios, a prerequisite for
successful HER2 molecular imaging.160
Aim:
To test the hypothesis the N-terminus histidine-based tags affect normal tissue
uptake of the G3 DARPin.
Objectives:
1) Assess (HE)3-G3, His6-G3 and untagged-G3 DARPin kinetics and affinities for
HER2.
2) Assess cold labelled (HE)3-G3, His6-G3 and untagged-G3 DARPin HER2
specificity in vitro.
3) Assess normal tissue biodistribution of (HE)3-G3, His6-G3 and untagged-G3
DARPins radiolabelled with
111In and
125I.
The G3 DARPin construct with the lowest normal tissue uptake was validated further
in vitro and assessed in HER2-positive tumour bearing mice in Chapter 5.161
4.2 Results
Prior to assessing the (HE)3-G3, His6-G3 and untagged-G3 DARPins in normal
mice, it was important to confirm that they had equivalent HER2 binding affinities
unaffected by DOTA-conjugation and equivalent HER2 specificities unaffected by
labelling with indium or iodine. This is because loss of HER2 affinity and or HER2
specificity would adversely affect clinical utility and discourage further pre-clinical
development.
4.2.1 G3 DARPin affinity and binding kinetics with HER2 extracellular domain
The unconjugated His6-G3 DARPin produced in P. pastoris and E. coli had sub-
nanomolar affinities for the HER2 ECD, 0.204 and 0.111 nmol/L, respectively (Table
4.1). All of the assessed unconjugated and conjugated G3 DARPins had picomolar
binding affinities for the HER2 ECD. DOTA conjugation of the G3 DARPins was not
expected to affect G3 DARPin kinetics and affinities, since the G3 DARPin C-
terminus (where DOTA binds) does not form part of the HER2 ECD binding site
(Epa, Dolezal et al. 2013). Instead, the two central ankyrin repeats within the four
ankyrin repeat G3 DARPin structure contribute to HER2 binding. These SPR results
suggest that DOTA conjugation did not markedly alter G3 DARPin binding kinetics
and affinities with the HER2 ECD (Table 4.1).
Table 4.1 G3 DARPin affinities and kinetics with the HER2 ECD assessed by
Surface Plasmon Resonance (data presented as mean of duplicate assessments).
G3 DARPin Production Ka or Kon (M
-1 s
-1) Kd or Koff (s
-1) KD (nmol/L)
Untagged-G3 P. pastoris 4.2x10
5 2.6x10
-4 0.649
DOTA-Untagged-G3 P. pastoris 6.7x10
5 2.6x10
-4 0.397
His6-G3 P. pastoris 9.7x10
5 2.0x10
-4 0.204
DOTA-His6-G3 P. pastoris 6.1x10
5 2.2x10
-4 0.361
(HE)3-G3 P. pastoris 1.0x10
6 1.9x10
-4 0.184
DOTA-(HE)3-G3 P. pastoris 1.0x10
6 2.4x10
-4 0.228
His6-G3* E. coli 2.7x10
6 2.9x10
-4 0.111
*Control His6-G3: His6-G3 produced in E. coli without a C-terminal cysteine which
has a reported binding affinity of 0.091 nM (Zahnd, Kawe et al. 2010).
4.2.2 G3 DARPin specificity for HER2 in vitro
Flow cytometry demonstrated that cold indium and cold iodine labelled G3 DARPins
bind to HER2-positive human breast adenocarcinoma cells (BT474) and HER2-
positive human gastro-oesophageal junction adenocarcinoma cells (OE-19).162
However, the cold labelled G3 DARPins did not bind to HER2-negative human
breast adenocarcinoma cells (MDA-MB-468). The unlabelled G3 DARPin with a C-
terminus His6 (G3-His6) was the first version of G3 DARPin produced at UCL in P.
pastoris and was used as a control. These results confirmed HER2 specificity of the
cold labelled His6-G3, (HE)3-G3 and untagged-G3 DARPins in vitro (Figure 4.1).
Figure 4.1 Flow cytometry of cold indium and cold iodine labelled G3 DARPins
assessed with HER2-positive and HER2-negative human cell lines.
A) Human HER2-positive breast adenocarcinoma cells (BT474), B) Human HER2-
positive gastro-oesophageal junction adenocarcinoma cells (OE-19) and C) Human
HER2-negative breast adenocarcinoma cells (MDA-MB-468).
G3-His6 was unlabelled. Omission control cells were treated with antibodies in the
absence of G3 DARPin.163
4.2.3 Biodistribution of
111In-G3 DARPins in non-tumour bearing mice
Untagged-G3, His6-G3 and (HE)3-G3 DARPins were radiolabelled with
111In via a C-
terminal DOTA for administration to female BALB/c mice. For each construct, eight
mice were assessed and four mice were euthanised at each time point, 4 h and 24 h
post-administration.
111In-(HE)3-G3 DARPin had lower uptake in the pancreas, spleen, stomach, liver,
heart, lung, blood, muscle and bone marrow at 4 h compared to
111In-His6-G3 and
111In-untagged-G3. At 24 h,
111In-(HE)3-G3 had lowest uptake in the intestine,
pancreas, spleen, stomach, liver, muscle and bone marrow compared to its
111In
radiolabelled counterparts (Figure 4.2). The kidneys are the main route of G3
DARPin excretion and kidney uptake was greater than 200% ID/g for all
111In-G3
DARPins at 4 h. Kidney uptake was higher at 4 h than 24 h post-administration, due
to radioactive decay and or excretion from the kidneys (Figure 4.2 and Table 4.2).
Bone uptake was largely attributed to the marrow, as marrow uptake was similar to
intact bone uptake.
At 4 h post-administration,
111In-(HE)3-G3 had significantly lower liver uptake (1.569
± 0.042% ID/g) than both
111In-untagged-G3 (4.312 ± 0.401% ID/g, p=0.001) and
111In-His6-G3 (3.724 ± 0.386% ID/g, p=0.001). In addition, at 24 h
111In-(HE)3-G3 had
significantly lower liver uptake than both
111In-untagged-G3 (p=0.002) and
111In-His6-
G3 (p=0.001) (Figure 4.2 and Table 4.2). Interestingly, there was no significant
difference in liver uptake between the
111In-untagged-G3 and
111In-His6-G3 at 4 h
and 24 h post-administration. This suggests a specific favourable influence of the
(HE)3-tag, rather than the liver preferentially binding to the His6-tag.164
Figure 4.2 Biodistribution of
111In-G3 DARPins in female BALB/c mice.
A) 4 h and B) 24 h post-administration. Data expressed as the mean % ID/g ± SD.
* Statistically significant difference between (HE)3-G3 and the other
111In-G3
DARPins.165
Table 4.2 Biodistribution of
111In-G3 DARPins in female BALB/c mice.
G3 DARPin with lowest uptake for each normal tissue is emboldened.
A) 4 hour post-administration of
111In-G3 DARPins
Tissue
Untagged-G3
111In
% ID/g ± SD at 4 h
(n=4)
His6-G3
111In
% ID/g ± SD at 4 h
(n=4)
(HE)3-G3
111In
% ID/g ± SD at 4 h
(n=4)
Intestine 0.314 ± 0.113 0.369 ± 0.070 0.345 ± 0.059
Pancreas 0.317 ± 0.099 0.582 ± 0.095 0.288 ± 0.085
Spleen 1.269 ± 0.374 0.906 ± 0.075 0.461 ± 0.056
Stomach 0.407 ± 0.135 0.377 ± 0.273 0.210 ± 0.047
Kidney 305.715 ± 27.245 235.727 ± 46.615 286.665 ± 38.607
Liver 4.312 ± 0.401 3.724 ± 0.386 1.569 ± 0.042
Heart 0.343 ± 0.025 0.420 ± 0.071 0.269 ± 0.048
Lung 0.588 ± 0.040 0.688 ± 0.446 0.503 ± 0.210
Blood 0.097 ± 0.017 0.326 ± 0.236 0.047 ± 0.008
Muscle 0.199 ± 0.065 0.269 ± 0.087 0.131 ± 0.066
Bone with marrow 0.713 ± 0.330 0.908 ± 0.142 0.788 ± 0.387
Bone marrow 1.549 ± 0.350 1.257± 0.154 0.908 ± 0.488
B) 24 hour post-administration of
111In-G3 DARPins
Tissue
Untagged-G3
111In
% ID/g ± SD at 4 h
(n=4)
His6 -G3
111In
% ID/g ± SD at 4 h
(n=4)
(HE)3-G3
111In
% ID/g ± SD at 4 h
(n=4)
Intestine 0.427 ± 0.012 0.459 ± 0.081 0.225 ± 0.026
Pancreas 0.256 ± 0.032 0.449 ± 0.024 0.240 ± 0.025
Spleen 0.991 ± 0.060 0.874 ± 0.108 0.383 ± 0.064
Stomach 0.317 ± 0.044 0.465 ± 0.041 0.110 ± 0.040
Kidney 191.954 ± 11.245 174.190 ± 18.759 228.576 ± 32.920
Liver 3.057 ± 0.432 3.449 ± 0.337 1.054 ± 0.054
Heart 0.260 ± 0.028 0.353 ± 0.083 0.390 ± 0.315
Lung 0.480 ± 0.091 0.679 ± 0.564 0.554 ± 0.274
Blood 0.046 ± 0.005 0.061 ± 0.005 0.130 ± 0.136
Muscle 0.224 ± 0.071 0.169 ± 0.048 0.158 ± 0.104
Bone with marrow 0.718 ± 0.153 0.714 ± 0.074 0.788 ± 0.143
Bone marrow 1.701 ± 1.169 1.773 ± 1.557 0.547 ± 0.103
4.2.4 Biodistribution of
125I-G3 DARPins in non-tumour bearing mice
At 4 h post-administration,
125I-(HE)3-G3 and
125I-untagged-G3 had the lowest
uptake in all assessed normal tissues (Figure 4.3).
125I-(HE)3-G3 had significantly
lower liver uptake than
125I-His6-G3 (p=0.015) at 4 h but there was no significant
difference in liver uptake between
125I-(HE)3-G3 and
125I-untagged-G3 (p=0.494) at 4
h. At 24 h,
125I-(HE)3-G3 had significantly lower liver uptake than
125I-untagged-G3166
(p=0.004) and His6-G3 (p=0.003). There was no significant difference in normal liver
uptake between
125I-His6-G3 and
125I-untagged-G3 at 4h and 24h.
Figure 4.3 Biodistribution of
125I-G3 DARPins in female BALB/c mice.
A) 4 h and B) 24 h post-administration. Data expressed as mean % ID/g ± SD.
* Statistically significant difference between (HE)3-G3 and the other
125I-G3
DARPins.
For
125I radiolabelled G3 DARPins, normal tissue uptake was considerably higher at
4 h than at 24 h post-administration, the normal tissue uptake was <1.3% ID/g for all
125I-G3 DARPins at 24 h. By contrast,
111In-G3 DARPin normal tissue uptake was
better maintained between 4 and 24 h (Figure 4.2 and Figure 4.3).
125I is a non-
residualising radio-isotope so it is not as well retained within tissues compared with
111In which is a residualising isotope. Kidney uptake was lower for
125I-G3 DARPins
than their
111In counterparts, while gastric uptake was higher for the
125I-G3
DARPins where ‘free’
125I (formed by de-iodination in vivo) is known to accumulate.167
(HE)3-G3 was selected for assessment in HER2-positive tumour bearing mice, on
the basis of its lower normal tissue uptake which could facilitate imaging of HER2-
positive tumours by achieving greater contrast between tumours and normal tissues.
Table 4.3 Biodistribution of
125I-G3 DARPins in female BALB/c mice.
The G3 DARPin with lowest uptake for each normal tissue is emboldened.
A) 4 h post-administration of
125I-G3 DARPins
Tissue Untagged-G3
125I mean
% ID/g ± SD at 4 h
(n=4)
His6-G3
125I mean %
ID/g ± SD at 4 h
(n=4)
(HE)3-G3
125I mean
% ID/g ± SD at 4 h
(n=4)
Intestine 0.971 ± 0.124 1.763 ± 0.460 1.054 ± 0.202
Pancreas 0.652 ± 0.142 2.994 ± 1.246 0.914 ± 0.170
Spleen 0.809 ± 0.088 1.772 ± 0.622 0.700 ± 0.105
Stomach 18.379 ± 4.471 22.553 ± 6.813 10.401 ± 1.052
Kidney 4.717 ± 0.400 6.119 ± 1.120 2.336 ± 0.348
Liver 0.980 ± 0.113 1.655 ± 0.337 0.841 ± 0.346
Heart 0.526 ± 0.050 1.372 ± 0.480 0.676 ± 0.077
Lung 0.960 ± 0.151 2.255 ± 0.698 1.450 ± 0.660
Blood 1.158 ± 0.151 2.771 ± 0.892 1.416 ± 0.159
Muscle 0.439 ± 0.270 1.749 ± 0.723 0.433 ± 0.077
Bone with marrow 1.369 ± 0.308 1.694 ± 0.545 1.291 ± 0.395
Bone marrow 0.861 ± 0.167 4.026 ± 1.947 Not isolated
B) 24 h post-administration of
125I-G3 DARPins
Tissue Untagged-G3
125I mean
% ID/g ± SD at 24 h
(n=4)
His6-G3
125I mean %
ID/g ± SD at 24 h
(n=4)
(HE)3–G3
125I mean %
ID/g ± SD at 24 h
(n=4)
Intestine 0.122 ± 0.043 0.138 ± 0.060 0.076 ± 0.063
Pancreas 0.038 ± 0.009 0.059 ± 0.018 0.033 ± 0.015
Spleen 0.116 ± 0.006 0.098 ± 0.024 0.039 ± 0.013
Stomach 0.260 ± 0.102 0.497 ± 0.287 0.256 ± 0.181
Kidney 1.020 ± 0.091 1.255 ± 0.171 0.188 ± 0.033
Liver 0.214 ± 0.039 0.233 ± 0.043 0.098 ± 0.029
Heart 0.044 ± 0.015 0.064 ± 0.015 0.041 ± 0.013
Lung 0.088 ± 0.021 0.112 ± 0.024 0.072 ± 0.019
Blood 0.083 ± 0.025 0.098 ± 0.041 0.068 ± 0.036
Muscle 0.017 ± 0.003 0.028 ± 0.006 0.018 ± 0.006
Bone with marrow 0.456 ± 0.113 0.418 ± 0.108 0.852 ± 0.280
Bone marrow Weight too low for
analysis 0.300 ± 0.200 Not isolated168
4.2.5 Binding affinity
On the basis of the biodistribution results in non-tumour bearing mice, the (HE)3-G3
DARPin was selected for further assessment. The binding affinity of radiolabelled
(HE)3-G3 to HER2-positive human breast adenocarcinoma cells (BT474) was
assessed by a saturation assay.
BMax calculates the maximum amount of radiolabelled (HE)3-G3 which can bind to
HER2 receptors in the BT474 cell preparation. For
111In-(HE)3-G3 and
125I-(HE)3-G3,
the BMax was not reached at the highest assessed DARPin concentration (20 nM),
so the BMax had to be extrapolated by extending the curve beyond the measured
values.
125I-(HE)3-G3 had a higher BMax than
111In-(HE)3-G3, so higher amounts of
125I-(HE)3-G3 DARPin were required to saturate the HER2 receptors of the BT474
preparation than for
111In-(HE)3-G3. The observed differences in BMax between
111In-
(HE)3-G3 and
125I-(HE)3-G3, could be due to different HER2 affinities and kinetics of
these radioligands. It could also reflect differences in HER2 expression levels
between the BT474 cell preparations. Furthermore, if 0.1% sodium azide failed to
prevent HER2 receptor internalisation, then the differences in BMax could reflect
different internalisation and externalisation rates of
125I-(HE)3-G3 and
111In-(HE)3-G3.
The KD (binding affinity) is calculated at half of the BMax (Figure 2.7). Affinity for the
HER2 receptor of the BT474 cells, was 12.82 nmol/L for
111In-(HE)3-G3, compared
with 15.74 nmol/L for
125I-(HE)3-G3 (Table 4.4 and Figure 4.4). The direct
radiolabelling of the (HE)3-G3 DARPin with
125I to tyrosine residue(s) does not
appear to impact greatly upon the affinity for HER2 of BT474 cells compared to
111In-
(HE)3-G3 which is site specifically radiolabelled via DOTA.
The G3 DARPin affinity measured by SPR was in the picomolar range (Table 4.1).
During SPR assessment the non-radiolabelled G3 DARPin flows directly over the
HER2 ECD. However, the membrane bound HER2 receptor is less accessible,
which could explain the lower affinities (nanomolar) for the radiolabelled (HE)3-G3
DARPin assessed by the saturation assay. Although DOTA conjugation does not
appear to affect HER2 binding affinity based on SPR assessment (Table 4.1), it is
possible that the
111In and
125I radiolabelling reactions could affect HER2 binding
affinity.169
Table 4.4 Binding affinity of
111In-DOTA-(HE)3-G3 and
125I-(HE)3-G3 to HER2-
positive human breast cells (BT474).
BMax
(fmol/mg)
KD assessed on BT474
cells (nmol/L)*
KD assessed by
SPR (nmol/L)
#
111In-DOTA-(HE)3-G3 3747 12.82 0.228
125I-(HE)3-G3 5219 15.74 0.184
*Single assessment and
#duplicate assessment.
A
B
Figure 4.4 Saturation binding assay with HER2-positive (BT474) cells.
A)
111In-(HE)3-G3 DARPin and B)
125I-(HE)3-G3 DARPin170
4.3 Discussion
The work in this Chapter was focused on investigating the research hypothesis, N-
terminus histidine-based tags affect normal tissue uptake of the G3 DARPin. It is
important to assess this, as the identification of metastases on imaging relies upon
minimising normal tissue radioligand uptake.
Initial, in vitro studies demonstrated that cold indium and iodine labelled untagged-
G3, His6-G3 and (HE)3-G3 DARPins specifically bind to HER2-positive cells.
Conjugation with DOTA did not alter the kinetics and binding affinities of the G3
DARPins with the HER2 ECD assessed by SPR, HER2 binding affinity is in the
picomolar range both pre- and post-conjugation. This is because the HER2 binding
site is not at the C-terminus where DOTA binds. However,
111In-(HE)3-G3 and
125I-
(HE)3-G3 have similar nanomolar binding affinities to the membrane-bound HER2
receptor of BT474 cells. The differences in HER2 binding affinities could reflect the
greater accessibility of the HER2 ECD on SPR than with the cell-based assay.
Histidine based tags enable IMAC purification and can be used for the chelation of
[
99mTc(CO)3]
+. The G3 DARPins assessed only differed at their N-terminal tags. The
presented
111In and
125I biodistribution studies, demonstrated that the presence of
the (HE)3 tag rather than the absence of the His6 tag is responsible for reducing
normal liver G3 DARPin uptake. Thus, confirming the research hypothesis.
For the affibody molecule, ZHER2:342 radiolabelled with [
99mTc(CO)3]
+, (HE)3-ZHER2:342
was associated with lower liver uptake than counterparts with different histidine tag
configurations (Tolmachev, Hofstrom et al. 2010; Hofstrom, Orlova et al. 2011;
Hofstrom, Altai et al. 2013). Yet, some of the comparative ZHER2:342 biodistribution
studies are limited, as there were other differences in the amino acid sequences
besides the composition of the histidine-based tags (Hofstrom, Orlova et al. 2011).
For affibody molecules radiolabelled with
111In via DOTA,
111In-His6-ZHER2:342-C had
higher liver uptake than
111In-untagged-ZHER2:342-C and
111In-(HE)3-ZHER2:342-C,
however the uptake in non-hepatic organs was similar for the different constructs
(Ahlgren, Orlova et al. 2008; Hofstrom, Orlova et al. 2011). The presented work
demonstrated that
111In-(HE)3-G3 had significantly lower liver uptake than
111In-171
untagged-G3 and
111In-His6-G3. In addition, there was no significant difference in
liver uptake between the
111In-untagged-G3 and
111In-His6-G3.
125I-HPEM-(HE)3-ZHER2:342-C and
125I-HPEM-His6-ZHER2:342-C (1-[2-(4-
hydroxyphenyl)ethyl]pyrrole-2,5-dione) have similar biodistribution profiles, including
low liver uptake, high stomach uptake and low kidney uptake in non-tumour bearing
mice (Hofstrom, Orlova et al. 2011). In addition, liver uptake for
125I-HPEM-(HE)3-
ZHER2:342-C and
125I-HPEM-His6-ZHER2:342-C at 4 h post-administration were similar
(Hofstrom, Orlova et al. 2011).
Direct iodination of the G3 DARPins results in higher stomach uptake where free
iodine (formed by de-iodination in vivo) is known to accumulate and lower kidney
uptake compared to their
111In radiolabelled counterparts.
111In is a residualising
radio-isotope so remains inside the cells post-internalisation, reflected by similar
uptake in the assessed normal tissues at 4 and 24 h. By contrast,
125I is a non-
residualising radioisotope, resulting in lower radio-iodine uptake in normal tissues at
24 h compared to 4 h. At 24 h post-administration, there was a significantly lower
liver uptake for
125I-(HE)3-G3 compared to both
125I-His6-G3 and
125I-untagged-G3.
The mechanism of (HE)3 tag mediated reduction in G3 DARPin liver uptake has not
been established. For affibody molecules, it has been proposed that positively
charged and hydrophobic tags enhance liver uptake (Hofstrom, Altai et al. 2013).
However, the untagged and His6-tagged affibody molecules have basic isoelectric
points (pI), which is brought to a more acidic region by switching to an (HE)3 tag,
such that the overall pI of the different affibody constructs tested differed greatly. By
contrast, the (HE)3, His6 and untagged-G3 DARPins have similar pIs of 4.79, 5.41
and 4.71, respectively (Hofstrom, Altai et al. 2013). Furthermore, the (HE)3, His6 and
untagged-G3 DARPins have similar grand average of hydropathy (GRAVY) scores
-0.12, -0.12 and +0.02, respectively, indicating other factors are involved, while the
corresponding affibody molecules have slightly more divergent scores of -1.03, -0.97
and -0.85.
In non-tumour bearing mice, (HE)3-G3 DARPin had lower or equivalent normal
tissue uptake compared with both His6-G3 and untagged-G3, so was selected for
assessment in HER2-positive tumour bearing mice. In particular,
111In-(HE)3-G3 had172
significantly lower liver uptake than
111In-His6-G3 and
111In-untagged-G3 at 4 and 24
h post-administration, while
125I-(HE)3-G3 had significantly lower liver uptake than
both of its
125I radiolabelled counterparts at 24 h. Comparing the 4 h normal liver
uptake of [
99mTc(CO)3]
+-His6-G3 (7.27 ± 1.04% ID/g) with
111In-(HE)3-G3 (1.569 ±
0.042% ID/g) and
125I-(HE)3-G3 (0.841 ± 0.346% ID/g), demonstrates that the
(HE)3-G3 DARPin represents a promising development that warrants further
investigation (Zahnd, Kawe et al. 2010).173
Chapter 5 SPECT imaging with indium-
111 and iodine-123/125 radiolabelled G3
DARPin174
5.1 Introduction
The work in this Chapter was primarily focused on evaluating HER2 SPECT imaging
with the
111In- and
123/125I-radiolabelled (HE)3-G3 DARPin. A preliminary study,
performed by Dr Kim Vigor (UCL Cancer Institute), had established HER2 tumour
specificity in vivo with a G3 DARPin radiolabelled with [
99mTc(CO)3]
+ via a C-terminal
His6-tag ([
99mTc(CO)3]
+-G3-His6) (Waibel, Alberto et al. 1999). [
99mTc(CO)3]
+-G3-His6
had significantly higher uptake in HER2-positive (BT474) tumours than in HER2-
negative (MDA-MB-468) tumours, 3.5 ± 1.1 vs. 1.0 ± 0.2% ID/g at 24 h post-
administration (p=0.004). Uptake in normal tissues was similar in the HER2-positive
and HER2-negative tumour bearing mice (Table 5.1). The differences in tumour
uptake were also apparent on microSPECT/CT scans (Figure 5.1). However,
[
99mTc(CO)3]
+-G3-His6 did not appear optimal for HER2 imaging, since in the HER2-
positive xenograft, the tumour-to-liver ratios were low (1.2:1 at 24 h), in the presence
of good tumour-to-blood ratios (26:1 at 24 h). As previously discussed, a similar G3
DARPin construct radiolabelled with [
99mTc(CO)3]
+ assessed in a SKOV3 tumour
model, demonstrated a low tumour-to-liver ratio (1.7:1 at 24 h) in the presence of a
high HER2-positive tumour uptake (8.06 ± 2.38 at 24 h) (Zahnd, Kawe et al. 2010).
Table 5.1 Biodistribution of [
99mTc(CO)3]
+-G3-His6 in HER2-positive and HER2-
negative tumour bearing SCID-beige mice (unpublished).
Organ HER2-positive (BT474) tumours
at 24 h, mean % ID/g ± SD (n=4)
HER2-negative (MDA-MB-468) tumours
at 24 h, mean % ID/g ± SD (n=4)
Tumour 3.5 ± 1.1 1.0 ± 0.2
Spleen 0.9 ± 0.2 1.0 ± 0.3
Kidney 108.0 ± 7.7 108.6 ± 10.6
Liver 3.0 ± 0.2 2.7 ± 0.7
Lung 0.5 ± 0.1 0.5 ± 0.2
Blood 0.1 ± 0.0 0.1 ± 0.0
Muscle 0.3 ± 0.1 0.2 ± 0.1
In view of the data presented in Chapter 4, all further investigations focused entirely
on the (HE)3-G3 DARPin. This included results from non-tumour bearing mice
studies, demonstrating that
111In-(HE)3-G3 and
125I-(HE)3-G3 had significantly lower
liver uptake than their radiolabelled His6-G3 and untagged-G3 counterparts. At 24 h,
the liver uptake of
111In-(HE)3-G3 (1.1 ± 0.1 % ID/g) and
125I-(HE)3-G3 (0.1 ± 0.0 %
ID/g) in non-tumour bearing mice were low, this compared favourably with the liver175
uptake for [
99mTc(CO)3]
+-His6 in HER2-positive tumour bearing mice (3.0 ± 0.2%
ID/g) (Table 5.1). Furthermore, the cold indium and cold iodine labelled (HE)3-G3
DARPin had specificity for HER2-positive cell lines in vitro. The (HE)3-G3 DARPin
had picomolar affinity for the HER2 ECD assessed by SPR, while
111In-(HE)3-G3
and
125I-(HE)3-G3 both had nanomolar affinities for HER2 expressed by BT474
human breast cancer cells.
Figure 5.1 MicroSPECT/CT scans at 1 h post-administration of [
99mTc(CO)3]
+-G3-
His6 to SCID-beige mice bearing tumours (unpublished).
A) HER2-positive human breast tumour (BT474) and B) HER2-negative human
breast tumour (MDA-MB-468). Tumours in left (L) side of mouse identified by an
arrow (A and B assessed at same level of sensitivity).
It would be advantageous if the G3 DARPin binds to HER2 in the presence of anti-
HER2 therapies, so that patients can be scanned without compromising treatment
schedules and efficacy. Structural modelling has determined that the G3 DARPin
and trastuzumab bind to adjacent but non-overlapping epitopes of subdomain 4 of
the HER2 ECD (Epa, Dolezal et al. 2013). However, a lack of competition has not
been confirmed in vivo. Pertuzumab binds to subdomain 2 of the HER2 ECD, so the
G3 DARPin should be able to bind in the presence of pertuzumab.176
In summary, G3 DARPins have high affinity for HER2, specificity for HER2-positive
breast tumours and could potentially bind to HER2 in the presence of pertuzumab
and trastuzumab. The (HE)3-G3 is the most promising variant as it has the lowest
normal liver uptake, justifying its investigation in HER2-positive tumour bearing
mice.
Aim:
To test the hypothesis, that the G3 DARPin radiolabelled with indium-111 and
iodine-123/125 can achieve high tumour-to-blood and high tumour-to-normal tissue
ratios for pre-clinical HER2 SPECT imaging.
Objectives:
To determine the suitability of radiolabelled (HE)3-G3 for HER2 imaging by
assessing:
1. Tumour uptake and tumour-to-normal tissue ratios in HER2-positive tumour
bearing mice.
2. Ability to image HER2-positive tumours in mice by microSPECT/CT scanning.
3. Effect of trastuzumab on tumour uptake in HER2-positive tumour bearing mice.
4. Stability in serum and PBS.177
5.2 Results
5.2.1 HER2 status of BT474 tumours excised from untreated mice
Prior to assessing (HE)3-G3 DARPin in HER2-positive tumour bearing mice, it was
important to confirm that the BT474 tumours inoculated into the mice were HER2-
positive, so tumours from four untreated mice were assessed. The 2013 update of
the ASCO/CAP guidelines for HER2 testing in breast cancer, defines IHC 3+, as
circumferential membrane staining that is complete, intense, and within >10% of
tumour cells (Wolff, Hammond et al. 2013).
The HercepTest (Dako) consists of a primary rabbit anti-human HER2 antibody and
a secondary goat anti-rabbit antibody with HRP for IHC assessment. The positive
control, HER2-positive human breast tumour tissue (SK-BR-3) scored 3+ with the
HercepTest primary and secondary antibodies. The negative control, SK-BR-3
tumour tissue tested with normal rabbit immunoglobulin and secondary goat anti-
rabbit antibody with HRP, scored 0 on IHC. Thus, confirming that there is no cross
reactivity between the secondary antibody and human breast cancer cells. The four
human breast tumours (BT474) excised from untreated SCID-beige mice all scored
3+ on IHC (Figure 5.2).
Figure 5.2 Immunohistochemistry of human breast tumours with HercepTest.
Primary, rabbit anti-human HER2 antibody and secondary, goat anti-rabbit antibody
with HRP, control SK-BR-3 (HER2-positive breast tumour), 20x magnification:
A) Positive control, SK-BR-3 tumour with primary and secondary Ig (3+).
B) Negative control, SK-BR-3 tumour with normal rabbit Ig and secondary Ig (0).
C) BT474 tumour from untreated SCID-beige mice tested with primary and
secondary Ig (3+).178
5.2.2 Normal tissue biodistribution of
111In-(HE)3-G3 and
125I-(HE)3-G3
DARPins in HER2-positive tumour bearing mice and non-tumour bearing mice
The decision to exclusively investigate (HE)3-G3 DARPin in tumour bearing mice
was based on its normal tissue biodistribution in BALB/c mice, including lower
normal liver uptake for (HE)3-G3 compared to untagged-G3 and His6-G3 DARPins
when radiolabelled with
125I and
111In. Thus, it was important to confirm that
111In-
(HE)3-G3 and
125I-(HE)3-G3 normal tissue uptake in BALB/c mice and tumour
bearing SCID-beige mice were comparable.
For
111In-(HE)3-G3, there was relatively similar normal tissue uptake in tumour
bearing SCID-beige mice and non-tumour bearing BALB/c mice at 4 and 24 h post-
administration. The major exceptions were the liver, heart, lung and bone, where
there was higher tissue uptake for BALB/c mice than SCID-beige mice.
111In-(HE)3-
G3 normal liver uptake was two-fold higher for BALB/c mice than tumour bearing
SCID-beige mice at 4 h, 1.6 ± 0.0 vs. 0.7 ± 0.1% ID/g, however the differences in
normal liver uptake were smaller at 24 h (Figure 5.3).
Figure 5.3 Biodistribution of
111In-(HE)3-G3 DARPin in female BALB/c mice and
female SCID-beige mice bearing HER2-positive human breast tumours (BT474)
(tumour uptake omitted). Data expressed as mean % ID/g ± SD.179
The normal tissue uptake for tumour bearing SCID-beige mice and non-tumour
bearing BALB/c mice treated with
125I-(HE)3-G3 were similar at 24 h but normal
tissue uptake was higher for most assessed normal tissues in tumour bearing SCID-
beige mice at 4 h. For example, 4 h blood uptake was 1.4 ± 0.2% ID/g for BALB/c
mice and 3.6 ± 2.2% ID/g for SCID-beige mice, yet blood levels were similar at 24 h
for both mice (Figure 5.4).
Figure 5.4 Biodistribution of
125I-(HE)3-G3 DARPin in female BALB/c mice and
female SCID-beige mice bearing HER2-positive human breast tumours (BT474
(tumour uptake omitted). Data expressed as mean % ID/g ± SD.
5.2.3 Biodistribution of
111In-(HE)3-G3 and
125I-(HE)3-G3 DARPins in HER2-
positive tumour bearing mice
At 4 h post-administration,
125I-(HE)3-G3 and
111In-(HE)3-G3 had similar uptake in
HER2-positive tumours, 11.3 ± 3.2 and 8.8 ± 1.3% ID/g, respectively.
111In is a
residualising radio-isotope and remains inside the tumour cells after internalisation,
by contrast
125I is a non-residualising radio-isotope and is not retained by cells.
Consequently, at 24 h post-administration HER2-positive tumour uptake was over 3
-fold higher for
111In-(HE)3-G3 than
125I-(HE)3-G3, 8.1 ± 0.9 vs. 2.4 ± 0.6% ID/g
(Figure 5.5 and Figure 5.6).180
Table 5.2 Tumour-to-normal tissue ratios of
111In-(HE)3-G3 and
125I-(HE)3-G3 in
female SCID-beige mice bearing HER2-positive human breast tumours (BT474).
Mean tumour-to-
tissue ratios
111In-(HE)3-G3
125I-(HE)3-G3
4h tumour-to-
tissue ratio
(n=4)
24h tumour-to-
tissue ratio
(n=4)
4h tumour-to-
tissue ratio
(n=4)
24h tumour-to-
tissue ratio
(n=4)
Intestine 39.4 ± 21.1 21.8 ± 5.1 8.0 ± 3.6 20.8 ± 10.9
Pancreas 50.1 ± 15.3 41.5 ± 12.7 6.6 ± 4.2 36.2 ± 11.6
Spleen 32.3 ± 9.6 28.6 ± 5.0 8.5 ± 5.1 34.2 ± 11.2
Stomach 148.8 ± 91.1 67.5 ± 46.6 1.3 ± 0.8 6.4 ± 2.501
Liver 12.4 ± 1.8 12.0 ± 3.6 9.3 ± 5.7 21.0 ± 8.1
Heart 69.3 ± 25.2 66.5 ± 8.1 10.4 ± 5.1 37.8 ± 11.5
Lung 46.4 ± 12.6 60.8 ± 24.9 5.4 ± 3.6 23.2 ± 9.1
Blood 174.7 ± 26.1 343.7 ± 161.3 4.4 ± 3.4 22.0 ± 11.3
Muscle 114.3 ± 55.5 105.8 ± 51.7 18.6 ± 17.0 58.0 ± 26.6
Bone with marrow 25.9 ± 8.3 28.1 ± 2.7 6.9 ± 2.0 5.2 ± 0.4
Kidney 0.04 ± 0.008 0.04 ± 0.005 4.3 ± 2.2 9.8 ± 2.5
Normal tissue uptake in HER2-positive tumour bearing mice was lower for
111In-
(HE)3-G3 than
125I-(HE)3-G3 at 4 h, except in the kidneys where uptake was higher
for
111In-(HE)3-G3. Consequently, tumour-to-normal tissue ratios at 4 h were higher
for
111In-(HE)3-G3 than
125I-(HE)3-G3 for all tissues, except the kidneys (Table 5.2).
High tumour-to-normal tissue ratios are favourable for tumour imaging. At 24 h, the
differences in tumour-to-normal tissue ratios were less marked between
111In-(HE)3-
G3 and
125I-(HE)3-G3 (Table 5.2).
111In-(HE)3-G3 kidney uptake was higher than any other tissue tested; it was 232.0 ±
24.1% ID/g at 4 h and decreased to 196.5 ± 31.0% ID/g at 24 h (Figure 5.5 and
Figure 5.6). Rapid serum clearance and or uptake of
111In-(HE)3-G3 via the kidneys
resulted in higher tumour-to-blood ratios of 174.7 ± 26.1 at 4 h for
111In-(HE)3-G3
compared to 4.4 ± 3.4 at 4 h for
125I-(HE)3-G3 (Table 5.2).181
Figure 5.5 Biodistribution of
111In-(HE)3-G3 DARPin in female SCID-beige mice
bearing HER2-positive human breast tumours (BT474). Data expressed as mean %
ID/g ± SD.
Figure 5.6 Biodistribution of
125I-(HE)3-G3 DARPin in female SCID-beige mice
bearing HER2-positive human breast tumours (BT474). Data expressed as mean %
ID/g ± SD.
5.2.4 SPECT/CT scans with
123I-(HE)3-G3 and
111In-(HE)3-G3 DARPins
123I-(HE)3-G3 DARPin was used for SPECT scanning, as
123I has higher gamma
energy emission than
125I (159 vs. 35.5 KeV). HER2-positive tumour uptake could be
detected on the
123I-(HE)3-G3 microSPECT/CT scan at 4 h but there was non-182
specific uptake in the stomach, kidneys, bladder and thyroid. On the
111In-(HE)3-G3
microSPECT/CT scan at 4 h, HER2-positive tumour uptake was detected and there
was minimal uptake in all organs, besides the kidneys (Figure 5.7). Thus, the
acquired SPECT/CT scan images reflect the biodistribution profiles of
125I-(HE)3-G3
and
111In-(HE)3-G3 DARPins in tumour and non-tumour bearing mice.
111In-(HE)3-G3
was selected for further development, in view of its higher tumour-to-blood ratios,
higher tumour-to-normal tissue uptake (except for the kidneys) and better
maintained HER2-positive tumour uptake over 24 h than
123/125I-(HE)3-G3.
Figure 5.7 MicroSPECT/CT scans of SCID-beige mice bearing HER2-positive
(BT474) tumours beside their left (L) hip (black arrow).
A)
123I-(HE)3-G3 DARPin at 4 h, demonstrating HER2-positive tumour uptake
associated with high uptake in the kidneys, bladder, stomach and thyroid.
B)
111In-(HE)3-G3 DARPin at 4 h, demonstrating HER2-positive tumour uptake
associated with high uptake in the kidneys and bladder (oestrogen pellet visible,
grey arrow).
5.2.5 Effect of trastuzumab on
111In-(HE)3-G3 DARPin HER2-positive tumour
uptake
Pre-administration of an 18-fold molar excess of intravenous non-radiolabelled
trastuzumab (350 µg trastuzumab/mouse) 24 h prior to intravenous
111In-(HE)3-G3
(1.9 µg
111In-(HE)3-G3 DARPin/mouse) did not significantly effect 4 h HER2-positive
tumour uptake compared to mice which only received
111In-(HE)3-G3, 7.2 ± 1.3 vs.183
7.1 ± 1.9% ID/g, respectively (p=0.95) (Figure 5.8). Confirming that the G3 DARPin
can bind in the presence of trastuzumab, as they bind to non-overlapping epitopes
within subdomain 4 of the HER2 ECD (Jost, Schilling et al. 2013).
Figure 5.8 Biodistribution of
111In-(HE)3-G3 DARPin at 4 h in the presence and
absence of trastuzumab.
Female SCID-beige mice bearing HER2-positive human breast tumours (BT474)
pre-treated with an 18-fold molar excess of trastuzumab, 24 h prior to G3 DARPin
administration compared with mice which only received G3 DARPin. Data
expressed as the mean % ID/g ± SD.
5.2.6 In vitro stability of selected radiolabelled DARPin
111In-(HE)3-G3 DARPin was stable in PBS at 4 °, 20 ° and 37 °C and serum:PBS
(1:1) at 37 °C, since > 95% of radiation activity was bound to (HE)3-G3 for 24 h post-
radiolabelling (Table 5.3).
Autoradiography of the SDS-PAGE gel of
111In-(HE)3-G3 DARPin stored in human
serum:PBS (1:1) and PBS alone determined that there was only a single
radiolabelled protein at 24 h post-radiolabelling, coomassie staining confirmed that
the radiolabelled proteins were the appropriate molecular weight (14-15 kDa). In
addition, there were no detectable radiolabelled or non-radiolabelled breakdown
products (Figure 5.9).184
Table 5.3 Stability of
111In-(HE)3-G3 DARPin assessed in PBS at 4 °, 20 ° and 37 °C
and in serum:PBS (1:1) at 37 °C for 24 h post-radiolabelling assessed by instant thin
layer chromatography.
Time post radiolabelling DARPin radiolabelling (%) Colloid (%) Other products (%)
Serum stability: 37 °C - 1 h 100 0 0
2 h 100 0 0
4 h 100 0 0
24 h 100 0 0
PBS stability: 37 °C- 1 h 100 0 0
2 h 100 0 0
4 h 100 0 0
24 h 96.4 0 3.6
PBS stability: 20 °C- 1 h 100 0 0
2 h 100 0 0
4 h 100 0 0
24 h 97.4 0 2.6
PBS stability: 4 °C- 1 h 100 0 0
2 h 100 0 0
4 h 100 0 0
24 h 95.9 0 4.1
Figure 5.9 SDS-PAGE gel of
111In-(HE)3-G3 DARPin stored in PBS and human
serum:PBS (1:1) at 24 h post-radiolabelling at a range of different temperatures.
Spectra Multicolor Broad Range Protein Ladder (Thermo Scientific), molecular
weights in kDa. Analysed by:
A) Autoradiography: demonstrated a single radiolabelled protein.
B) Coomassie staining: confirmed appropriate size of
111In-(HE)3-G3 DARPin.185
5.3 Discussion
The work in this Chapter demonstrated that
111In-(HE)3-G3 is a promising radioligand
for HER2 SPECT imaging, which maintains high HER2-positive tumour uptake over
24 h, as
111In is a residualising radioisotope so remains inside the tumour cells post-
internalisation. For
111In-(HE)3-G3 the combination of high and well-maintained
HER2-positive tumour uptake over 24 h with low normal tissue uptake (except for
the kidneys), results in high tumour-to-blood and high tumour-to-normal tissue
ratios. This includes tumour-to-liver ratios ≥ 12 over 24 h.  
111In-(HE)3-G3 DARPin achieves higher tumour-to-blood ratios within 24 h of
administration to mice bearing HER2-positive tumours than any other reported
HER2 radioligand, including whole antibodies, Fab regions of trastuzumab and small
high affinity proteins (Smith-Jones, Solit et al. 2004; Dijkers, Kosterink et al. 2009;
Reddy, Shaller et al. 2011; Perols, Honarvar et al. 2012).
By contrast,
125I-(HE)3-G3 has high tumour uptake at 4 h but falls by approximately
4-fold at 24 h, since
125I is non-residualising and is not retained within the tumour
cells after internalisation.
125I-(HE)3-G3 achieves lower tumour-to-blood ratios than
111In-(HE)3-G3, as it is compromised at 4 h by relatively high serum levels and at 24
h by falling HER2-positive tumour levels.
The microSPECT/CT scans at 4 h post-administration reflect the biodistribution
results at this time point, confirming that
111In-(HE)3-G3 is superior to
123I-(HE)3-G3
for HER2 whole body imaging, since it is associated with less uptake in normal
tissues. Furthermore,
111In-(HE)3-G3 exhibits stability in serum and PBS over 24 h,
demonstrated by the lack of G3 DARPin protein breakdown and well-maintained
radio-chemical purity.
Pertuzumab binds to subdomain 2 of the HER2 ECD, while trastuzumab and G3
bind to non-overlapping epitopes of subdomain 4 (Zahnd, Pecorari et al. 2006;
Zahnd, Wyler et al. 2007; Epa, Dolezal et al. 2013). It has been confirmed that
111In-
(HE)3-G3 DARPin can bind to HER2-positive tumours in the presence of
trastuzumab in vivo, as an 18-fold molar excess of trastuzumab did not alter
111In-
(HE)3-G3 HER2-positive tumour uptake. Thus,
111In-(HE)3-G3 DARPin could
potentially image treatment naïve patients and patients receiving concomitant anti-
HER2 therapy without effecting treatment schedules.186
The results for
111In-(HE)3-G3 confirmed the research hypothesis that ‘The G3
DARPin radiolabelled with indium-111 and iodine-123/125 can achieve high tumour-
to-blood and high tumour-to-normal tissue ratios for pre-clinical HER2 SPECT
imaging’. However,
123I/
125I-(HE)3-G3 is a less promising radioligand for HER2
SPECT imaging with less impressive ratios.
In conclusion,
111In-(HE)3-G3 has key characteristics needed for a HER2 SPECT
imaging agent and represents a significant improvement compared to the His6
tagged G3 DARPins previously assessed (Zahnd, Kawe et al. 2010).187
Chapter 6 PET imaging with gallium-68
radiolabelled G3 DARPin188
6.1 Introduction
The work in Chapter 5 outlined the development of G3 DARPin HER2 SPECT
imaging. However, PET imaging has a higher sensitivity than SPECT imaging by
approximately two to three orders of magnitude, as PET is able to detect a higher
proportion of emitted events, justifying investigation of G3 DARPin HER2 PET
imaging.
SPECT imaging rejects photons which do not approach the lead collimator at the
correct angle to pass through its holes; as a result SPECT detects approximately
0.01% of emitted events. Physical collimators are not required for PET imaging, as
each positron interaction with an electron, generates two photons which travel in
opposite directions reaching the oppositely paired PET cameras simultaneously
(coincidence detection). Consequently, PET detects approximately 1% of emitted
events (Rahmim and Zaidi 2008).
The enhanced sensitivity of PET compared with SPECT has a series of important
implications for imaging, including:
1. Improved image quality, as superior signal-to-noise ratios are achieved.
2. Shorter scan time to acquire images with equivalent signal-to-noise ratios.
3. Improved temporal resolution, enabling the capture of multiple images of an
object in the field of view, to facilitate the study of dynamic biological processes
(Rahmim and Zaidi 2008).
68Ga was selected for investigation of G3 DARPin PET scanning for several
reasons. Firstly, it has a high positron yield, including an 88% positron branching
(88% of decay by positron emission and 12% of decay by electron capture) and high
maximum energy of 1.9 megaelectronvolts (MeV).
68Ga is convenient, as it is formed
by the decay of its parent isotope, germanium-68 (
68Ge) which has a long half-life
(280 days), so it is available from in-house
68Ge/
68Ga generators.
68Ga has a short
half-life (68 min), which is compatible with G3 DARPins half-life (several minutes)
(Zahnd, Kawe et al. 2010). Finally,
68Ga forms stable complexes with peptides via
bifunctional chelators, thus it is suitable for in vivo investigation (Morgat, Hindie et al.
2013).189
In aqueous solutions,
68Ga is only stable as a trivalent cation Ga
3+ under acidic
solutions (Morgat, Hindie et al. 2013). At higher pH conditions, Ga(OH)3 is formed
(Prata 2012). Therefore,
68Ga is eluted from the
68Ge/
68Ga generator in 0.1 M HCl
and radiolabelling is performed in acidic conditions. However, the stability of the G3
DARPin under acidic conditions is unknown.
Conventionally,
68Ga radiolabelling of DOTA is performed at 100 °C in acidic
conditions (pH 4.4) for 30 min, while
68Ga radiolabelling of NOTA is performed at pH
3.6 for 10 min at RT (Figure 6.1 and Figure 6.2) (Berry, Ma et al. 2011). Berry et al.
have developed a novel tripodal tris(hydroxypyridinone) bifunctional chelator,
YM103 (maleimide form of CP256), for
68Ga radiolabelling of proteins. CP256 is
based on the structure of a powerful Fe
3+ chelator, since Ga
3+ and Fe
3+ have similar
co-ordination chemistry (Figure 6.3). CP256 can be radiolabelled with
68Ga to a high
specific activity when performed at pH 6.5 and RT over 5 min. In vitro,
68Ga-CP256
is stable in serum and is stable when challenged with over a 100–fold excess of
apotransferrin (which could potentially compete for
68Ga binding). Furthermore,
68Ga-CP256 is stable in vivo for at least 90 min (Berry, Ma et al. 2011).
Figure 6.1 Structure of mal-DOTA (Chemical formula: C22H34N6O9, MW: 526.54 Da,
1Ga:1DOTA).
Figure 6.2 Structure of mal-NOTA (Chemical formula: C18H27N5O7, MW: 425.44 Da,
1Ga:1NOTA).190
Figure 6.3 Structure of YM103 (Chemical formula: C44H58N9O13, MW: 920.42 Da,
1Ga:1YM103).
In Chapter 3, the untagged-G3 was formed by HRV 3C cleavage of the Leu(L)-
Glu(E)-Val(V)-Leu(L)-Phe(F)-Gln(Q) * Gly(G)-Pro(P) site, converting the cleavable
tag-G3 into the untagged-G3 DARPin. Consequently, the (HE)3-G3 and His6-G3
DARPins assessed in Chapter 4 and 5 incorporated a Gly(G)-Pro(P) site, to
maintain consistency with the untagged-G3 DARPin.
In Chapter 6 and 7, the assessed (HE)3-G3 DARPin did not contain an N-terminal
Gly(G)-Pro(P) site but was produced by the P. pastoris production platform as
outlined in the Material and Methods (Figure 6.4). The N-terminus of the G3 DARPin
does not participate in binding to the HER2 ECD. Interestingly, the presence or
absence of a Gly(G)-Pro(P) site does not affect the pI (4.79) of the G3 DARPin, so
this change in amino acid sequence was not expected to effect biodistribution and
HER2 binding.
A) HEHEHEGP-[G3 DARPin]-C
B) HEHEHE-[G3 DARPin]-C
Figure 6.4 (HE)3-G3 DARPin amino acid sequences.
A) (HE)3-G3 with a glycine-proline site assessed in Chapter 4 and 5.
B) (HE)3-G3 without a glycine-proline site used in the
68Ga PET studies (Chapter 6)
and pre-clinical toxicity studies (Chapter 7)
(C- C-terminal cysteine, N-terminal tags underlined and GP glycine-proline).191
Aim:
To test the hypothesis that the, G3 DARPin can be radiolabelled with gallium-68 for
pre-clinical HER2 PET imaging.
Objectives:
1. Assess the HER2 specificity and normal tissue biodistribution of (HE)3-G3
without a glycine-proline site.
2. Select an appropriate bifunctional chelator for
68Ga radiolabelling of (HE)3-G3,
whose radiolabelling conditions will not affect DARPin HER2 binding function.
3. Assess
68Ga-(HE)3-G3 tumour uptake and tumour-to-normal tissue ratios in mice
bearing HER2-positive tumour xenografts.
4. Assess the ability of
68Ga-(HE)3-G3 to image mice with HER2-positive tumour
xenografts by PET/CT scanning.192
6.2 Results
6.2.1 In vitro HER2 specificity of (HE)3-G3 DARPin-DOTA without a GP site
Flow cytometry demonstrated that the unlabelled and cold indium labelled DOTA-
(HE)3-G3 without a GP-site bound to HER2-positive BT474 and OE-19 cells but did
not bind to HER2-negative MDA-MB-468 cells (Figure 6.5). In Chapter 4, the cold
indium labelled (HE)3-G3 DARPin-DOTA with a GP-site achieved similar results with
BT474, OE-19 and MDA-MB-468 cells, 94.1%, 80.7% and 0.5%, respectively. Thus,
confirming that removal of the GP-site did not affect HER2 specificity in vitro.
A
B
C
Figure 6.5 Flow cytometry of cold indium labelled and unlabelled (HE)3-G3 DARPin-
DOTA without an N-terminus glycine-proline.
A) HER2-positive breast (BT474), B) HER2-positive gastro-oesophageal junction
(OE-19) and C) HER2-negative breast adenocarcinoma cells (MDA-MB-468).
Omission control cells treated with antibodies in absence of G3 DARPin.193
6.2.2 Biodistribution of
111In-DOTA-(HE)3-G3 DARPins with and without an N-
terminus glycine-proline in non-tumour bearing mice
Assessment of the
111In-DOTA-(HE)3-G3 DARPins with and without a GP-site in
female BALB/c mice demonstrated that both formats had similar normal tissue
uptake (Figure 6.6). Urine was also collected from the mice which received
111In-
DOTA-(HE)3-G3 without a GP-site, this demonstrated that radioactivity was excreted
in urine. The quantity of
111In-DOTA-(HE)3-G3 DARPin and or free
111In in mouse
urine was below the detection limit for auto-radiography and SDS-PAGE analysis by
coomassie staining at 4 and 24 h post-administration, so the urinary excreted
radiolabelled product was not further characterised. All subsequent studies in this
thesis assessed the (HE)3-G3 DARPin without a GP-site.
Figure 6.6 Biodistribution of
111In-(HE)3-G3 DARPins with and without an N-terminus
glycine-proline (GP) in female BALB/c mice.
A) 4 h and B) 24 h post-administration. Data expressed as the mean % ID/g ± SD.194
6.2.3 Temperature stability of DOTA-(HE)3-G3 DARPin
In Chapter 4 and 5, DOTA-(HE)3-G3 was efficiently radiolabelled with
111In at 37 °C
(pH 6.0) over 2 h. Importantly, these radiolabelling conditions did not affect the
kinetics and affinity of the DOTA-(HE)3-G3 for the HER2 ECD assessed by SPR
(Table 6.1).
Table 6.1 Affinities and kinetics of DOTA-(HE)3-G3 with HER2 ECD assessed by
Surface Plasmon Resonance after heating to 37 °C for 2 h at pH 6.0.
G3 DARPin
conditions
Production
platform
Ka or Kon
(M
-1 s
-1)
#
Kd or Koff
(s
-1)
#
KD
(nmol/L)
#
DOTA-(HE)3-G3
control (pH 6.0)* P. pastoris 9.26 x10
5 2.95 x10
-4 0.322
DOTA-(HE)3-G3
heated to 37°C for
2 h (pH 6.0)
P. pastoris 6.04 x10
5 3.01 x10
-4 0.502
*Control was not heated,
#mean of duplicate assessments
Labelling of DOTA with
68Ga requires heating to 100 °C in acidic conditions (pH 4.4)
for 30 min (Berry, Ma et al. 2011). Radiolabelling for 30 min is not ideal, as
68Ga has
a short half-life (68 min). Heating DOTA-(HE)3-G3 at 80 °C for 15 min resulted in a
slower association rate (Ka) with a maintained dissociation rate (Kd). In addition,
heating DOTA-(HE)3-G3 to 80 °C decreased its binding affinity for the HER2 ECD
(Table 4.1). Consequently, DOTA-(HE)3-G3 DARPin is appropriate for
111In
radiolabelling but not for
68Ga radiolabelling.
Table 6.2 Affinities and kinetics of DOTA-(HE)3-G3 with HER2 ECD assessed by
Surface Plasmon Resonance after heating to 80 °C for 15 min.
G3 DARPin
conditions
Production
platform
Ka or Kon
(M
-1 s
-1)
#
Kd or Koff
(s
-1)
#
KD
(nmol/L)
#
DOTA-(HE)3-G3
control (pH 6.5)* P. pastoris 8.8 x10
5 2.43 x10
-4 0.277
DOTA-(HE)3-G3
heated to 80 °C for
15 min (pH 6.5)
P. pastoris 1.4 x10
5 2.43 x10
-4 2.02
*Control was not heated and
#mean of duplicate assessments195
6.2.4 NOTA-(HE)3-G3 stability in acidic conditions
6.2.4.1 Surface Plasmon Resonance of acid-treated NOTA-(HE)3-G3
(HE)3-G3 DARPin has a pI of 4.79, so at pH 4.79 it does not have a net electrical
charge and is at risk of precipitating out of solution. Radiolabelling of NOTA with
68Ga is optimal at low pH conditions, conventionally pH 3.6 for 10 min at RT. Based
on SPR analysis, NOTA-(HE)3-G3 subjected to pH 3.6, 4.6 and 6.5 have similar
kinetics and affinities for the HER2 ECD. However, (HE)3-G3 maintained at pH 7
appeared to have superior HER2 binding affinity and faster dissociation than acid-
treated NOTA-(HE)3-G3 (Table 6.3).
Table 6.3 Affinities and kinetics of NOTA-(HE)3-G3 with HER2 ECD assessed by
Surface  Plasmon  Resonance  after  treatment  at  pH  ≤  7  and  maintained  at  room 
temperature.
G3 DARPin
(treatment
conditions)*
Production
platform
Ka or Kon
(M
-1 s
-1)
#
Kd or Koff
(s
-1)
#
KD
(nmol/L)
#
(HE)3-G3
(pH 7.0 for 1 day) P. pastoris 5.6 x10
5 2.0 x10
-4 0.362
NOTA-(HE)3-G3
(pH 6.5 for 1 day) P. pastoris 6.3 x10
5 2.9 x10
-4 0.462
NOTA-(HE)3-G3
(pH 4.6 for 20 min) P. pastoris 7.2 x10
5 2.9 x10
-4 0.398
NOTA-(HE)3-G3
(pH 4.6 for 90 min) P. pastoris 5.5 x10
5 3.0 x10
-4 0.540
NOTA-(HE)3-G3
(pH 3.6 for 20 min) P. pastoris 5.7 x10
5 3.0 x10
-4 0.527
NOTA-(HE)3-G3
(pH 3.6 for 90 min) P. pastoris 5.2 x10
5 3.0 x10
-4 0.579
*NOTA-(HE)3-G3 was neutralised to physiological pH with PBS after being
subjected to acidic pH conditions for the stated periods of time, prior to assessment.
#Mean of duplicate assessments.
6.2.4.2 Flow cytometry analysis of acidic treated NOTA-(HE)3-G3
NOTA-(HE)3-G3 subjected to pH 3.6, 4.6 and 6.5 bound to HER2-positive BT474
cells. On flow cytometry, (HE)3-G3 maintained at pH 7 appeared to bind better to
BT474 cells than acid treated NOTA-(HE)3-G3 (Figure 6.7). This is consistent with
the finding that (HE)3-G3 maintained at pH 7 had superior HER2 ECD binding
affinity than the acid treated NOTA-(HE)3-G3 assessed by SPR (Table 6.3).196
Figure 6.7 Flow cytometry profiles for BT474 cells treated with unconjugated and
NOTA-conjugated (HE)3-G3 DARPins subjected to different pH conditions.
A) Treatment samples and B) Controls.
All (HE)3-G3 DARPins were neutralised to physiological pH with Dulbecco’s-PBS
prior to cell application, negative controls were not treated with G3 DARPin.
(HE)3-G3 maintained at pH 7 bound poorly to HER2-negative, MDA-MB-468 cells.
NOTA-(HE)3-G3 subjected to pH 3.6 bound better to MBA-MB-468 cells than NOTA-
(HE)3-G3 subjected to pH 4.6 and pH 6.5 conditions (Figure 6.8). The effect of pH
3.6 treatment upon NOTA-(HE)3-G3 binding, could reflect either loss of specificity or
increased sensitivity but is more likely to be due to loss of specificity. This is
because BT474 cells have 2.75 × 10
6HER2 receptors per cell and the lower pH (pH
3.6) did not improve BT474 binding assessed by flow cytometry but it did improve
binding for MDA-MB-468 cells which have only 1X10
3 HER2 receptors per cell
(Figure 6.7 and Figure 6.8) (DeFazio-Eli, Strommen et al. 2011; Hathaway, Butler et
al. 2011).197
Figure 6.8 Flow cytometry profiles for MDA-MB-468 cells treated with unconjugated
and NOTA-conjugated (HE)3-G3 DARPins subjected to different pH conditions.
A) Treatment samples and B) Controls.
All (HE)3-G3 DARPins were neutralised to physiological pH with PBS prior to cell
application, negative controls were not treated with G3 DARPins.
6.2.5 Gallium-68 radiolabelling of (HE)3-G3 DARPin at different pH conditions
The flow cytometry results suggested that performing
68Ga radiolabelling of NOTA-
(HE)3-G3  at  pH  ≥  4.6  would  preserve  HER2  specificity.  Fortunately, 
68Ga
radiolabelling of NOTA-(HE)3-G3 was most efficient at pH 4.6 (Table 6.4). NOTA-
(HE)3-G3 maintained at pH 4.6, selectively bound to HER2-positive breast cancer
cells (BT474) and had picomolar affinity for the HER2 ECD (Table 6.3, Figure 6.7
and Figure 6.8). Thus, it appears to be feasible to radiolabel NOTA-(HE)3-G3 with
68Ga at pH 4.6.
Table 6.4 Radiochemical purity of
68Ga-NOTA-(HE)3-G3 radiolabelled at different pH
conditions.
68Ga-NOTA-(HE)3-G3 radiolabelling pH* Radiochemical purity (%)
pH 7.7 9.2
pH 6.2 10.7
pH 5.5 24.4
pH 4.6 83.8
pH 3.6 5.6
*Each reaction was performed with 10 µg of NOTA-(HE)3-G3 and 2 MBq of
68Ga.198
By contrast, YM103 (maleimide form of CP256) can be radiolabelled with
68Ga to a
high specific activity when performed at pH 4.6 to 6.5 and RT over 5 min (Berry, Ma
et al. 2011). However, in view of the SPR and flow cytometry results for NOTA-
(HE)3-G3, it is unlikely that these
68Ga radiolabelling conditions (pH 4.6-6.5) would
affect YM103-(HE)3-G3 HER2 binding function but this was not formally assessed.
6.2.6
68Ga-NOTA-(HE)3-G3 and
68Ga-YM103-(HE)3-G3 biodistribution in HER2-
positive tumour bearing mice
The normal tissue biodistribution profiles of
68Ga-NOTA-(HE)3-G3 and
68Ga-YM103-
(HE)3-G3 differed greatly from each other. In particular,
68Ga-YM103-(HE)3-G3 had
higher liver, lung and spleen uptake, while
68Ga-NOTA-(HE)3-G3 had higher kidney
and blood uptake. At 1 h post administration,
68Ga-NOTA-(HE)3-G3 and
68Ga-
YM103-(HE)3-G3 HER2-positive tumour uptake were 11.8 ± 6.9% ID/g and 6.8 ±
0.9% ID/g, respectively (Figure 6.9).
For all of the assessed tissues,
68Ga-NOTA-(HE)3-G3 achieved higher or equivalent
tumour-to-tissue ratios compared with
68Ga-YM103-(HE)3-G3, with the exception of
blood uptake. The tumour-to-blood ratio achieved with
68Ga-YM103-(HE)3-G3 was
12.6 ± 5.1, compared to 5.9 ± 3.1 for
68Ga-NOTA-(HE)3-G3, as
68Ga-YM103-(HE)3-
G3 had lower blood levels (Table 6.5). Owing to the inferior tumour-to-normal tissue
ratios,
68Ga-YM103-(HE)3-G3 was not investigated any further.
Table 6.5
68Ga-NOTA-(HE)3-G3 and
68Ga-YM103-(HE)3-G3 DARPin tumour-to-
normal tissue ratios of in female SCID-beige mice bearing HER2-positive human
breast tumours (BT474).
Mean tumour-to-tissue
ratios
68Ga-NOTA-(HE)3-G3
at 1 h (n=4)
68Ga-YM103-(HE)3-G3
at 1 h (n=4)
Intestine 21.2 ± 11.7 8.3 ± 3.1
Pancreas 10.5 ± 4.2 6.6 ± 1.8
Spleen 3.3 ± 1.1 0.7 ± 0.2
Stomach 29.0 ± 29.0 6.9 ± 0.4
Liver 1.5 ± 0.6 0.1 ± 0.0
Heart 7.8 ± 3.8 5.5 ± 7.1
Lung 4.6 ± 1.4 1.4 ± 0.7
Blood 5.9 ± 3.1 12.6 ± 5.1
Muscle 25.6 ± 7.0 10.1 ± 3.7
Bone with marrow 10.1 ± 3.9 2.7 ± 0.7
Kidney 0.1 ± 0.1 0.1 ± 0.0199
Figure 6.9 Biodistribution of
68Ga-NOTA-(HE)3-G3 and
68Ga-YM103-(HE)3-G3
DARPin in female SCID-beige mice bearing HER2-positive human breast tumours
(BT474) at 1 h post-administration. Data expressed as mean % ID/g ± SD.
6.2.7 PET/CT scans with
68Ga-NOTA-(HE)3-G3
HER2-positive tumours can be detected on PET/CT scanning at 30-120 min post
68Ga-NOTA-(HE)3-G3 administration. The kidneys received the highest dose and
uptake in other visible normal organs appeared to be low but normal organ uptake
was partially obscured by the kidneys (Figure 6.10). The HER2-positive tumour
uptake for the scanned mouse was 15.6% ID/g at 2 h, however the liver uptake was
12.6% ID/g at 2 h post-administration (Table 6.6).200
Figure 6.10 PET/CT scan of SCID-beige mouse bearing a HER2-positive (BT474)
tumour beside its left (L) hip, acquired 30-120 min post-administration of
68Ga-
NOTA-(HE)3-G3.
Table 6.6 Biodistribution of PET/CT scanned female SCID-beige mouse bearing
HER2-positive human breast tumours (BT474), at 2 h post-administration of
68Ga-
NOTA-(HE)3-G3.
Tissue Uptake (% ID/g) at 2 h (n=1)
Intestine 0.7
Pancreas 0.7
Spleen 3.4
Stomach 0.7
Kidney 206.0
Liver 12.6
Heart 1.2
Lung 2.0
Blood 1.7
Muscle 0.5
Bone with marrow 1.6
Tumour 15.6201
6.3 Discussion
Based on HER2 binding function, the DOTA conjugated (HE)3-G3 DARPin can
tolerate heating to 37 °C but does not tolerate heating to 80 °C. Therefore, (HE)3-G3
DARPin conjugated with DOTA is not suitable for
68Ga radiolabelling, as the
radiolabelling reaction must be performed at high temperatures (100 °C) for 30 min.
Consequently, YM103-(HE)3-G3 and NOTA-(HE)3-G3 were investigated as
alternatives, since these chelators can be radiolabelled with
68Ga at room
temperature.
The contrasting biodistribution profiles for
68Ga-YM103-(HE)3-G3 and
68Ga-NOTA-
(HE)3-G3 could be related to differences in the hydrophilicity of their respective
bifunctional chelators. The mal-NOTA bifunctional chelator contains two carboxyl
groups, which are polar and contribute to hydrophilicity. While YM103 has a higher
molecular weight than mal-NOTA (920.42 vs. 425.44 Da) and is composed of
multiple carbon rings and a long unbranched non-polar hydrocarbon chain
connecting CP256 to a maleimide group, these components enhance hydrophobicity
(Figure 6.2 and Figure 6.3).
The Octanol-Water Partition Coefficient (KOW) can be used to determine a
compound’s hydrophilicity. KOW represents the ratio of a compound’s solubility in
octanol (fatty alcohol) compared to its solubility in water. The logP refers to the
logarithm of KOW in the assessed compound’s non-ionised (neutral) form. Generally,
logP values are inversely related to water solubility and directly proportional to
molecular weight. Experimentally-derived logP and calculated logP (ClogP) values
correlate well with each other (Kah and Brown 2008). The ClogP for mal-NOTA is
-7.82 compared with -1.71 for YM103 (Table 6.7). Thus, confirming that YM103 is
less hydrophilic than mal-NOTA. As the G3 DARPin is a low molecular weight
protein, it is likely that YM103-(HE)3-G3 is relatively hydrophobic compared to
NOTA-(HE)3-G3. Consequently,
68Ga-YM103-(HE)3-G3 was found to have higher
liver uptake, lower kidney uptake and lower blood uptake than
68Ga-NOTA-(HE)3-
G3.202
Table 6.7 Calculated log of the Octanol-Water Partition Coefficient (ClogP) for mal-
DOTA, mal-NOTA and YM103.
Bi-functional chelator Molecular
weight (Da)
ClogP
(Relative water solubility)
Mal-DOTA 526.54 -10.1 (High water solubility)
Mal-NOTA 425.44 -7.82 (High water solubility)
YM103 (maleimide form of CP256) 920.42 -1.71 (Low water solubility)
It is difficult to compare the biodistribution data for
111In-DOTA-(HE)3-G3 and
68Ga-
NOTA-(HE)3-G3, as the
111In treated mice were euthanised at 4 or 24 h, while the
68Ga treated mice were euthanised at 1 h post-administration. Both constructs have
high kidney uptake and achieve similar HER2-positive tumour uptake, 8.8 ± 1.3%
ID/g for
111In-DOTA-(HE)3-G3 at 4 h and 11.8 ± 7.0% ID/g for
68Ga-NOTA-(HE)3-G3
at 1 h.
A protocol for
68Ga radiolabelling of (HE)3-G3 DARPin via NOTA has been
successfully developed. In HER2-positive tumour xenografts,
68Ga-NOTA-(HE)3-G3
achieves a tumour-to-blood ratio of 5.9 ± 3.1 and tumour-to-liver ratio of 1.5 ± 0.6 at
1 h. It is unlikely that this tumour-to-liver ratio will be sufficient to identify HER2-
positive liver metastases on PET/CT scanning.
68Ga-NOTA-(HE)3-G3 is capable of
imaging HER2-positive tumours in the flank region of mice. Therefore, the
hypothesis that the ‘G3 DARPin can be radiolabelled with gallium-68 for pre-clinical
HER2 PET imaging’ is in part confirmed. However, the lead construct
68Ga-NOTA-
(HE)3-G3 has significant limitations for imaging visceral HER2-positive metastases
due to low tumour-to-normal tissue ratios, which will adversely affect the
identification of splenic, hepatic, lung and renal metastases.203
Chapter 7 Pre-clinical toxicity assessment
of the G3-DARPin204
7.1 Introduction
The
111In-DOTA-(HE)3-G3 DARPin was the most promising radioligand investigated
for HER2 imaging within this thesis, so it was selected for investigation in a first-in-
human HER2 SPECT imaging trial. Thus, the work in this Chapter focused on
assessing whether it had any toxic effects. The proposed dose of
111In-(HE)3-G3
DARPin for the clinical trial is 0.5 mg with 300 MBq of radiation activity. This dose
has been selected on the basis of safety and efficacy considerations, while using the
approaches of other HER2 imaging trials as a benchmark (Table 7.1).
The rationale for using 0.5 mg of (HE)3-G3 DARPin (3.4 X10
-8 mol, MW ~14.4 kDa)
is based on the reported HER2 molecular imaging trials with trastuzumab and the
second generation HER2 binding affibody molecule (ABY-025). Perik et al.
investigated SPECT imaging with 5 mg of
111In-DTPA-trastuzumab, equivalent to
approximately 3.4 X10
-8 mol of trastuzumab (148 kDa) (Perik, Lub-De Hooge et al.
2006). Patients received 0.1 mg of
111In-DOTA-ABY-025 (6.5 kDa) for HER2 SPECT
imaging, equivalent to approximately 1.5 X10
-8 mol (Sorensen, Sandberg et al.
2014). Thus, the proposed molar dose of (HE)3-G3-DARPin is approximately 2.3
times higher than the
111In-DOTA-ABY-025 molar dose and equivalent to the
111In-
DTPA-trastuzumab molar dose assessed in clinical trials (Perik, Lub-De Hooge et al.
2006; Baum, Prasad et al. 2010).
For 300 MBq of radioactivity, there are 2.1 X10
14 metal atoms, composed of indium
and its decay product cadmium. Using the Avogadro constant (6.022 X10
23), 0.5 mg
or 3.4 X10
-8 mol of (HE)3-G3 DARPin equates to 2.1 X10
16 (HE)3-G3 DARPin
molecules. Consequently, for each metal ion there will be approximately 100 (HE)3-
G3 DARPin molecules. This DARPin excess will help to minimise the amount of
‘free’ metals which can be absorbed and damage normal organs. In prior HER2
SPECT/CT imaging trials, 150 MBq of radiation activity was administered for the
111In-DTPA-trastuzumab trial (~90-fold excess of trastuzumab vs. metal atoms),
while 140 MBq of radiation activity was administered for the
111In-DOTA-ABY-025
trial (~175-fold excess of affibody vs. metal atoms) (Table 7.1) (Perik, Lub-De
Hooge et al. 2006; Sorensen, Sandberg et al. 2014).
It is vital to have high specific activity (high radiation activity per ligand dose) for
tumour receptor imaging, as non-radiolabelled ligand can potentially saturate the205
receptor and limit the ability to visualise tumour receptor expression. Clinical tumour
receptor SPECT imaging has been most successful with nanomolar doses of
radioligands (Mankoff, Link et al. 2008). The specific activity of the proposed
111In-
(HE)3-G3 DARPin dose is 8.6 MBq/nmol, which is similar to the specific activity of
111In-DOTA-ABY-025 successfully used in a clinical trial (9.1 MBq/nmol) (Sorensen,
Sandberg et al. 2014).
Table 7.1 Doses assessed in previous HER2 SPECT imaging trials with
111In and
proposed
111In-(HE)3-G3 DARPin dose.
Radioligand Activity
(MBq)
Ligand
MW (Da)
Ligand
dose (mg)
Ligand
dose (mol)
Ligand-to-
metal ion
ratio
Specific
activity
(MBq/nmol)
111In-ABY-025
Affibody
(Sorensen,
Sandberg et
al. 2014)
140 MBq 6,500 0.1 1.5X10
-8 175 9.1
111In-
trastuzumab
(Perik, Lub-De
Hooge et al.
2006)
150 MBq 148,000 5 3.4 X10
-8 90 4.5
111In-(HE)3-G3
DARPin
proposed dose
300 MBq 14,400 0.5 3.4 X10
-8 100 8.6
Hemizygous (one allele within a diploid organism) B6.Cg-Tg(Wap-
ERBB2)229Wzw/J transgenic mice, express human HER2 under the control of the
mouse whey acidic protein (WAP) promoter. They had been generated by
microinjection of the WAP regulated human HER2 transgene into mouse embryos
(C57BL/6 x C3H) and backcrossed to C57BL/6 for over 25 generations. This HER2
transgenic mouse model was selected for pre-clinical toxicity testing. The WAP
promoter directs expression of human HER2 to the mammary glands and molecular
layer of the cerebellum (Piechocki, Ho et al. 2003). Thus, potentially enabling the
assessment of DARPin related adverse events due to HER2 mediated toxicity and
off-target toxicity.
A preliminary toxicity study with the unconjugated and non-radiolabelled (HE)3-G3
DARPin was proposed prior to a regulatory GLP standard toxicity study.206
Aim:
To test the hypothesis that unconjugated G3 DARPin is well tolerated by HER2
transgenic and non-transgenic mice.
Objectives:
1) Genotype and breed HER2 transgenic mice for assessment.
2) Prepare unconjugated (HE)3-G3 DARPin for mouse administration.
3) Assess toxicity related to the unconjugated (HE)3-G3 DARPin at 50-100 times
the human equivalent dose (HED) in HER2 transgenic and non-transgenic mice,
by blood sampling and histological assessment of major organs.207
7.2 Results
7.2.1 Genotyping HER2 transgenic mice
Genotyping of the 13 mice purchased from The Jackson Laboratory, demonstrated
that there were four female and four male HER2 transgenic mice, which was
consistent with The Jackson Laboratory genotype results (Table 7.2). The mouse IL-
2 gene was present in all samples, confirming that DNA had been successfully
extracted for human HER2 gene assessment (Figure 7.1). The negative control
mouse, a C57 Black mouse, had the mouse IL-2 gene but did not have the human
HER2 gene. As expected, the water sample did not have the mouse IL-2 gene and
human HER2 gene.
Figure 7.1 Agarose gels (1.5%) of PCRs to assess human HER2 gene status of
mice purchased from The Jackson Laboratory.
A) Human HER2 gene (139 bp) and B) Mouse IL-2 gene (internal control, 324 bp).
The identification numbers are in red for HER2 transgenic mice and in black for wild
type mice. Controls were a C57 Black mouse and water sample. Bioline hyperladder
I used.208
DNA of HER2 PCRs extracted from agarose gel bands for mice 2, 6 and 8
contained the human HER2 gene. In addition, extracted DNA from mice 2, 3 and 4
IL-2 PCRs contained the mouse IL-2 gene. Since the homozygous mice die in utero,
the mice were successfully bred from wild and HER2 transgenic parents.
Table 7.2 Consistent genotyping results performed at UCL and The Jackson
Laboratory.
Mouse Identification Number Gender Genotype
1 F Wild
2 F HER2
3 F HER2
4 F HER2
5 F HER2
6 M HER2
7 M HER2
8 M HER2
9 M Wild
10 M HER2
11 M Wild
12 M Wild
13 M Wild
7.2.2 Preparation and assessment of the (HE)3-G3 DARPin without a GP-site
for mouse administration
As previously outlined in Chapter 6, the HE3-G3 DARPin selected for clinical
development was produced without the GP residue at the N-terminus.
7.2.2.1 Endotoxin levels
To minimise toxic effects in mice unrelated to the (HE)3-G3 DARPin, endotoxins and
the reducing agent (DTT) were removed prior to administration. Endotoxins arise
from Gram-negative bacteria outer cell membranes and are not found in P. pastoris
cells. Yet, prior to endotoxin removal, the (HE)3-G3 DARPin endotoxin concentration
was 67.3 Endotoxin Units (EU) per ml, from possible bacterial contaminants. After
elution from the first endotoxin column, the endotoxin concentration was 2.16 EU/ml
and decreased to 1.19 EU/ml after elution from the fifth endotoxin column (Figure
7.2). Following buffer exchange into DTT-free PBS buffer with a PD-10 column, the
(HE)3-G3 DARPin had 0.65-0.74 EU/ml (DARPin concentration 1.5-2.0 mg/ml).209
Figure 7.2 Endotoxin removal from (HE)3-G3 DARPin by endotoxin removal
columns, followed by elution into DTT-free PBS with a PD-10 column collected as
three separate aliquots.
7.2.2.2 Dimerisation status
The (HE)3-G3 DARPin in DTT-free PBS was predominantly in monomer form but
contained a higher proportion of dimer than the (HE)3-G3 DARPin in PBS with 10
mmol DTT prior to endotoxin removal (Figure 7.3). In addition, there was a single
peak at 90 ml on the Analytical FPLC column which corresponds to the molecular
weight of the (HE)3-G3 DARPin (14.4 kDa) (Figure 3.14 and Figure 7.4).
Figure 7.3 SDS-PAGE on a 16% Tris-Glycine gel stained with coomassie blue, to
assess (HE)3-G3 DARPin dimerisation status pre- and post-endotoxin removal.
Samples were processed with 4x SDS-PAGE non-reducing buffer. Molecular weight
marker was SeeBlue Plus2 (Life Technologies).210
Figure 7.4 FPLC trace of (HE)3-G3 DARPin run on a Analytical Superdex 75 column
(125 ml bed volume) (GE Healthcare).
Protein (2 ml, ~3-4 mg) was run through the column at 1 ml/min in filtered PBS at
maximum pressure of 0.3 MPa. Blue line relates to UV.
7.2.3 Bloods results
All DARPin-treated mice which underwent blood sampling were treated at 100X
HED of (HE)3-G3 DARPin. The control mice were treated with PBS alone. Blood
sampling was only performed at 24 h post treatment. It was not possible to obtain
pre-DARPin treatment blood samples, as each sample required relatively high blood
volumes.
7.2.3.1 Haematology
All HER2 transgenic (4/4) and wild type mice (7/7) treated at 100X HED of (HE)3-G3
DARPin had normal haemoglobin concentrations and normal total white cell counts.
However, the mice were euthanized at 24 h post DARPin administration, so it is
unlikely that any myelosuppressive effects would have been detected at this early
time point.
Thombocytopenia affected transgenic (2/4) and wild type mice (2/5) treated at 100X
HED of (HE)3-G3 DARPin, as well as PBS treated control mice (1/2). Assessment of
platelet counts was limited by blood clot formation in samples. Among the mice
treated at 100X HED of (HE)3-G3 DARPin, 1/7 of the wild type mice and 1/4 of the211
transgenic mice had increased eosinophil counts, compared with none of the PBS
treated control mice (0/4) (Table 7.3). The eosinophilia could possibly reflect an
immune response to the (HE)3-G3 DARPin.
Table 7.3 Haematology results.
Animal Sex Gene Hb
(g/dl)
PCV
(%)
MCV
(fl)
Platelet
(10
3/ul)
WBC
(10
3/µl)
Neut
(%)
Lymph
(%)
Mono
(%)
Eosin
(%)
Baso
(%)
Ref. range male (M) 12.3-
15.7
39.6-
50.3
42.7-
57.4
953-
2044
2.82-
13.39
0-
37.1
56.4-
97.0
0.5-
4.3
0.5-
4.4
0-
0.7
Ref. range female (F) 12.7-
15.8
40.5-
50.1
43.3-
58.0
832-
1777
1.56-
11.68
0.9-
25.1
65.5-
95.3
0-
6.7
0.6-
5.1
0-
0.8
Control (C) mice treated with PBS, age 3 months*
C1 F Wild 15.3 48.7 47.8 572 8.93 7.5 84.8 1.9 4.3 0.2
C2 F Wild 14.6 46.8 47.0 CLOT 9.15 5.3 89.5 1.1 2.2 0.3
C3 M Wild 10.2 34.5 46.5 1239 8.00 22.0 72.2 0.8 3.9 0.1
C4 M Wild 14.4 46.2 46.2 CLOT 9.63 13.7 80.2 1.2 3.1 0.3
Wild (W) mice treated with 100X HED (HE)3-G3 DARPin, age 5-6 months
W1 F Wild 14.6 46.9 45.7 941 9.11 8.5 86.7 1.2 2.1 0.2
W2 F Wild 13.9 46.0 46.9 736 7.15 9.0 86.0 2.0 2.0 0.2
W3 F Wild 13.4 43.3 46.9 905 4.05 10.0 75.5 3.8 6.8 0.2
W4 M Wild 15.6 48.7 46.6 777 11.48 7.3 86.9 1.4 2.1 0.2
W5 M Wild INS INS INS INS INS INS INS INS INS INS
W6 M Wild 14.2 47.5 48.1 1132 13.34 8.3 85.4 1.5 3.2 0.2
W7 M Wild 12.8 40.6 45.7 CLOT 4.84 5.4 90.4 1.3 2.0 0.1
W8 F Wild 15.0 46.7 46.5 CLOT 9.64 5.8 88.2 1.6 2.2 0.3
HER2 transgenic (T) mice treated with 100X HED (HE)3-G3 DARPin, age 9 months
T1 F Her2 13.2 43.5 45.6 796 5.47 9.9 82.6 1.3 4.5 0.1
T2 F Her2 14.2 45.3 47.8 883 8.84 8.2 83.8 1.2 5.4 0.1
T3 M Her2 12.8 41.8 46.8 1407 4.33 10.9 83.5 1.7 3.1 0.1
T4 M Her2 14.1 45.0 47.0 599 8.30 7.7 87.4 0.9 2.4 0.1
*Control (C) mice 5-10 did not undergo haematological assessment.
Abnormal results in red, CLOT = clot in sample, INS = insufficient sample.
7.2.3.2 Clinical Chemistry
Hyperglycaemia affected 2/4 HER2 transgenic (aged 9 months) and 2/8 wild type
mice (aged 5-6 months) treated with (HE)3-G3 DARPin at 100X HED. The younger
control mice (C1-4, aged 3 months) were all normoglycaemic, while 3/6 of the older
control mice (C5-10, aged 9-12 months) were hyperglycaemia. In all cases, the
blood glucose concentrations were <20% above the upper limit of the reference
range. Thus, it is likely that hyperglycaemia is age and or weight related, rather than
(HE)3-G3 DARPin related.
The DARPin treated HER2 transgenic mice (0/4) and PBS treated control mice
(0/10) did not have any biochemical features of kidney impairment. Among the eight
DARPin treated wild type mice, one mouse had a slightly increased creatinine
concentration, 0.13 mg/dL (reference range 0.04-0.11) associated with a normal212
urea concentration. It is difficult to know whether this case of mild renal impairment
is DARPin related (Table 7.4 and Table 7.5).
There was no evidence of liver dysfunction in DARPin treated HER2 transgenic and
wild type mice. Among the wild type DARPin treated mice, 2/8 had a raised albumin
which is not a feature of liver impairment (Table 7.4 and Table 7.5).213
Table 7.4. Blood chemistry results for control and wild mice (AP: alkaline phosphatase, ALT & AST: alanine & aspartate transaminase).
Animal Sex Gene Na
+
(mmol/L)
K
+
(mmol/L)
Urea
(mg/dL)
Creatinine
(mg/dL)
Ca
+
(mg/dL)
Glucose
(mg/dL)
Cholesterol
(mg/dL)
AP
(U/L)
ALT
(U/L)
AST
(U/L)
Total protein
(g/dL)
Albumin
(g/dL)
Bilirubin
(mg/dL)
Ref. Range Male (M) 145-154 3.3-5.0 27.9-58.0 0.04-0.11 9.2-10.5 150-318 92-182 22 -152 0-685 0-302 4.6-5.7 2.6-3.5 0.05-0.19
Ref. Range Female (F) 145-153 2.7-4.4 25.0-54.4 0.05-0.12 9.2-10.7 133-301 64-137 37-171 0-118 0-173 4.7-5.6 3.1-3.8 0.06-0.14
Control (C) mice treated with PBS, C1-4 age 3 months and C5-10 age 9-12 months
C1 F Wild 148 4.0 39.8 0.09 9.6 189 60 83 25 71 4.7 3.3 0.20
C2 F Wild 151 3.7 47.4 0.09 9.1 291 80 71 25 128 4.9 3.5 0.09
C3 M Wild 151 3.6 45.2 0.08 9.1 270 85 37 34 59 4.2 2.5 0.06
C4 M Wild 151 3.8 45.1 0.07 9.8 247 117 45 34 76 4.8 3.1 0.08
C5 M Her2 150 4.6 51.9 0.07 9.8 324 137 65 31 63 4.9 3.1 0.01
C6 M Wild 148 5.2 53.0 0.09 9.4 319 129 62 53 229 4.9 2.9 0.04
C7 M Her2 152 4.5 57.6 0.07 9.8 234 133 61 31 62 5.2 3.4 0.02
C8 M Wild 153 3.6 45.2 0.06 9.5 226 142 56 35 61 5.3 3.6 0.05
C9 M Wild 150 4.7 44.8 0.09 9.6 328 146 43 42 153 4.9 3.2 0.04
C10 M Her2 149 3.8 49.9 0.09 9.4 268 110 48 27 49 4.9 2.9 0.04
Wild (W) mice treated with 100X (HE)3-G3 DARPin, age 5-6 months
W1 F Wild 149 4.1 44.7 0.10 9.8 276 135 85 39 69 5.6 3.9 0.10
W2 F Wild 150 3.5 45.3 0.10 9.8 278 101 78 20 67 5.1 3.5 0.12
W3 F Wild 148 4.4 42.6 0.09 9.3 269 80 59 18 49 5.1 3.6 0.13
W4 M Wild 149 4.2 37.4 0.13 9.6 237 127 88 56 109 5.2 3.5 0.10
W5 M Wild 151 4.0 46.8 0.07 9.8 246 132 82 89 89 5.5 3.7 0.07
W6 M Wild 151 3.8 43.0 0.07 10.0 360 127 56 31 47 5.2 3.4 0.08
W7 M Wild 150 3.4 40.8 0.07 9.9 352 121 74 49 87 5.1 3.5 0.08
W8 F Wild 152 3.7 44.1 0.09 9.5 218 104 82 27 83 5.1 3.6 0.12214
Table 7.5 Blood chemistry results for transgenic mice (AP: alkaline phosphatase, ALT & AST: alanine & aspartate transaminase).
Animal Sex Gene Na
+
(mmol/L)
K
+
(mmol/L)
Urea
(mg/dL)
Creatinine
(mg/dL)
Ca
+
(mg/dL)
Glucose
(mg/dL)
Cholesterol
(mg/dL)
AP
(U/L)
ALT
(U/L)
AST
(U/L)
Total protein
(g/dL)
Albumin
(g/dL)
Bilirubin
(mg/dL)
Ref. Range Male (M) 145-154 3.3-5.0 27.9-58.0 0.04-0.11 9.2-10.5 150-318 92-182 22 -152 0-685 0-302 4.6-5.7 2.6-3.5 0.05-0.19
Ref. Range Female (F) 145-153 2.7-4.4 25.0-54.4 0.05-0.12 9.2-10.7 133-301 64-137 37-171 0-118 0-173 4.7-5.6 3.1-3.8 0.06-0.14
HER2 transgenic (T) mice treated with 100X (HE)3-G3 DARPin, age 9 months
T1 F Her2 150 4.4 40.9 0.10 9.2 227 85 63 25 83 5.1 3.2 0.10
T2 F Her2 149 3.4 47.0 0.07 9.6 350 124 74 71 157 5.7 3.7 0.13
T3 M Her2 151 3.7 41.7 0.05 9.9 296 139 56 33 50 5.3 3.4 0.10
T4 M Her2 150 4.0 32.8 0.09 10.0 368 154 79 51 66 5.2 3.4 0.09215
7.2.4 Histology results
7.2.4.1 HER2 transgenic and wild type mouse study
The heart, kidneys, spleen, brain, adrenal glands and mammary glands of the PBS
treated control mice (n=4 wild type mice aged 3 months) and mice treated at 100X
HED of (HE)3-G3 DARPin (n=8 wild mice aged 5-6 months and n=4 transgenic mice
aged 9 months) were normal on histological examination.
Figure 7.5 Haemotoxylin and Eosin staining of mouse livers, post (HE)3-G3 DARPin
administration.
A) Normal mouse liver.
B) Abnormal mouse liver with vacuolated hepatocytes due to fat accumulation (blue
arrow) and hepatocytes containing lysosome bound glycogen (red arrow).
Performed by Dr Noel Downes, Pathologist at Sequani.
Fat and glycogen related hepatic vacuolation was seen in PBS and DARPin treated
mice on Haemotoxylin and Eosin (H&E) staining (Figure 7.5). Hepatic vacuolation
was identified in PBS treated male wild type mice (2/5) and PBS treated male
transgenic mice (1/3). However, hepatic vacuolation was not identified in the PBS
treated female wild type mice (0/2), who were younger than their male counterparts.
All DARPin treated male wild type mice (4/4) had hepatic vacuolation but age
matched DARPin treated female wild type mice (0/4) did not have hepatic
vacuolation on histological analysis. All of the DARPin treated male transgenic (2/2)
and DARPin treated female transgenic (2/2) mice had evidence of hepatic
vacuolation. Since hepatic vacuolation affected both PBS and DARPin treated mice,216
it is probably a phenotype of the mice rather than related to DARPin administration
(Table 7.6).
Table 7.6 Prevalence and severity of hepatic vacuolation in mice treated at 100 X
HED of (HE)3-G3 DARPin and control mice treated with PBS (n/a: not available).
Gender Males Females
Treatment &
genotype
PBS
Wild
PBS
Transgenic
DARPin
Wild
DARPin
Transgenic
PBS
Wild
DARPin
Wild
DARPin
Transgenic
Mice examined 5 3 4 2 2 4 2
Age range
(months)
3-9 9-12 5-6 9 3 5-6 9
Weight range
(g)
n/a n/a 48-51 47-48 n/a 26-43 36-51
Mice with
hepatocyte
vacuolation
2 1 4 2 0 0 2
7.2.4.2 CD-1 mouse study
To clarify whether the hepatic histological abnormalities observed in the transgenic
and wild type mice were a phenotype of this mouse strain or DARPin-related, 2
month old CD-1 mice were also assessed. The CD-1 mice were treated with 100X
HED of (HE)3-G3 DARPin, 50X HED of (HE)3-G3 DARPin or PBS, then they were
euthanised at 24 h for histological examination.
Examination of the livers from the CD-1 mice aged 2 months (weight 31-36 g),
revealed that there were no abnormal histological changes in the PBS treated
control mice (n=6), 50X HED DARPin treated mice (n=6) and 100X HED DARPin
treated mice (n=6). Thus, suggesting that the vacuolated hepatocytes previously
observed in the transgenic and wild type mice, was related to the mouse strain
(generated from C57BL/6 and C3H mice) rather than caused by the (HE)3-G3
DARPin.
7.2.4.3 Human HER2 status of transgenic and wild mouse livers
The livers from transgenic and wild type mice were assessed for expression of
human HER2, to determine whether there was a mechanism for preferential (HE)3-
G3 DARPin hepatic binding in these mice. Initially, a panel of human breast cancer
TMAs confirmed that the Bond Polymer Refine Detection assessed human HER2
status appropriately (Figure 7.6).217
Figure 7.6 Immunohistochemistry with Bond Polymer Refine Detection of human
breast cancer tissue microarrays.
(Known HER2 status displayed on left side, x10 magnification, UCL Advanced
Diagnostics).
The livers from the transgenic and wild type mice did not express human HER2
protein, so they are unlikely to preferentially bind to (HE)3-G3 DARPin. Thus,
consistent with reports that human HER2 receptor expression is limited to the
mammary glands and cerebellum of the transgenic mice (Figure 7.7 and Figure 7.8)
(Piechocki, Ho et al. 2003).
Figure 7.7 Immunohistochemistry of a transgenic mouse liver with the Bond Polymer
Refine Detection.
A) Haemotoxylin and Eosin stain, B) Negative control (primary antibody omitted), C)
Assessment with the primary and secondary antibodies (x10 magnification, UCL
Advanced Diagnostics).
Figure 7.8 Immunohistochemistry of a wild type mouse liver with the Bond Polymer
Refine Detection.
A) Haemotoxylin and Eosin stain, B) Negative control (primary antibody omitted), C)
Assessment with the primary and secondary antibodies (x10 magnification, UCL
Advanced Diagnostics).218
It was not possible to assess HER2/CEP17 ratios, as the chromosome 17 detection
signal utilises a goat anti-mouse antibody which results in a non-specific background
red signal in the mouse livers. In fact, determination of the HER2/CEP17 ratio was
not relevant, as the human HER2 gene is under the control of the WAP promoter in
the transgenic mice, while in humans it is located on chromosome 17 (Piechocki, Ho
et al. 2003). The nuclei of the assessed wild type mouse hepatocytes did not have
any human HER2 genes, while the nuclei of the transgenic mouse hepatocytes had
up to four human HER2 genes per nucleus (Figure 7.9). Thus, the transgenic mice
had human HER2 genes but did not express membranous HER2 in their livers. The
lack of membranous human HER2 expression in the wild and transgenic mouse
hepatocytes substantiates the view that the observed hepatic vacuolation was not
related to (HE)3-G3 DARPin administration.
Figure 7.9 Chromogenic in situ hybridisation: Images taken at 40x magnification.
A) Wild type mouse liver: No black in situ hybridisation reaction for HER2 DNA
detection in liver nuclei.
B) Transgenic mouse liver: Up to four black in situ hybridisation reactions for HER2
DNA detection in each liver nucleus (UCL Advanced Diagnostics).219
7.3 Discussion
In the preliminary pre-clinical toxicity study, the (HE)3-G3 DARPin was well tolerated
by the transgenic, wild type and CD-1 mice treated at 50-100 X HED over 24 h post-
administration. The main abnormal findings were hyperglycaemia and hepatic
vacuolation related to fat and glycogen retention. However, it is unlikely that these
abnormalities were DARPin related, as they were also observed in control mice
treated with PBS.
The DARPin treated transgenic and wild type mice with hepatocyte vacuolation were
generally older and heavier (5-9 months and weight 26-51 g), than the DARPin
treated CD-1 mice (2 months old, weight 31-36 g) whose livers were histologically
normal. In addition, hepatic vacuolation was observed in PBS treated male
transgenic and male wild type mice. The histological abnormalities in the livers were
not associated with biochemical evidence of liver impairment. Furthermore, the
transgenic and wild type mice livers are unlikely to preferentially bind to (HE)3-G3
DARPin, as they do not express membranous human HER2 protein.
In humans, non-alcoholic fatty liver disease (NAFLD) is characterised by lipid
deposition in the hepatocytes in the absence of significant alcohol consumption and
is usually related to obesity (Tannapfel, Denk et al. 2011). An inflammatory reaction
to hepatocyte fat deposition results in non-alcoholic steatohepatitis (NASH), which
may lead to liver cirrhosis. Patients with NASH exhibit fatty degeneration of
hepatocytes characterised by vacuolation (Tannapfel, Denk et al. 2011).
The mice received the 2018 Teklad Global 18% Protein Rodent Diet (Harlan
Laboratories) which supports gestation, lactation, and growth. In this diet 18% and
58% of the calories are derived from fats and carbohydrates, respectively. Studies
have shown that rodents consuming high fat diets for 4 weeks develop hepatocyte
vacuolation and necrosis as found in NAFLD, these findings were not seen in
rodents who received a standard diet (4% fat) (Dhibi, Brahmi et al. 2011). Thus, the
hepatocyte vacuolation of the DARPin treated transgenic and wild type mice is
probably caused by prolonged high fat dietary intake. In addition, hyperglycaemia
which affected both the PBS and DARPin treated mice probably reflects weight gain
and insulin resistance caused by their diet.220
This study only assessed acute adverse effects of the (HE)3-G3 DARPin, the
medium and long-term adverse effects of (HE)3-G3 DARPin in mice are unknown,
including any possible myelosuppressive effects. The HER2 transgenic mice were
selected to assess direct toxic effects related to the interaction between the DARPin
and human HER2 in the mouse brains and mammary glands. However, human
HER2 is only expressed in the mammary glands during pregnancy and lactation, so
was probably not expressed in the mammary glands of the assessed transgenic
mice. In addition, human HER2 is constitutively expressed in the Bergman glia cells
within the molecular layer of the cerebellum, compared to the normal human brain
where HER2 is consistently found in oligodendrocytes, astrocytes and microglial
cells (Cannella, Pitt et al. 1999; Piechocki, Ho et al. 2003). Thus, even in the
absence of histological abnormalities in the brain and mammary glands of the
assessed HER2 transgenic mice, direct toxic effects cannot be entirely excluded
based on this study. Furthermore, it is unknown whether ligand binding to the
human HER2 of transgenic mice has any intracellular effects and it is unknown
whether any potential intracellular effects in mice are comparable with the effects in
humans.
The regulatory pre-clinical toxicity study will need to be conducted to GLP
standards, so will be performed entirely by Sequani. Following a meeting with the
Medicines and Healthcare Products Regulatory Agency (MHRA) in which the data
herein was presented, the design of the regulatory pre-clinical toxicity study was
agreed. The regulatory study will assess both acute and long term toxic effects in
CD-1 mice who will receive intravenous (HE)3-G3 DARPin conjugated with DOTA at
50X HED. CD-1 mice have been selected as their phenotype is better characterised
than the HER2 transgenic mice, so it will easier to identity DARPin related adverse
events (Morgan, Elangbam et al. 2013).221
Chapter 8 Discussion and future
directions222
8.1 Discussion
For breast cancer, the reported rates of HER2 discordance between primary and
metastatic sites, range from 0 to 34 % (Turner and Di Leo 2013). The literature is
predominantly based on retrospective studies and include cases of both HER2 loss
and HER2 gain (Turner and Di Leo 2013). To determine HER2 evolution and
heterogeneity, HER2 imaging could provide whole body assessment of HER2
expression at tumour sites over time and during therapy, which is both more feasible
and acceptable to patients than serial and multiple biopsies. Furthermore,
considerably less is known about gastric cancer HER2 biology and HER2 imaging
could help to address this knowledge gap (Boku 2014).
HER2 is an important therapeutic target in cancer and HER2 imaging could be used
to select patients for therapy by identifying HER2 gain and the need to introduce
anti-HER2 therapy, as well as HER2 loss necessitating discontinuation of anti-HER2
therapy (Arteaga, Sliwkowski et al. 2012). Whole body HER2 scans could potentially
improve clinical outcomes and ensure appropriate allocation of expensive anti-HER2
therapies.
Molecular imaging requires high tumour uptake and low normal tissue uptake, to
facilitate high tumour-to-normal tissue ratios. The liver is a common site for breast
cancer metastases and is involved in drug metabolism and excretion. Therefore, it is
important to minimise normal liver uptake to enable identification of liver metastases
on imaging. Factors which are known to influence radioligand liver uptake, include
the composition of the histidine tag, chelator structure, radioisotope residualising
properties, radioisotope-chelator stability and radio-colloid impurities (Hosseinimehr,
Tolmachev et al. 2012). To determine the G3 DARPin construct with lowest normal
liver uptake, His6-G3, (HE)3-G3 and untagged-G3 DARPins were produced using a
GMP-compatible P. pastoris protocol for initial in vivo assessment with
111In
(residualising) and
125I (non-residualising).
The His6-G3 and (HE)3-G3 DARPins were designed to commence at their histidine-
based tags. However, the initial production of His6-G3 and (HE)3-G3 DARPins from
the template which incorporated LEKREAEA preceding the histidine based tags,
resulted in G3 DARPins commencing with EAEAH or EAH residues. This occurred
as the Ste13 gene product was inefficient in EA cleavage, while the Kex2 gene223
product efficiently removed LEKR residues (Sasagawa, Matsui et al. 2011).
Consequently, it was necessary to produce pPICZαB/G3 DARPin DNA which did 
not encode EAEA residues. The modified pro-sequence of the α-factor secretion 
signal still enabled DARPin secretion from the cytoplasm into the media for
harvesting. It was not necessary to re-produce the cleavable tag-G3 without EAEA
residues, as HRV 3C protease cleavage ensured that the untagged-G3 commenced
at the appropriate N-terminus site (GP).
For direct radiolabelling with
125I and site-specific radiolabelling with
111In via DOTA
of the G3 DARPins, the (HE)3 tag rather than the absence or presence of the His6
tag was associated with significantly lower liver uptake without compromising uptake
in other assessed normal tissues. Direct iodination of the G3 DARPins resulted in a
considerably different biodistribution profile compared to site-specific
111In
radiolabelling.
125I-(HE)3-G3 had higher stomach uptake (where free iodine is known
to accumulate) and lower kidney uptake than
111In-(HE)3-G3.
For the HER2 affibody molecule, ZHER2:342 radiolabelled with [
99mTc(CO)3]
+ and
111In,
the N-terminal (HE)3 tagged variant is associated with lowest normal liver uptake
(Hofstrom, Orlova et al. 2011; Hofstrom, Altai et al. 2013). Yet, some of the ZHER2:342
biodistribution studies are limited, as there were other differences in the amino acid
sequences besides the composition of the histidine-based tags (Hofstrom, Orlova et
al. 2011). The G3 DARPins assessed in this thesis, which confirmed that (HE)3-G3
DARPin had the lowest normal liver uptake, only differed by the presence or
composition of their histidine-based tags.
Hofström et al. concluded that for ZHER2:342 radiolabelled with [
99mTc(CO)3]
+, lipophilic
and positively charged N-terminal histidine based tags promote liver uptake
(Hofstrom, Altai et al. 2013). The charge of (HE)3-ZHER2:342 and His6-ZHER2:342 differ
greatly; by contrast (HE)3, His6 and untagged-G3 have similar isoelectric points (pI)
(Hofstrom, Altai et al. 2013). In addition, (HE)3, His6 and untagged-G3 DARPins
have similar grand average of hydropathy (GRAVY) scores -0.12, -0.12 and +0.02,
respectively, indicating other factors are involved.
111In-(HE)3-G3 achieves a higher tumour-to-blood ratio than
125I-(HE)3-G3, as it is
cleared faster from the blood stream and
111In is residualising, so remains within the
HER2-positive tumours over 24 h. HER2-positive tumour uptake of
111In-(HE)3-G3 is224
unaffected by the presence of trastuzumab, so DARPin HER2 imaging should not
affect treatment scheduling. MicroSPECT/CT imaging demonstrates that HER2-
positive tumour uptake is associated with high renal uptake for
111In-(HE)3-G3 and
123I-(HE)3-G3 but considerably greater non-specific uptake with
123I-(HE)3-G3,
including higher gastric uptake. Consequently,
123I-(HE)3-G3 SPECT scanning would
not be suitable for assessing gastric and gastro-oesophageal junction cancer
patients.
Although DOTA-(HE)3-G3 was successfully used for
111In radiolabelling, it was not
feasible to use it for
68Ga radiolabelling. This is because
68Ga radiolabelling of DOTA
requires heating to 100 °C for 30 min and the G3 DARPin is not stable at this
temperature, confirmed by the loss of HER2 ECD binding affinity on SPR. By
contrast, NOTA-(HE)3-G3 is potentially suitable for
68Ga radiolabelling, as it does not
require heating and the G3 DARPin can tolerate the acidic radiolabelling conditions
(pH 4.6). In HER2-positive tumour bearing mice,
68Ga-NOTA-(HE)3-G3 achieved
good HER2-positive tumour uptake but had a low tumour-to-liver ratio (< 2) at 1 h
post administration, which would limit the identification of liver metastases, so is not
suitable for clinical application.
In pre-clinical toxicity studies, CD-1 mice, wild type mice and HER2 transgenic mice
tolerated 50 to 100 times the HED of unconjugated and non-radiolabelled (HE)3-G3
DARPin over 24 h. The main abnormal findings were hyperglycaemia and hepatic
vacuolation related to fat and glycogen retention within the liver. However, it is
unlikely that either of these abnormalities were DARPin-related, as they affected
both PBS and DARPin treated transgenic and wild type mice. Furthermore, human
HER2 was not expressed in the livers of HER2 transgenic and wild type mice to
mediate preferential G3 DARPin binding and there was no evidence of hepatic
vacuolation in CD-1 mice treated with similar doses of (HE)3-G3 DARPin. This
(HE)3-G3 DARPin toxicity study only assessed acute toxic effects, so the longer
term effects will be assessed in a subsequent pre-clinical toxicity study.
The HER2 transgenic mice were selected to assess direct toxic effects related to the
interaction between the G3 DARPin and human HER2 in the mouse brains and
mammary glands. However, in the transgenic mice, human HER2 is only expressed
in the Bergman glia cells within the molecular layer of the cerebellar cortex and in225
the mammary glands during pregnancy and lactation (Piechocki, Ho et al. 2003).
Consequently, there may have been no mammary gland human HER2 expression
and only focal cerebellar human HER2 expression in the assessed HER2 transgenic
mice, so direct toxic effects cannot be entirely excluded with this mouse model.
Imaging trials of most HER2 radioligands have had disappointing results, due to
limitations related to their pharmacokinetics for imaging, which were predictable
based on their pre-clinical performance (Smith-Jones, Solit et al. 2004; Dijkers,
Kosterink et al. 2009; Reddy, Shaller et al. 2011; Perols, Honarvar et al. 2012). It
should be noted that the majority of clinical HER2 imaging studies have not
assessed HER2 tumour status histologically for correlation with HER2 scans, thus
limiting the evaluation of these imaging agents.
Trastuzumab radiolabelled with
64Cu,
89Zr or
111In demonstrated the potential for
HER2 imaging by identifying known and or previously unknown tumour lesions in
patients but lacked sensitivity compared to conventional imaging, owing to its long
half-life and high blood pool activity (Perik, Lub-De Hooge et al. 2006; Dijkers, Oude
Munnink et al. 2010; Mortimer, Bading et al. 2013). Fab fragments of trastuzumab
were developed for HER2 imaging, since their lower molecular weight is associated
with a shorter half-life in serum than trastuzumab. However,
68Ga-F(ab’)2-
trastuzumab PET imaging failed to identify any tumours among four of the eight
metastatic HER2-positive breast cancer patients assessed. This poor performance
was due to relatively high liver uptake and high blood pool activity, as well as
potential competition with therapeutically administered trastuzumab (Beylergil,
Morris et al. 2013).
The radiolabelled HER2 binding affibody molecule, ZHER2:342 assessed three patients
with HER2-positive metastatic breast cancer by PET (
68Ga) and or SPECT (
111In)
imaging. Although for two patients not all known tumour lesions were identified,
there was limited tumour biopsy sampling to systematically evaluate the accuracy of
the HER2 affibody molecule imaging. Unfortunately, there was high background liver
uptake in this initial study which limited its clinical potential (Baum, Prasad et al.
2010). Recently, a phase I trial demonstrated that the second generation affibody
111In-ABY-025 had superior distribution, dosimetry, and accuracy for assessing
patients with HER2-positive and HER2-negative metastatic breast cancer than its226
first generation counterpart. There was good correlation between HER2 status
assessed by
111In-ABY-025 SPECT/CT imaging and immunohistochemistry with the
HercepTest. This included confirmation that a patient who had had HER2-positive
primary disease developed HER2-negative metastases, furthermore HER2-positive
brain metastases were detected (Sorensen, Sandberg et al. 2014).
The pharmacokinetics of
111In-(HE)3-G3 is well suited for HER2 imaging, including
short half-life in serum, high tumour-to-blood ratios and low non renal tissue uptake.
The kidneys received the highest radiation dose. Based on medical internal radiation
dose (MIRD) estimates, the maximum absorbed kidney dose in patients with the
proposed clinical dose of
111In-(HE)3-G3 (300 MBq) is 1,000-fold lower than the dose
associated with a 5 % rate of radiation nephritis within 5 years of administration
(TD5/5), 9.75 mGy vs. 10 Gy (Wessels, Konijnenberg et al. 2008). However, MIRD
estimates are based on external beam radiation administration, so are limited in
determining the potential toxicity related to intravenous radioligands.
Conventionally, His6 tagged proteins have been produced for human administration
and (HE)3 tagged proteins represent a relatively new development, so less is known
about their safety in humans. Interestingly, a Blast search (NCBI) for a short input
sequence with HEHEHE as the query, yielded a variety of hits within the Homo
sapiens database of almost identical sequences, e.g. HEHEH in the human zinc
transporter (Gene ID: SLC39A9) and HEHEQE in kinase 3 (Gene ID: TAOK3). The
HHHHHH sequence cannot be found using a Blast search within the Homo sapiens
database. Instead clusters of histidine are found that co-ordinate with metal ions,
e.g. Ca
2+, Mg
2+ and Zn
2+.
HER2 molecular imaging for breast cancer and gastric or gastro-oesophageal
junction cancer needs a radioligand with minimal normal liver and gastric uptake, as
well as the ability to bind to HER2 in the presence of concomitant anti-HER2
therapy. The work in this thesis has demonstrated that
111In-DOTA-(HE)3-G3
DARPin has high affinity for HER2, binds in the presence of trastuzumab, achieves
high tumour-to-blood ratios and tumour to non-renal tissue ratios, including a
tumour-to-liver ratio ≥ 12 over 24 h. In addition, (HE)3-G3 can be radiolabelled with
68Ga for PET imaging but does not achieve sufficiently high tumour-to-liver ratios
which will compromise its utility. To develop (HE)3-G3 PET/CT imaging,227
investigation of alternatives radio-isotopes and or bifunctional chelators must be
performed. Initially, a first in human study is planned to assess
111In-DOTA- (HE)3-
G3 SPECT/CT imaging.
8.2 Milestones achieved towards phase I trial implementation
 Trial sponsorship:
During the course of the PhD I have been involved in a successful application to
Cancer Research UK (CRUK). CRUK have agreed to fund the regulatory GMP pre-
clinical toxicity study and sponsor the proposed clinical trial.
 Regulatory approval:
I helped to organise a Scientific Advice Meeting with the MHRA to discuss the
design of the proposed regulatory GMP pre-clinical toxicity study and proposed
phase I trial. This meeting was informative and will hopefully facilitate the application
for Clinical Trial Authorisation.
 Clinical trial protocol development
I attended the Methods in Clinical Cancer Research, Waldhaus Flims, Switzerland in
June 2011. This was a great opportunity to develop the clinical trial design and write
a draft clinical trial protocol with support from leading experts in cancer imaging
trials.228
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Chapter 2 and Chapter 3
Plasmids/DARPin templates used to generate His6-G3 and (HE)3-G3 DARPin
Figure  A:  Plasmid  pPICZαB/EAEAHis3  which  had  been  generated  during  the 
EAEAHis6-G3 DARPin production was used to produce His6-G3. The EAEAHis-3
DNA differed from the proposed His6-G3 DARPin construct in one respect there
would be no glutamic acid (E) and Alanine (A) residues preceding the His6 tag. The
pPICZαB  sequence  is  highlighted  (grey)  and  includes  part  of  the XhoI  and XbaI 
restriction endonucleases sites.
ctcgagaaaagagaggctgaagctcatcaccatcatcaccatggaccaggttctgatttg
L E K R E A E A H H H H H H G P G S D L
ggaaagaaattgttggaagctgctagagctggtcaagatgatgaagttagaattttgatg
G K K L L E A A R A G Q D D E V R I L M
gctaacggtgctgatgttaacgctaaggatgaatacggtttgactccattgtacttggct
A N G A D V N A K D E Y G L T P L Y L A
actgctcatggtcatttggaaattgttgaagttttgttgaagaatggagctgatgttaac
T A H G H L E I V E V L L K N G A D V N
gctgttgatgctattggttttactccattgcatttggctgcttttattggtcatttggaa
A V D A I G F T P L H L A A F I G H L E
attgctgaagttttgttgaagcatggtgccgacgttaacgctcaggataagtttggaaag
I A E V L L K H G A D V N A Q D K F G K
actgcttttgatatttctattggtaacggtaacgaagatttggctgaaattttgcaaaag
T A F D I S I G N G N E D L A E I L Q K
ttgaacggaggttgctaataatctagaacaaaaactcatctcagaagaggatctgaatag
L N G G C - - S R T K T H L R R G S E -
cgccgtcgacca
R R R P
Figure B: Plasmid  pPICZαB/EAEAHE3  which  had  been  generated  during 
EAEA(HE)3-G3 DARPin production was used to produce (HE)3-G3. The EAEAHE3
DNA differed from the proposed (HE)3-G3 DARPin construct in one respect there
would be no glutamic acid (E) and Alanine (A) residues preceding the (HE)3 tag.
The pPICZαB sequence is highlighted (grey) and includes part of the XhoI and XbaI 
restriction endonucleases sites.
ctcgagaaaagagaggctgaagctcatgagcatgaacacgaaggaccaggttctgatttg
L E K R E A E A H E H E H E G P G S D L
ggaaagaaattgttggaagctgctagagctggtcaagatgatgaagttagaattttgatg
G K K L L E A A R A G Q D D E V R I L M
gctaacggtgctgatgttaacgctaaggatgaatacggtttgactccattgtacttggct
A N G A D V N A K D E Y G L T P L Y L A
actgctcatggtcatttggaaattgttgaagttttgttgaagaatggagctgatgttaac
T A H G H L E I V E V L L K N G A D V N
gctgttgatgctattggttttactccattgcatttggctgcttttattggtcatttggaa
A V D A I G F T P L H L A A F I G H L E
attgctgaagttttgttgaagcatggtgccgacgttaacgctcaggataagtttggaaag
I A E V L L K H G A D V N A Q D K F G K
actgcttttgatatttctattggtaacggtaacgaagatttggctgaaattttgcaaaag
T A F D I S I G N G N E D L A E I L Q K
Ttgaacggaggttgctaataatctagaacaaaaactcatctcagaagaggatctgaatag
L N G G C - - S R T K T H L R R G S E -
cgccgtcgacca
R R R P230
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